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vAbstract 
Targeted cancer therapy is a very promising concept; however, small molecule inhibitors 
only exist for a limited number of oncoproteins and resistance development limits their 
clinical use. Different engineered non-antibody scaffolds are being explored to develop 
potent protein-based inhibitors of oncoproteins, which can overcome these hurdles.  
The first goal of this thesis was to characterize monobodies, engineered binders based on 
the fibronectin type 3 domain, which were selected to bind the SH2 domains of 6 
members of the Src kinase family that play a role in different types of cancer. I have 
shown that the monobodies bind specifically to their target in cells by performing 
tandem affinity purifications with subsequent mass spectrometry analysis. When 
expressed in T cells, the Lck-targeting monobodies ML1 and ML3 inhibit the 
phosphorylation of Zap70, a kinase which is activated downstream of T cell activation. 
Moreover, the fusion of ML1 or ML3 to VHL, the substrate receptor of an E3 ubiquitin 
ligase, resulted in the targeted degradation of Lck. The selected monobodies therefore 
have great potential to interfere with cancer cell signaling and to be used in therapeutic 
approaches.  
The development of protein-based inhibitors is currently limited to extracellular targets 
due to the inability of proteins to cross the cell membrane. Many approaches to achieve 
cellular delivery are hampered by non-selective cytotoxicity or endosomal entrapment of 
the protein cargo. The second aim of my thesis was to explore different methods to 
deliver functional monobodies into cancer cells.  
Firstly, I tested cell penetrating poly-disulfides (CPDs). CPD-monobody adducts showed 
toxic effects on the tested cell line, and mainly followed an endocytic uptake route 
leading to lysosomal degradation, when used at subtoxic concentrations.  
Secondly, bacterial toxins have naturally evolved to deliver their payload into the 
cytoplasm of host cells. Both Shiga-like toxins and Exotoxin A from Pseudomonas 
aeruginosa are taken up into the cytosol via a retrograde trafficking route, avoiding 
endosomal entrapment. To deliver monobodies to the cytosol, we have tested a 
combination of their non-toxic subunits: The B subunit of Shiga-like toxin (Stx2B), 
binding to the sphingolipid Gb3 in the cell membrane, and the translocation domain of 
Exotoxin A (TDP). We could show that recombinant Stx2B-TDP-Monobody fusion 
proteins are taken up in HeLa cells, which naturally express Gb3. Colocalization analyses 
with markers for endocytic compartments demonstrated that the major part of the 
monobodies escape early endosomes and are not degraded in lysosomes. A recombinant 
fusion protein of the Stx2B-TDP construct with the monobody AS25, which 
allosterically inhibits Bcr-Abl kinase, leads to apoptosis in Bcr-Abl-dependent chronic 
myeloid leukemia cells. Furthermore, the delivery of the VHL-ML3 fusion protein into 
Jurkat T cells results in decreased Lck levels. The delivery of both constructs is dependent 
on Gb3 on the cell surface as well as the Stx2B-TDP subunits.  
These results demonstrate that functional monobodies can be delivered to the cytosol and 
bind to their target protein in cells. This method could facilitate the development of 
protein-based inhibitors of intracellular proteins for cancer treatment. 
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Résumé 
La thérapie ciblée du cancer est prometteuse, mais les petites molécules inhibitrices 
n'existent que pour un nombre limité d'oncoprotéines et le développement de résistances 
limite leur utilisation clinique. Différentes matrices protéiques non-anticorps ont été 
explorées pour développer des inhibiteurs d'oncoprotéines surmontant ces limitations. 
Le premier objectif de ma thèse était de caractériser des monobodies, liants synthétiques 
sélectionnés pour se lier aux domaines SH2 de 6 membres de la famille des kinases Src 
impliquées dans certains cancers. J’ai montré que les monobodies se lient spécifiquement 
à leur cible dans des cellules en faisant une purification d’affinité tandem suivie d’une 
analyse de spectrométrie de masse. Exprimés dans des cellules T, les monobodies ML1 et 
ML3 (se liant à Lck) inhibent la phosphorylation de Zap70, une kinase activée après 
activation des cellules T. En outre, la fusion de ML1 ou ML3 à VHL, le récepteur d’une 
ligase d’ubiquitine E3, mène à la dégradation ciblée de Lck, ce qui indique leur potentiel 
thérapeutique. 
Le développement d’inhibiteurs protéiniques est actuellement limité aux cibles 
extracellulaires, car les protéines ne peuvent pas franchir la membrane cellulaire. 
Beaucoup d’approches pour délivrer des protéines dans les cellules se heurtent à une 
toxicité non-spécifique ou à un confinement endosomique. Le deuxième objectif de ma 
thèse était d’explorer des méthodes pour délivrer des monobodies fonctionnels dans les 
cellules cancéreuses. 
J’ai d’abord testé des polydisulfides pénétrant les cellules (CPDs). Les adduits entre CPD 
et monobody se révèlent toxiques pour la lignée cellulaire testée et à des concentrations 
non toxiques ils entrent dans la cellule principalement par une route endocytique menant 
à la dégradation lysosomale.  
Puis j’ai testé les toxines bactérielles, organismes ayant évolué pour faire rentrer leur 
charge dans les cellules. Les toxines du type Shiga (Stx) ainsi que l’exotoxine A de 
Pseudomonas aeruginosa (TDP) suivent une voie rétrograde pour entrer dans les cellules, 
tout en évitant d’être confinées dans des endosomes. Afin de mener des monobodies au 
cytosole, nous avons testé une combinaison de domaines non-toxiques : la sous-unité B 
de Stx (Stx2B), qui se lie au sphigolipide Gb3 dans la membrane cellulaire, et le domaine 
de translocation de TDP. Nous avons démontré que la fusion entre Stx2B, TDP et un 
monobody entre dans des cellules HeLa, qui naturellement expriment Gb3. Des analyses 
de colocalisation avec des marqueurs de compartiments endocytiques démontrent que la 
majorité des monobodies échappent aux endosomes précoces et ne sont pas dégradés dans 
des lysosomes. Une fusion entre Stx2B-TDP et le monobody AS25, qui inhibe la kinase 
Bcr-Abl de manière allostérique, induit l’apoptose de cellules de leucémie myéloïde 
chronique qui dépendent de Bcr-Abl. Par ailleurs, le transfert de la fusion VHL-ML3 
dans des cellules T Jurkat réduit la teneur en Lck. Le transfert des 2 protéines est 
dépendant de Gb3 à la surface cellulaire et de Stx2B-TDP.  
Ces résultats montrent que des monobodies fonctionnels peuvent être délivrés dans le 
cytosole et se lient à leur protéine cible dans les cellules, et pourraient faciliter le 
développement d’inhibiteurs protéiniques pour le traitement de cancers. 
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Mots clés: Monobody, domaine protéinique SH2, Famille de kinases Src, Lck, 
phosphorylation de tyrosine, transfert cellulaire de protéines, toxine bactérielle, 
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1? Introduction 
1.1? Targeted cancer therapies and their limitations 
Most chemotherapeutic cancer drugs act non-specifically on all rapidly dividing cells in 
the body, leading to numerous side-effects. Targeted drugs take advantage of the 
scientific discoveries of specific proteins and signaling pathways, which are mutated or 
over-expressed in cancer cells and drive proliferation and resistance to programmed cell 
death among other cancer hallmarks. Two types of targeted cancer therapeutics are 
currently used in the clinics: Monoclonal antibodies bind to extracellular targets or 
cellular receptors, whereas small-molecule inhibitors are cell-permeable and act on 
intracellular proteins, kinase inhibitors being the prevalent class.1,2 Even though targeted 
therapies have led to a number of advances in cancer therapy, including increased overall 
survival rates and improved patient conditions, several limitations have emerged since 
they entered the clinics.  
First of all, patients often develop a resistance towards the inhibitor, that is caused by 
evasive mutations in the targeted protein.3 Moreover, many targeted small molecule 
drugs, in particular kinase inhibitors, have several off-targets, which leads to side effects 
and limits their efficacy.2 Lastly, the majority of known oncoproteins remain untargeted, 
due to several reasons.4 Most small molecule drugs target enzymes, which have defined 
deep substrate-binding pockets where small molecules can bind with high affinity and 
selectivity and act as inhibitors. However, many untargeted oncoproteins lack such 
cavities, or their mechanism of action relies on protein-protein interactions which are 
difficult to target due to the lack of defined small-molecule binding pockets. In addition, 
many untargeted proteins have close relatives so that very selective binding is hard to 
achieve with small molecules. Monoclonal antibodies are generally more selective than 
small molecules, since they bind to their target involving a larger surface interaction. 
They can be developed to bind virtually any target and do not rely on the presence of a 
specific binding pocket. However, due to their large size, they are unable to cross the 
lipid bilayer and can therefore not be used intracellularly.5 
Many alternative scaffolds are being explored to enlarge the spectrum of protein-based 
inhibitors.6 They could overcome several of the current limitations of small molecules 
and are smaller in size than classical antibodies. Despite their potential to be developed as 
protein-based therapeutics, they are not able to cross the cell membrane, an issue which I 
will address in the present thesis.  
1.2? Protein tyrosine kinases 
The human protein tyrosine kinase family counts 90 members which can be divided into 
receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (CTKs, 34 members).7 
Their catalytic activity is defined by the transfer of the gamma-phosphate of ATP to a 
tyrosine residue in the substrate protein, where it becomes covalently attached. Protein 
phosphorylation was first discovered by the lab of Tony Hunter in 1979, and has since 
then emerged as a fundamentally important mechanism of signal transduction and 
regulation in all metazoan cells.8,9 
2 
The large group of CTKs is further subdivided into 8 distinct families, named after their 
most prominent member. For this thesis, both the Abl and the Src kinase families are of 
particular importance. All the members of both the Abl and the Src family contain a 
central kinase domain, as well as an SH2 and an SH3 domain N-terminal to the kinase 
domain. SH2 domains play a particular role in this thesis, as I used monobodies selected 
to bind the SH2 domain of different Src-family kinases and of Abl. 
1.2.1? The SH2 domain 
The human genome encodes for 121 different SH2 domains which are found in 110 
human proteins with different functions, such as kinases, phosphatases, small GTPase 
regulators and scaffolding proteins.10 They interact specifically with phospho-tyrosine 
(pY)-containing motifs in other proteins, thus promoting protein-protein interactions 
important for the propagation and amplification of cellular signals.11 Since the selectivity 
of the active site of most tyrosine kinases is limited and determined only by a small 
number of amino acids surrounding it, there must be other mechanisms to confer 
specificity and to avoid the disastrous effects of uncontrolled substrate phosphorylation.  
In 1986, short 2-amino-acid insertions into a region N-terminal to the Fes kinase 
domain, which is not required for catalytic activity, were found to modify kinase activity 
and substrate recognition.12,13 This finding suggested that the kinase specificity we see in 
cells is mediated by this non-catalytic domain adjacent to the kinase domain. The authors 
named it Src homology domain 2 (SH2) because of its homology in all Src and Abl 
kinases. Later discoveries showed that not only kinases contain SH2 domains, but also 
many other proteins exerting different functions, like for example the phospholipase C 
gamma (PLC?), the Ras GTPase activating protein (RasGAP) and the phosphatases 
SHP1 and SHP2.14-19 SH2 domains act as the coupling link between kinase signaling and 
a range of cellular functions like phospholipid metabolism, Ras activation and 
transcription factor activation.13 
In 1992, the first crystal structure of an SH2 domain was solved, showing how this 
domain is folded, and giving an insight into the nature of the SH2-pY interaction.20 
Indeed, the negatively charged phosphate on the tyrosine fits into a pocket where it forms 
a hydrogen bond with a conserved arginine residue. In addition, a second pocket was 
discovered through this crystal structure, which confers additional selectivity to the SH2 
domain. Indeed, not only the pY alone but also the sequence context is important for 
peptide recognition, as together they form a motif which is selectively bound by only 
certain SH2-containing proteins, thus making up for the lacking specificity of kinase 
domains.21 One year later, Lewis Cantley’s lab showed that residues C-terminal to the pY, 
and in particular the residue at position +3 to the pY, are recognized and bind to this 
second pocket in the SH2 domain. Selectivity is conferred by the recognition of a set of 
permissive and non-permissive residues, which vary from one SH2 domain to another.22 
(Figure 1.1) 
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Figure 1.1 Lck SH2 domain bound to the phosphorylated EPQpYEEIPIYL peptide. The SH2 domain 
is shown as a dark blue cartoon and the peptide as sticks. The surface representation of the SH2 domain 
(gray) shows the pockets where the phospho-tyrosine binds (phospho-tyrosine binding pocket) and where 
the isoleucine at position +3, relative to the pY, binds (specificity-pocket). PDB entry: 1LCJ, figure 
assembly using Pymol. 
However, even when this specificity-pocket is taken into account, a non-negligible degree 
of promiscuity remains and the highly specific pY signaling that we see taking place in 
cells is difficult to explain, especially as cells are crowded with different SH2 domains and 
pY containing proteins. Therefore, there must be other mechanisms that guarantee the 
specificity of protein-protein interactions. The formation of multiprotein signaling 
complexes, the recruitment to specific subcellular compartments or a temporal control 
through changes in protein abundance could all contribute to this specificity.23 A recent 
study has shown that indeed, about 90% of SH2 domains bind plasma membrane lipids 
using surface cationic patches that are distinct from the pY binding pocket.24 These 
interactions could contribute to a spatiotemporal coordination of multiple SH2 domain 
proteins during cellular signaling cascades. 
1.3 The Src kinase family 
The name-giving member of the Src family has first been discovered as a retroviral 
oncogene. In fact, v-Src was found to be the transforming gene in Rous Sarcoma Virus 
(RSV), which was first isolated from a chicken sarcoma by Peyton Rous in 1910.25 Later 
studies showed that v-src is homologous to a host cellular gene (c-src) that is highly 
conserved in eukaryotic species.26 This discovery led not only to the insight that protein 
kinases can have high transforming ability but also to the understanding that retroviruses 
can incorporate host cellular proto-oncogenes like c-Src into their genome by 
recombination with host DNA.  
The Src-kinase family consists of 9 members: Src, Yes, Fyn, Lck, Hck, Blk, Lyn, Fgr and 
Yrk, which are further subdivided in the SrcA group (Yes, Src, Fyn and Fgr) and the SrcB 
group (Lck, Hck, Blk, Lyn and Yrk) based on sequence homology. Yes, Src and Fyn are 
ubiquitously expressed whereas Blk, Fgr, Hck, Lck, and Lyn are found primarily in 
hematopoietic cells. Lyn and Hck for example are expressed in myeloid cells, Blk in B-
cells and Lck in T- and NK-cells.27,28 Some of these kinases are expressed as alternatively 
spliced mRNAs in specific cell types.29 
Phospho-Tyrosine
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Src family kinases (SFKs) function as signal amplifiers downstream of receptor tyrosine 
kinases, G-protein-coupled receptors and immune cell receptors. They are implicated in a 
broad range of physiological cellular activities as well as hallmarks of tumor development, 
such as proliferation, differentiation, cytoskeletal modulation, metastasis and migration.30 
Due to their transforming ability upon deregulation, SFKs are tumor drivers in a variety 
of malignancies, such as leukemia, lymphoma, breast, colorectal or lung cancer and 
therefore have become important therapeutic targets.31 
1.3.1? Lck: A Src kinase family member essential for T-cell receptor 
activation 
In this thesis, I worked on targeting the SFK Lck, which is essential for T-cell 
development, activation and proliferation. Since aberrant Lck signaling drives T-cell 
leukemias, lymphomas and autoimmune diseases, there is an unmet therapeutic need to 
selectively inhibit Lck. 
The majority of T-cell receptors are composed of an ?- and a ?-chain forming a 
heterodimer, whereas about 1-10% of all TCRs are ?-? heterodimers in humans. Each 
T-cell expresses several copies of the same TCR, which specifically recognizes a unique
peptide-MHC complex on antigen-presenting cells. Each TCR is associated with one
CD3??, one CD3??, and one ?-chain homodimer, together forming the TCR complex,
which constitutes one signaling unit.32
Since the TCR complex itself has no enzymatic activity, it relies on the kinase activity of 
associated Src-family kinases, in particular on Lck, as well as Zap70 and ITK. Depending 
on the T cell subtype, Lck is bound to either of the co-receptors CD4 or CD8.27 When 
TCR:pMHC binding occurs, CD4 or CD8 brings Lck in close proximity to the TCR 
complex. pY residues in the immunoreceptor tyrosine-based activation motifs (ITAMs) 
in the cytoplasmic tails of the CD3 and ?-chains, which are partially phosphorylated in 
resting T cells, are recognized by Lck via its SH2 domain.33 Lck then phosphorylates 
further tyrosines in the ITAMs, creating doubly phosphorylated ITAMs which serve as 
docking sites for the tandem-SH2 domain of Zap70 (?-chain associated protein kinase of 
70 kDa).34,35 (Figure 1.2) Zap70 in turn is phosphorylated and activated by Lck and then 
phosphorylates the adaptor protein linker for activation of T-cells (LAT), which recruits 
additional signaling proteins to form a multiprotein complex called the LAT 
signalosome.36,37  
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Figure 1.2 Early signaling events following T cell activation. Following TCR engagement, CD4-
associated Lck is brought into proximity of the CD3 complex and phosphorylates ITAMs in the ?-chain 
(phoshorylation depicted as red dots). Doubly phosphorylated ITAMs then interact with the tandem SH2 
domains of Zap70. After ITAM binding, Zap70 can be phosphorylated by Lck, which results in activation 
of Zap70 catalytic activity and its autophosphorylation. (Figure taken from 36) 
The threshold for T cell activation needs to be precisely set and the downstream signaling 
pathways accurately coordinated in order to ensure tolerance towards self-antigens and to 
limit effector responses. Among the proteins negatively regulating T cell activation are 
Csk, phosphorylating the inhibitory tyrosine in the C-terminal tail of Lck, as well as the 
phosphatases CD45 and SHP1, which dephosphorylate the activation loop tyrosine in 
Lck.38 
Moreover, in resting T cells, the intracellular domains of the CD3? and ? chains are 
associated with the plasma membrane, preventing phosphorylation of the ITAM tyrosine 
residues by Lck.39 The interaction of these domains with the membrane are primarily 
mediated by clusters of basic residues that interact with negatively charged lipids, such as 
phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2).39 TCR 
activation by binding to an MHC:peptide complex on an antigen presenting cell induces 
local changes in the lipid composition of these TCR microclusters. 40 Importantly, the 
density of PS in the inner leaflet of the plasma membrane is reduced and thus the 
negative charge, inducing the dissociation of the CD3? and ? cytoplasmic domains from 
the plasma membrane. 40 
There is still some debate about these early steps of T cell receptor signaling and it is not 
fully understood how these events allow the T cell to discriminate between self and 
foreign. The nowadays most widely accepted model is the kinetic segregation model, 
which proposes a segregation of phosphatases like CD45 out of the close-contact zones 
formed by the interaction of the TCR and CD4 or CD8 with a peptide-MHC. This is 
explained by the size of CD45 which is too bulky to remain in the close contact zone 
with an APC. This segregation leads to a net increase of ITAM phosphorylation by the 
spatial separation from CD45. For downstream phosphorylation to be initiated, the 
interaction between TCR and peptide-MHC needs to be stable enough so that enough 
ITAMs are phosphorylated before dissociation occurs, which is only the case with high 
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affinity interactions. Therefore, the increase in phosphorylation at the TCR occurs in an 
antigen-specific way and allows for a discrimination between foreign and self-antigens.41 
However, only a small proportion of coreceptors are associated with Lck. Moreover, the 
associated Lck kinases can be in either an active or an inactive conformation.32 A recent 
study proposes a “coreceptor scanning” model explaining that of multiple coreceptors 
which rapidly bind and unbind the TCR-peptide-MHC complex, only the ones that are 
bound to active Lck will promote TCR complex phosphorylation. The authors propose 
this as the rate-limiting step in the kinetic proofreading of the events leading to signal 
propagation.42  
Once the TCR signaling is successfully initiated, different proteins are recruited to the 
LAT signalosome, leading to a number of downstream signaling events:  
(a) The recruitment of the guanine nucleotide exchange factor (GEF) Vav1 activates the 
small RHO GTPases CDC42 and RAC1, driving actin nucleation and the 
reorganization of the actin cytoskeleton, which is essential for T cell activation, 
proliferation, migration and adhesion.43  
(b) The upregulation of integrin affinity promotes cell adhesion.38 
(c) The activation of phospholipase C?1 (PLC?1) leads to the propagation of the signal 
into 3 major signaling pathways, all activating different transcription factors: (i) PLC?1 
hydrolyses PIP2 to generate the secondary messengers inositol-1,4,5-triphosphate (InsP3) 
and diacylglycerol (DAG). InsP3 causes the opening of Ca2+ channels in the ER 
membrane and subsequently in the plasma membrane.44 The resulting calcium influx 
activates the transcription factor NFAT and leads to actin remodeling.45 (ii) DAG 
activates protein kinase C (PKC) which, together with the recruitment of Grb2 and SOS 
to the LAT signalosome leads to the activation of the Ras-MAP kinase pathway and AP-1 
transcription factors.32 (iii) The activation of PKC also triggers the assembly of the 
CARMA1-BCL10-MALT1 complex which leads to the activation and translocation of 
NF-?B into the nucleus.46  
The activation of all these transcription factors leads to changes in gene expression that 
are necessary for T cell growth and differentiation as well as cytokine release. In addition 
to the assembly of the LAT signalosome, the TCR and the costimulatory molecule CD28 
activate PI3K. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) in the 
membrane to yield phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting ITK 
kinase to the membrane. ITK phosphorylates PLC?1, thereby contributing to its 
activation.47 This requirement for a costimulatory molecule to elicit a full T cell 
activation prevents self-reactive T cells from being activated by the engagement of their 
TCR alone. All these processes contribute to the differentiation of the responding T cell 
into an effector T cell and to its proliferation. Figure 1.3 provides an overview of these 
different signaling pathways. 
    7 
 
Figure 1.3 Overview of TCR signaling. The first molecule to be recruited to the TCR–CD3 complex 
upon binding of a peptide:MHC is Lck, which phosphorylates ITAMs of the CD3 ?, ? and ? chains and 
the ? chains. Phosphorylation of the ? chain ITAMs enables the recruitment of Zap70, its phosphorylation 
by Lck and its activation. Activated Zap70 phosphorylates four key tyrosine residues on LAT, which 
recruits numerous signaling molecules to form a multiprotein complex, termed the LAT signalosome. 
Important molecules that constitute this complex include PLC?1, GRB2, GADS, SLP76, ADAP, ITK, 
NCK1 and VAV1. The LAT signalosome propagates signal branching to three major signaling pathways, 
the Ca2+, the MAP kinase and the NF-?B signaling pathways, leading to the mobilization of transcription 
factors that are critical for gene expression and essential for T cell growth and differentiation. Signals 
initiated from the TCR also result in actin reorganization and the activation of integrins by inside-out 
signaling. (Figure from 38) 
1.3.2? The Abl kinase family 
The Abl family of cytoplasmic tyrosine kinases counts only two members: c-Abl (ABL1, 
Abelson tyrosine kinase) and Arg (ABL2, Abl related gene). Both c-Abl and Arg are 
highly conserved and ubiquitously expressed. The localization of c-Abl in the cell is 
mostly cytoplasmic, but can also be found in the nucleus, at different intracellular 
membranes, bound to the actin cytoskeleton or in the mitochondria depending on the 
tissue and on external stimuli.48,49 c-Abl is implicated in a whole set of cellular activities 
like cell cycle regulation, actin dynamics, migration and oxidative stress and DNA 
damage response.49,50 
1.3.3? Abl and Src tyrosine kinase regulation 
Members of both the Abl and Src families of kinases share a similar domain organization. 
(Figure 1.4) The kinase domain is preceded by a Src-homology-2 (SH2) and a Src-
homology-3 (SH3) domain, which both play an important role in target recognition and 
binding as well as in protein regulation.50 The N-terminal region of both kinases contains 
post-translational modifications, in Abl kinases it is myristoylated and in Src-family 
kinases both myristoylated and palmitoylated.  
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Figure 1.4 Domain structures of the Src and Abl tyrosin kinase families as well as the oncogenic fusion 
kinase Bcr-Abl. (Figure modified from 50) 
Since members of the Src and Abl families control many aspects of cell growth and 
differentiation, their catalytic activity must be under tight control. The deregulation of 
protein kinases through mutations or other structural changes can lead to the activation 
of the kinase, uncontrolled cell growth and cancer. In healthy cells, kinases are therefore 
mostly found in an auto-inhibited conformation, which relies on a range of 
intramolecular interactions. The overall structures of auto-inhibited c-Abl and Src 
resemble each other but differ in some aspects between the Abl and the Src family. 
(Figure 1.5) 
Even before the first crystal structures were available, several groups have found that a 
tyrosine residue in the activation loop of the kinase domain (Tyr-416 in Src) needs to 
become phosphorylated for full activity of the enzyme.51,52 Another tyrosine residue, Tyr-
527, which is located in the C-terminal tail of Src family kinases, was found to render the 
enzyme less active when phosphorylated.53 In vivo, Tyr-527 gets phosphorylated by the 
Src-specific kinase Csk54 or its homolog Chk.55,56 
The first crystal structures of nearly full-length c-Src57,58 have shown that the SH3 and 
the SH2 domains pack against the N and C lobes, respectively, of the kinase domain, 
opposing the active site.59 Together, they form a clamp, which keeps the kinase domain 
in an inactive conformation. The SH3 domain binds to a proline-rich region in the 
segment that links the SH2 domain and the N lobe of the kinase (SH2-linker) and to the 
N-lobe itself.60,61 In Src-family kinases, the SH2 domain binds to a phosphorylated
tyrosine residue (Tyr 527 in Src) in the C-terminal tail of the protein.62 In c-Abl, the
much larger last exon region replaces this C-terminal tail, and the clamp is held in place
by a tight protein–protein interface between the SH2 domain and the C-lobe of the
kinase domain.
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Figure 1.5 Structures of regulated c-Abl in complex with the kinase inhibitor PD166326 (left, PDB 
entry 1OPK) and c-Src in complex with the ATP analogue AMP-PNP (right, PDB entry 2SRC). 
(Figure from 50.) 
Another difference between Abl and Src auto-inhibiton lies in the conformation of the 
kinase domain itself. In Src-family kinases, the SH2-SH3 clamp imposes a closed 
conformation on the kinase domain. In this closed conformation, the activation loop 
forms a helix situated between the N-and C-lobes, burying and thereby protecting Tyr-
416 from phosphorylation and preventing the access of the substrate and ATP to the 
active site.59 Moreover, Glu-310 in the ?C-helix of Src is turned away from the active 
site, which disrupts a critical salt bridge with the catalytic lysine (Lys-295 in Src). 59,61  
In contrast to Src kinases, the Abl kinase domain must be in an open conformation to 
allow the tight binding of the C-lobe with the SH2 domain.  
Another particularity of Abl kinase is the myristoylated N-terminal peptide of c-Abl, 
which binds to a hydrophobic pocket in the C-lobe, causing a conformational change 
that breaks a C-terminal ?-helix and renders the C-lobe accessible for docking of the 
SH2 domain.63 The N-terminal domain harboring this myristoylated tail is called “cap” 
region. In Src-family kinases, it is replaced by the SH4 domain, which can also contain 
myristoyl and/or palmitoyl groups. However, they are not involved in kinase inhibition, 
but in anchoring the protein to membranes.64  
1.3.4? The Bcr-Abl fusion protein is the hallmark of chronic myeloid 
leukemia 
Much like Src, the c-Abl gene was discovered as the cellular homologue of a transforming 
gene from a virus. Abelson murine leukemia virus (A-MuLV) was first isolated in 1970 
by Abelson and Rabstein from a mouse infected with Moloney murine leukemia virus 
(Mo-MuLV), which developed unusual tumors of the lymph node. This virus causes an 
oncogenic transformation of B-cells, and its transforming gene was named v-Abl.65 
Chronic Myeloid Leukemia (CML) is a cancer of the blood characterized by the 
expansion of myeloid cells. The disease can be divided in three phases: The chronic phase 
during which myeloid progenitor cells expand from stem cells in the bone marrow but 
differentiate in a normal way. This phase is largely asymptomatic. Several years later, the 
disease progresses into the second phase called accelerated phase, marked by a substantial 
increase in myeloid cell expansion and thereafter reaches blast crisis. This final phase is 
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marked by a block of the hematopoietic differentiation and the blast cells accumulate in 
both the blood and bone marrow, causing symptoms like fatigue, weight loss, increased 
infection rate, and upon disease progression also anemia, splenomegaly and 
thrombocytopenia.66 
Whereas the disease has been described as early as in 1845 by the pathologist John 
Hughes Bennet, its underlying cause was only defined in 1960 with the discovery of the 
Philadelphia chromosome by Nowell and Hungerford, the first discovered genetic 
aberration in cancer.67 The breakthrough then came when in 1973, when Janet Rowley 
discovered that the Philadelphia chromosome results from a translocation between 
chromosomes 9 and 22, creating a shorter version of chromosome 22, called Philadelphia 
chromosome.68 This translocation event fuses the gene encoding c-Abl kinase on 
chromosome 9 with the breakpoint cluster region (BCR) gene on chromosome 22. 
(Figure 1.6) The product of this fusion gene is a constitutively active tyrosine kinase 
called Bcr-Abl, which contains most part of the ABL1 kinase - only lacking the first few 
amino acids - and drives the oncogenic transformation of the myeloid cells giving rise to 
CML. Depending on the position of the break in the BCR gene, three main isoforms of
Bcr-Abl can occur, which are called p190, p210 and p230, based on their molecular
weight. Although the enzymatically active part of the encoded fusion protein, which lies
in the Abl kinase part, is the same in all 3 proteins, they are associated with different
types of leukemia.69
The p210 isoform is the hallmark of CML and a subset of B-cell acute lymphoblastic 
leukemia (B-ALL) patients, whereas the p190 isoform is only associated with the much 
more aggressive B-ALL type of leukemia. P230 occurs less often and is associated with 
chronic neutrophilic leukemia.71 In all 3 isoforms, a coiled-coil domain located in the 
amino-terminal region of Bcr is essential for the transforming function of the fusion 
protein, driving constitutive tyrosine kinase activation.72 Bcr-Abl activation then results 
in activation of major pro-proliferative and anti-apoptotic pathways, including the Ras-
MAP-Kinase, the PI3K-Akt and the STAT3/5 signaling pathways.  
9 22
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BCR Figure 1.6 The Bcr-Abl oncogene results from a 
translocation between chromosomes 9 and 22, 
creating the so-called Philadelphia chromosome. 
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1.4? Monobodies 
In addition to antibodies, several other protein scaffolds are being explored to create 
specific protein binders, able to disrupt protein-protein interactions, block active sites of 
enzymes or bind to allosteric regulatory sites in target proteins. Monobodies constitutes 
one example of such an alternative protein scaffold. 
Monobodies are small engineered proteins of 10 kDa that are based on the molecular 
scaffold of the 10th fibronectin type 3 (FN3) domain of human fibronectin. The FN3 
domain is part of the immunoglobulin superfamily and its structure resembles that of an 
antibody VH domain, except that it is composed of only 7 ??strands, connected by 3 
flexible loops on each side.73 Figure 1.7 A shows a comparison between an 
immunoglobulin domain and the FN3 domain.  
Figure 1.7 Monobody structure. A: Comparison of the structures of a variable domain of an antibody 
heavy chain (VHH, left) and the 10th fibronectin type 3 domain (FN3, right). B: Schematic showing the 
diversified amino acids (yellow spheres) in the monobody “loop” library (left) and “side and loop” library 
(right). (Figure modified from 74,75.) 
Large combinatorial libraries have been created by diversifying residues either in the loop 
regions only (loop-library) or in the ??strands as well as loop regions (side-and-loop 
library).74 (Figure 1.7 B) Potent binders are selected from these libraries by phage- and 
yeast-display. In multiple selection rounds, high affinity and specificity to their targets 
can be achieved, making monobodies a robust alternative to antibodies.75 A major 
advantage of monobodies in contrast to antibodies is that they do not contain disulfide 
bonds, making them functional in the reducing environment of the cytosol. They can 
therefore be used as genetically encoded inhibitors in mammalian cells and their 
expression in Escherichia coli is straightforward.73 
1.4.1? Monobodies interfering with Bcr-Abl signaling 
Several monobodies have already been developed in the lab of Shohei Koide as well as in 
our lab. HA4 was the first monobody selected to bind the SH2 domain of Abl and was 
shown to block Bcr-Abl-mediated Stat5 phosphorylation in cells, also demonstrating the 
utility of monobodies to dissect signaling networks.76 A tandem monobody between HA4 
and 7c12, which binds to an allosteric site in the SH2 domain of Abl, opposite to the 
HA4 binding site was later developed. This tandem monobody potently blocks the 
formation of the SH2-kinase interface necessary for Bcr-Abl activation and induces 
apoptosis in Bcr-Abl dependent cell lines.77 A second set of monobodies termed AS25 
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and AS27, targeting the SH2-kinase interface with higher affinity than 7c12 were able to 
inhibit Bcr-Abl signaling and induce apoptosis in Bcr-Abl dependent cell lines, without 
the need of a tandem to increase the local concentration.78  
1.5? Intracellular protein delivery 
1.5.1? Why is cellular protein delivery desirable? 
Since the introduction of the first therapeutic antibodies in the clinic – Rituximab 
(Rituxan/Mabthera) targeting CD20 and the HER2 antagonist Trastuzumab (Herceptin) 
– we see a rapid growth of protein-based therapeutics in the pharmaceutical industry as 
well as in academic research.79 Protein-based inhibitors are a promising alternative to 
small molecules. Protein-protein interactions mostly involve a larger surface interaction 
than protein-small molecule interactions, including regions outside of the active site of 
the enzyme, which can promote a higher selectivity.80 Moreover, many non-enzymatic 
proteins lack defined substrate binding pockets which could be used as binding sites for 
small molecules.81 
Currently, antibodies are the best represented class of protein-based therapeutics on the 
market, and many alternative scaffolds are being explored to enlarge the spectrum of 
possible protein-based therapeutics.75,79,82 
However, most proteins are not readily able to cross the cell membrane to reach potential 
intracellular targets and are therefore limited to extracellular or receptor targets.81 As a 
result, different approaches for the delivery of proteins to the cytosol of mammalian cells 
are being explored. Additionally, the possibility to use viral carriers to deliver exogenous 
protein-encoding nuclear acids has been extensively studied, yet this approach is 
hampered by the safety issues related to genetic modifications.83,84 
Direct protein delivery approaches are ranging from the use of cell-penetrating peptides, 
over numerous different nanocarriers to bacterial toxin domains as carriers to transport 
the payload across cell membranes. I will present a few approaches here as well as their 
advantages and limitations. 
 
1.5.2? Cell penetrating peptides 
The first protein which was discovered to enable cell membrane permeability was the 
trans-activating (Tat) protein on the surface of the human immunodeficiency virus 
(HIV).85,86 The smallest peptide sequence endowing the Tat protein with this property 
was soon identified to be a 13 amino acid sequence rich in positively charged amino acids 
and named Tat peptide (GRKKRRQRRRPPQ).87 Other peptides able to deliver cargo 
like fluorescent dyes or RNA into cells were discovered, most of which also have a very 
high positive net charge. The most widely used ones include the third helix of the 
homeodomain of the Drosophila protein antennapedia which is called pentratin 
(RQIKIWFQNRRMKWKK), and a sequence of 9 arginine residues called polyarginine 
(R9).88,89 These positively charged peptides are believed to interact with the outer leaflet 
of mammalian cell membranes by engaging negatively charged glycosaminoglycans like 
heparin sulfate on the surface.90,91 Especially arginine is believed to be essential, since its 
guanidine head can form bidentate hydrogen bonds with negatively charged groups. The 
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mechanism by which the peptide-cargo is then translocated into the cytoplasm after this 
first binding step is still under debate and is likely to differ between CPPs and cargos. In 
addition to the electrostatic interactions that can induce the direct uptake of small 
peptides through the lipid bilayer,92 different endocytic mechanisms are thought to play a 
major role. These include macropinocytosis, clathrin-mediated endocytosis, caveolae-
mediated endocytosis and clathrin/caveolae-independent endocytosis, the preferred 
mechanism depending on the size and charge of the attached cargo, the peptide sequence 
as well as the cell type specific membrane composition.93,94 Local membrane 
destabilization and pore formation have also been proposed to contribute to peptide-
cargo uptake.95 
Another type of CPPs are amphipathic peptides, presenting a helical fold of which one 
side is hydrophilic and the other side is hydrophobic, favoring interactions with the 
hydrophobic tails of membrane lipids. The model amphipathic peptide (MAP, 
KLALKLALKALKAALKLA)96 is one example, as well as Pep-1 
(KETWWETWWTEWSQPKKKRKV)95,97 and transportan.98 Some amphipathic CPPs 
like buforin-II have been derived from antimicrobial peptides, which often act by 
damaging bacterial membranes.99 
Despite the multitude of different CPPs that have been described, they all share a 
number of drawbacks. Most CPPs unspecifically bind to and are taken up in any cell 
types. This lack of specificity has been partially overcome by conjugation with receptor-
binding moieties or the selection of CPPs to specifically bind a certain cell type, although 
the molecular mechanism for CPP-cell selectivity remains unclear.100 Moreover, many 
groups use enzymes like Cre-recombinase or fluorescent dyes or proteins as cargo, to 
provide a proof-of-concept of the studied CPP. However, an extremely low 
concentration of cargo reaching the cytosol is often sufficient to see a qualitative effect. 
Most studies lack a precise quantification of the amount of the delivered cargo, which 
makes it impossible to assess and compare the efficiency of these systems. 
1.5.3? The endosomal escape problem 
Another well-known limitation of CPPs and of other approaches is the endosomal 
entrapment and subsequent lysosomal degradation of CPP-cargo conjugates. The 
amount of protein reaching the cytosol is limited and varies with the CPP itself, the cargo 
and the cell line used. 36-aa miniature proteins have been optimized to escape endosomes 
by clustering arginine residues on the same face of an ?-helix.101 So-called proton-sponge 
polymers like polyethylenimine (PEI) are believed to mediate endosome bursting by 
making use of the pH change occurring during endosome maturation - the pH in early 
endosomes is 6.5, it then drops as they mature into late endosomes while in lysosomes 
the pH is about 4.5. These polymers contain many secondary and tertiary amines and 
have pKa values between the physiological and lysosomal pH. During the acidification of 
endosomes, they get protonated and thereby act as a buffer, causing the ATPase at the 
membrane to transport more protons in an attempt to reach the desired pH. The 
accumulation of protons is counterbalanced by the enhanced influx of chloride ions, 
leading to osmotic swelling and lysis of the endosome.102-104 Some naturally occurring 
peptides rich in glutamate, aspartate, and histidine show similar properties. These amino 
acids can be protonated at low pH and act as a proton sponge.105, 106 Examples include the 
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major component of bee venom, melittin, and H2A, a peptide rich in glutamate derived 
from the hemagglutinin H2A subunit of the influenza virus.107,108   
Aromatic ring containing residues like tryptophan and phenylalanine have also been 
shown to favor endosomal membrane destabilization by insertion into the lipid bilayer.109 
Kim et al. described an antibody that can induce membrane destabilization through 
structural changes exposing a so-called endosomal escape motif, rich in aromatic residues. 
After internalization, the acidic pH in the endosomes protonates aspartate and glutamate 
residues in the antibody, which thereby become more hydrophobic, facilitating 
hydrophobic interactions with other residues. This leads to structural changes in the 
antibody, the endosomal escape motif YYH becomes exposed and the clustered aromatic 
side chains intercalate into the endosomal membrane. When a critical concentration is 
reached, the antibody escapes into the cytosol by inducing membrane lipid flip-flop and 
pore formation.110 
The group of Shiroh Futaki introduced a novel endosomolytic peptide derived from the 
cationic and membrane-lytic spider venom peptide M-lycotoxin. By simple co-delivery, 
they showed cellular uptake of Cre recombinase, Saporin, which is a protein that is 
cytotoxic at low concentrations, and an IgG antibody.111 
1.5.4? Cell penetrating polydisulfides (CPDs) 
Cell penetrating polydisulfides (CPDs) are poly(amino amine)s containing disulfide 
linkages in their amino units.112 Gasparini and colleagues introduced a method to grow 
CPDs directly on the cargo to deliver, using it as a substrate for polymerization 
initiation.113 A thiol group on the substrate acts as an initiator of the polymerization. A 
monomer composed of a lipoic acid bound to an arginine readily forms a covalent 
disulfide bond with the initiator, by nucleophilic disulfide exchange. This reaction also 
generates a reactive thiol to attack the next monomer, starting the polymerization. The 
polymerization is terminated by addition of iodoacetamide, which allows for some 
control over the polymer length by the timepoint of termination.  
The authors propose a combination of counter-ion mediated translocation, which is 
similar to what has been proposed for CPPs, and thiol-mediated translocation as uptake 
route.113 They hypothesize that CPDs bind covalently to the membrane surface by 
disulfide exchange with exofacial thiols, and cross the membrane along transient micellar 
defects, upon which they detach into the cytosol by disulfide exchange with intracellular 
glutathione.114 They claim endocytosis to be almost irrelevant, and thereby also 
endosomal entrapment. The self-inactivation by glutathione immediately after reaching 
the cytosol would explain the non-toxicity of CPDs. In the initial study, fluorophores 
have been used as polymerization initiators, which allowed the visualization of the uptake 
in HeLa cells. However, proteins cannot be used as substrates directly, due to the 
denaturing polymerization conditions. Two following studies simultaneously published a 
strategy linking a biotin to a thiol group in the initiator. The resulting biotinylated CPD 
is then used to form complexes with tetrameric streptavidin and biotinylated 
proteins.115,116 The successful uptake of these complexes, which were visualized by adding 
fluorescently labeled biotin, into HeLa cells was shown. Fu et al. also used NTA as an 
initiator and coupled the resulting CPD to a His-tagged caspase-3, which induced 
apoptosis in the delivered cell line upon delivery, showing that functional caspase-3 had 
reached the cytosol. Furthermore, they functionalized a fluorescently labelled antibody 
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with a bis-sulfone reagent to covalently attach it to a tetrazine-CPD and demonstrated its 
delivery based on fluorescent imaging.115 
1.5.5? Bacterial toxins 
Bacterial toxins could overcome the limitations of CPPs and other protein delivery agents 
in terms of cytotoxicity and endosomal entrapment, as they have naturally evolved to 
deliver their payload to host cells and to escape endosomes. Moreover, they require 
binding to a specific host cell receptor for their entry, making them cell-selective. 
Of particular interest for protein delivery are the so-called AB toxins, which are 
composed of two subunits, A (for activity) and B (for binding). The A subunit is the 
toxic protein while the B subunit binds to a specific receptor on the cell membrane and 
facilitates the internalization.117 AB-toxins typically need to be proteolytically cleaved in 
order to release their active A-subunit.118 In some cases, the cleavage occurs in the 
bacteria, like for cholera toxin, other toxins, like Diphtheria toxin, Shiga toxin and 
Pseudomonas Exotoxin A, contain a furin cleavage site which is processed in the target 
cell.118,119 
For Anthrax and Clostridium botulinum C2 toxins, the B-subunit first needs to be 
processed and to oligomerize for the A-subunit to bind non-covalently.120,121 Most of 
these toxins are internalized via endocytosis, but the mechanisms of translocation to the 
cytosol vary. Shiga toxin, Cholera toxin and Pseudomonas Exotoxin A utilize the host 
cell’s retrograde trafficking machinery to reach the cytosol via the trans-Golgi-network 
and endoplasmic reticulum (ER)122, while Diphteria and Anthrax toxins rely on the 
acidification of the endosome to translocate directly to the cytosol.123 In the case of 
Anthrax toxin, the low pH triggers a conformational change in the protective antigen 
(PA) or B subunit heptamer to form a pore through which the effector proteins are 
transported to the cytosol.124 
Many bacterial AB-toxins have been explored for the delivery of exogenous proteins, by 
either replacing the A subunit, or by fusion to a mutated A-subunit. Here I will describe 
a few of them more in detail and point out the advances made for the delivery of 
exogenous proteins. 
1.5.5.1? Anthrax toxin 
Anthrax toxin is a virulence factor secreted by Bacillus anthracis that is composed of 3 
distinct proteins: the receptor targeting and pore forming protective antigen (PA), the 
lethal factor (LF), which can bind cleaved PA by its N-terminal domain and edema factor 
(EF).125 PA mediates the transport of the enzymatically active LF and EF into the cytosol 
of mammalian cells, where they exert their cytotoxic activity. Full length PA (83 kDa) 
binds to the host cell receptors Capillary Morphogenesis protein 2 (CMG2) and Tumor 
Endothelial Marker 8 (TEM8) and gets cleaved by a protease of the furin-family to yield 
a 63-kDa isoform that forms ring-shaped heptamers on the cell surface.121,126-129 LF and 
EF can bind to these heptamers and the whole complex is taken up via clathrin-mediated 
endocytosis.130,131 Early studies have shown that even exogenous proteins bound to the 
truncated and inactive N-terminal domain of LF are taken up into the cytosol when 
administered together with PA.132 Following studies have focused on the delivery of 
peptides for vaccine development133, enzymes134 or toxins135,136, of which a few copies are 
sufficient to see the desired effect. However, it is difficult to measure the exact amount of 
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protein reaching the cytosol and to assess whether exogenous proteins also reach the 
cytosol with a similar efficacy as EF and LF or whether the majority stays in endosomes. 
In 2014, Liao et al. used this system to deliver diverse antibody mimics including 
monobodies, aiming at perturbing intracellular protein-protein interactions. They used 
the tandem monobody HA4-7c12, designed to bind Bcr-Abl and interfere with 
downstream signaling77, and could indeed induce apoptosis in a fraction of cells.137 
However, they only observed a modest decrease in activation loop phosphorylation of 
Bcr-Abl. They reasoned that this modest effect, which is much lower than that achieved 
by the small molecule Abl-inhibitor Imatinib or transfection of HA4-7c12, is due to the 
low concentration of the monobody reaching the cytosol.137 Even though the cytosolic 
delivery was rather inefficient, this study serves as a proof-of concept, that intracellularly 
delivered monobodies can perturb the activity of endogenous oncoproteins.  
In order to pass through the PA pore in the endosomal membrane, which can only 
accommodate structures of up to 15 Å in diameter, protein cargo must be at least 
partially unfolded by the PA’s intrinsic machinery.138,139 Verdurmen et al. found that 
exogenous proteins with a high thermodynamic stability are less efficiently translocated to 
the cytosol through the PA pore, and that the amount of protein reaching the cytosol can 
be increased by destabilizing the protein cargo.140 
1.5.5.2? Pseudomonas exotoxin A 
Exotoxin A (ETA) is a virulence factor secreted by the opportunistic bacterium 
Pseudomonas aeruginosa and consists of a single polypeptide chain composed of 3 
functional domains. Domain Ia binds to the cognate receptor of the toxin, ?2 
macroglobulin receptor/low density lipoprotein receptor on target cells.141 Domain II is 
also called translocation domain because it enables the toxin to translocate across cell 
membranes and domain Ib serves as a linker between domains II and III.142 Domain III is 
the catalytically active part of ETA, which acts as ADP-ribosyltransferase, potently 
inhibiting elongation factor 2, (eEF2) and thereby blocking protein synthesis in target 
cells.143 
After binding to the receptor, the toxin is internalized by endocytosis either via clathrin-
coated pits or by association with lipid rafts and caveolin-mediated endocytosis.144 
In the early endosome, the toxin undergoes a conformational change, exposing a furin-
cleavage site in the translocation (II) domain. After cleavage by a cellular furin protease, 
the disulfide bond still connecting the two fragments is reduced by protein-disulfide 
isomerases, and a 37-kDa fragment is detached, containing domain III and part of 
domain II.145 After transport to late endosomes, this fragment reaches the ER via two 
different pathways. It can exploit a pathway regulated by the GTPase Rab9 to traffic to 
the trans-Golgi-network (TGN) and then bind to KDEL receptors cycling between the 
TGN and ER via its C-terminal REDL motif.146 It can alternatively reach the TGN by a 
Rab-9 independent pathway and then utilize a Rab6-controlled lipid-dependent sorting 
pathway to reach the ER.147,148 
The 37-kDa fragment comprising the cytotoxic domain III is then shuttled from the ER 
to the cytosol by the cellular ER-associated protein degradation pathway (ERAD).149 
Sequences inside the PE-domain II are recognized by the Sec61 translocon, which 
normally exports unfolded or misfolded proteins from the ER to the cytosol for 
subsequent proteasomal degradation.150,151 How the toxin then escapes the proteasome 
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once it reaches the cytosol is not completely understood, it might simply avoid 
recognition by ubiquitin ligases because of the lack of any lysine residues to covalently 
attach ubiquitin.  
 
In order to create targeted chimeric toxins, Domain I has been replaced by different 
receptor-binding ligands or antibody domains to redirect the toxin to specific cell types, 
creating a whole set of different immunotoxins.152,153  
Mohammed et al. for the first time used the translocation domain II only, to deliver 
exogenous molecules into cells. They fused it to polyarginine (R10), a cationic CPP, 
which, used on its own, leads to internalization and endosomal entrapment of the cargo. 
The combination of polyarginine with Pseudomonas exotoxin domain II enabled the 
cytosolic delivery of the green fluorescent protein eGFP into HeLa cells.154 It is 
presumably taken up by the same entry route as the full-length toxin, as it co-stains with 
ER markers after 4-8 hours. Unfortunately, the authors did not demonstrate the delivery 
of any functional protein by this method. 
Verdurmen et al. have used the translocation domain of Exotoxin A with the same 
domain boundaries and expressed it as a fusion protein with a designed ankyrin repeat 
protein (DARPin) for EGF receptor targeting and another DARPin as cargo.140 They 
have developed a biotin ligase assay that allows to precisely quantify the amount of 
protein reaching the cytosol after delivery. It is based on the prokaryotic biotin ligase 
BirA, which specifically recognizes and biotinylates a 15-amino acid tag called Avi-tag 
fused to the delivered cargo protein.140 Since BirA is only expressed in the cytosol of 
reporter cell lines, only the cytosolically delivered cargo is detected by streptavidin in 
western blots of cell lysates.140 Using this assay, they showed that their cargo DARPin was 
efficiently delivered to the cytosol, and that even thermodynamically very stable 
DARPins were successfully translocated from the ER to the cytosol, in contrast to 
proteins delivered by Anthrax protective antigen pores.140 This is presumably due to the 
more potent cellular machinery used for unfolding prior to translocation by the ER 
associated degradation pathway.140 However, this study is lacking a functional assay, 
showing that the delivered proteins are well folded and still able to bind their target once 
they reach the cytosol. 
A slightly shorter version of the translocation domain was used by the group of Hak-
Sung Kim, who fused it to an EGFR binding repebody, another alternative scaffold 
binder, to achieve targeting to EGFR expressing cancer cell lines.155 They used this 
construct to deliver the ribosome-inactivating plant toxin Gelonin, which induced tumor 
regression in a xenograft mouse model.155 Since this is a very potent toxin, the delivery of 
extremely low concentrations to the cytosol is probably sufficient to reach a cytotoxic 
concentration. 
1.5.5.3? Diphtheria toxin 
Diphtheria toxin (DT) is secreted by Corynebacterium diphtheria and is in many ways 
very similar to exotoxin A. It also consists of a single polypeptide chain, which is 
proteolytically cleaved into fragments A and B which remain linked by a disulfide 
bond.156 Its catalytic domain residing in fragment A follows the same host cell killing 
strategy as Exotoxin A, by inhibition of elongation factor 2 (eEF2).156-158  The B domain 
can be separated into the alpha-helical transmembrane (T) domain and the receptor 
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binding (R) domain with a beta-barrel structure.156-158 The R domain binds to the 
membrane-anchored form of heparin-binding EGF-like growth factor (pro-HB-EGF).159 
Receptor bound toxin is internalized by clathrin-dependent endocytosis and the acidic 
environment in the endosome then triggers the refolding of the transmembrane domain 
(T), leading to its insertion into the endosomal membrane to form a 18–22 Å pore.160,161 
The catalytic domain is at least partially unfolded to enable its translocation through the 
pore, and is released into the cytosol upon reduction of the disulfide bond between 
fragments A and B.162,163 
Auger et al. have shown that both the green fluorescent protein eGFP and the 
thermodynamically more stable red fluorescent mCherry proteins can be translocated as 
passenger proteins into the cytosol when fused to wild-type or catalytically inactive 
diphtheria toxin. These results suggest that cargo proteins do not need to unfold in order 
to be translocated through the pore formed by the transmembrane domain. They also 
showed the delivery of functional ??amylase into cells, even though it only showed a 
limited effect on the cellular glycogen content.164 However, the question remained, 
whether is it feasible to stoichiometrically target highly abundant intracellular proteins.165 
In order to answer this question, a precise method to quantify the amount of the 
delivered protein in the cytosol is first needed. Attempts based on fluorescence or cellular 
fractionation are prone to artifacts and are rather unprecise.166,167 
Verdurmen et al. were the first to conduct a comparative study to quantified the cytosolic 
uptake of cargo proteins delivered to four different cell lines using different bacterial 
toxins, supercharged proteins and cell penetrating peptides, using their previously 
introduced biotin ligase assay.168 
The bacterial toxins studied were Anthrax protective antigen, catalytically inactive 
Diphtheria toxin and the translocation domain of Pseudomonas exotoxin A. 168 Whereas 
cargo delivered by Anthrax or Pseudomonas toxin domains reached the cytosol in high 
concentrations, cytosolic delivery by diphtheria toxin was only achieved in one out of 
four cell lines.168 
1.5.5.4? Shiga toxin and Shiga-like toxins 
Shiga toxin was discovered in 1897 by Kiyoshi Shiga to be secreted by the pathogenic 
Shigella dysenteriae and is the prototype of the Shiga-toxin family.169 This family also 
includes its very close homologue Shiga-like toxin 1 (Stx1), which differs only in one 
amino acid from Shiga toxin and is secreted by Shiga-like toxin producing Escherichia 
coli (STEC).170,171 This pathogenic E. coli strain can produce two variants of Stx1 (Stx1 
and Stx1c) as well as five different variants of Shiga-like toxin 2 (Stx2, Stx2c, Stx2d, 
Stx2e, Stx2f), which cause more severe disease. Stx2 is only 56% identical to Stx1 at the 
amino acid level, and the Stx2 variants are 84-99% homologous to Stx2.172 Shiga-like 
toxins are also called verotoxins, based on the discovery in 1977 that they kill Vero cells 
in culture.173 STEC serotype O157:H7, also called enterohaemorrhagic Escherichia coli 
(EHEC), causes the most severe forms of hemorrhagic colitis in humans, which 
progresses to the life-threatening haemolytic uraemic syndrome (HUS) in about 15% of 
patients.174-176  
Both Shiga toxin as well as all Shiga-like toxins share the same cellular receptor, the 
neutral glycosphingolipid globotriaosylceramide (Gb3; also known as CD77). All Shiga 
toxin family members have a very similar structure, where the B subunit forms a 
pentamer to which one A-subunit is non-covalently bound.177,178 Each B-subunit 
monomer can bind up to three Gb3 molecules on the cell surface, so that each AB5 unit 
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binds up to 15 Gb3 units.179-182 This way, B-subunit binding to Gb3 induces receptor 
clustering on the cell membrane and membrane invaginations. The toxin is then taken 
up by clathrin-independent and clathrin-dependent endocytosis. Which of these 
mechanisms is predominant, is still a subject of debate.183 From early and recycling 
endosomes, Shiga toxin is transferred by the retrograde transport route to the trans-Golgi 
network (TGN), in a process dependent on the recruitment of clathrin to the endosome 
by EpsinR and on the retromer complex.184 This pathway is different from the recycling 
pathway of the mannose-6-phosphate receptor between late endosomes and the TGN.172 
The toxin is then transported from the TGN through the Golgi apparatus to the ER in a 
coat protein complex I (COPI)-independent manner.185  
In the early endosome, the A subunit of the toxin gets cleaved by the endoprotease furin 
at a consensus cleavage site close to the B-subunit binding site, dividing it into the 
catalytically active A1 fragment and the short A2 fragment which is bound to the B 
subunit pentamer.186,187 The 2 fragments stay linked by a disulfide bond, which is only 
cleaved once the toxin reaches the ER.172, 188 The A1 fragment then uses the cellular ER-
associated protein degradation (ERAD) pathway by binding to human ER-associated 
DNA-J protein 9 (HEDJ) and the Sec61 translocon to unfold and translocate to the 
cytosol, in a similar fashion as the catalytically active fragment of Pseudomonas exotoxin 
A.189 (Figure 1.8 and Figure 1.9)  
 
Figure 1.8 Overview of intracellular trafficking of Shiga toxins. (Figure from 172.) 
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The Shiga toxin B subunit has been used for immunotherapy applications, to deliver viral 
or cancer antigens to dendritic cells, where they are presented on major 
histocompatibility complex class I (MHCI) molecules and can induce a cytotoxic T 
lymphocyte response.190-193 
Moreover, since Gb3 is upregulated on a number of cancers, including colorectal, breast 
and ovarian carcinomas and Burkitt’s lymphomas172, diverse cytotoxins and contrast 
agents have been coupled to the Shiga toxin B for tumor targeting and imaging.194 El 
Alaoui et al. have coupled a prodrug based on SN-38, a camptothecin derivative that 
inhibits topoisomerase I and is used to treat colorectal cancer, to the Shiga toxin B 
subunit to achieve better cancer cell selectivity.195 Photosensitizing compounds have also 
been bound to Shiga toxin B subunit to improve specific cellular delivery and cell killing 
by exposure to light.196,197 
The group of Hak-Sung Kim has fused the green fluorescent protein EGFP to a 
truncated, inactive A subunit, which still contains the furin-sensitive loop as well as the B 
subunit binding part.198 They expressed and purified it as a fusion construct with the B 
subunit, with a ribosome binding site 5’ to the EGFP-A-subunit and 5’ to the B subunit, 
so that both the whole protein as well as B subunit alone are expressed.198 They showed 
that the truncated A subunit fused to EGFP bound to the pentameric B subunit in the 
same way as wild type Shiga toxin and that it was able to deliver EGFP to Vero cells.198 
They also demonstrated that the receptor targeting of StxB can be changed, by fusing an 
integrin-binding protein to the B subunit that they mutated to abolish Gb3 binding.198 
In a second study, they combined the receptor binding domain of Shiga-like toxin (B 
subunit) and the translocation domain of Pseudomonas aeruginosa exotoxin A to create a 
more potent delivery system. They argue that this system is more versatile than Shiga-
toxin alone, since it allows the fusion of diverse cargos, which was not possible with the 
previous construct.199 They then used it to deliver different enzymes, including luciferase 
and adenylate cyclase, as well as the 12-amino acid peptide N8A, a mouse double minute 
2 (MDM2) inhibitor.199 For all these cargos, a small number of molecules reaching the 
cytosol are likely to be sufficient to elicit a cellular response, and a quantification of the 
delivery efficiency was not shown.  
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Figure 1.9 The Endoplasmatic Reticulum-Associated Degradation (ERAD) pathway. A: misfolded 
proteins are unfolded by a multi-chaperone complex and translocated to the cytosol through the Sec61-
associated translocon channel. In the cytosol, they are ubiquitinated and degraded. B: Following cleavage 
by furin, the Shiga toxin A subunit is released from the B subunit following disulfide bond reduction. The 
A subunit associates with host ER chaperones and is translocated into the cytosol through the Sec61-
associated translocon channel. In the cytosol, it avoids proteasomal degradation, presumably due to a lack 
of lysine residues. (Figure from 172) 
1.6 Targeted degradation 
Methods to remove distinct endogenous proteins from the proteome in a targeted way 
are of great utility for research and therapy. Currently, this is mostly achieved through 
modifications of the genome or transcriptome, either by using DNA knockout, DNA 
editing or RNA interference. Recently, endogenous proteins have been directly targeted 
for degradation by making use of the cellular ubiquitination and proteasomal degradation 
machineries.
Fulcher et al have developed the so-called affinity-directed protein missile system 
(AdPROM), which directs an E3 ubiquitin ligase to the protein of interest by means of 
alternative scaffold protein binders, like monobodies.200,201 The monobody, or other 
protein binder of choice, is genetically fused to the Von-Hippel-Lindau (VHL) protein, 
and the construct is introduced into the target cells by transfection or viral transduction. 
VHL is the substrate receptor for the E3 ubiquitin ligase complex composed of Cullin 2, 
the RING-box protein 1 (RBX1) E3 ubiquitin ligase and the adaptor proteins Elongin B 
and C.202 Upon expression of the VHL-monobody fusion, this complex will be recruited 
to the monobody target, which induces its ubiquitination by the RBX1 E3 ubiquitin 
ligase and subsequent degradation by the proteasome.200 (Figure 1.10 A)
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The authors have demonstrated the efficacy of this system for the degradation of the 
phosphatase SHP-2 by monobodies as well as ASC (Apoptosis-associated speck-like 
protein containing a CARD), a common adaptor protein of inflammasomes, using a 
nanobody.201  
The PROTAC (proteolysis targeting chimera) approach is also harnessing the VHL-
ElonginB/C-Cullin2 complex for targeted protein degradation, however, PROTACS are 
composed of two small molecules covalently linked via a PEG linker. One small molecule 
is a VHL-ligand and the other can in principle be any drug or other small molecule 
binder to a target protein of choice.203 By binding to VHL and the target protein at the 
same time, the PROTAC brings them in close proximity and triggers the recruitment of 
the ElonginB/C-Cullin2 E3 ligase complex, inducing the ubiquitination and degradation 
of the target protein. Various PROTACs were constructed using thalidomide and its 
derivatives that bind and activate the cereblon substrate adaptor of the DDB1-Cullin4-X-
box E3 ligase complex.204 These PROTACs were used for the targeted degradation of a 
variety of substrates, such as Bcr-Abl kinase and the epigenetic regulator BRD4, which 
led to a suppression of the transcription factor myc.204 In contrast to the AdPROM 
approach, PROTACs are not degraded and can subsequently engage in another round of 
target binding. The PROTAC approach has been applied to a variety of target proteins, 
including receptor tyrosine kinases.205 (Figure 1.10 B) 
Even though the AdPROM approach is targeting endogenous proteins for degradation, 
there remains the need to genetically modify the cells and the method cannot be applied 
to non-dividing primary cells where genome-editing is limited. 
In order to overcome this limitation, Clift et al. have developed a method to degrade 
endogenous proteins by microinjecting antibodies against the target protein.206 They 
make use of TRIM21, an E3 ubiquitin ligase expressed in diverse cell types that binds 
with high affinity to the Fc domain of antibodies.207 The targeted protein is degraded 
within minutes following antibody injection into cells.206 While in few cells, endogenous 
TRIM21 levels are sufficient to induce the ubiquitination and degradation of the target 
proteins, the authors had to overexpress TRIM21 in many cell lines in order to degrade 
the target protein efficiently. They reasoned that the antibody and TRIM21 protein 
become degraded at the same time as the target protein and therefore need to be present 
in excess, which can be achieved either by overexpressing TRIM21 genetically or by 
microinjecting recombinant TRIM21 protein along with the antibody.206 (Figure 1.10 C) 
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Figure 1.10 Methods for targeted degradation. A: AdPROM approach: protein 
binder(monobody/nanobody) fused to VHL recruits the ElonginB/C-CUL2 E3 ubiquitin compex to the 
target protein, which gets ubiquitinated and degraded. B: PROTAC approach working in the same way as 
the AdPROM approach, except that a fusion small molecule (PROTAC) composed of a VHL-binder and a 
target protein-binder brings the target protein in close proximity to VHL, leading to its ubiquitination and 
degradation. C: TRIM-away approach: An antibody binding a target protein is delivered by electroporation 
and reruits TRIM21, inducing the ubiquitination and degradation of the target protein. (Figures modified 
from 201,206,208) 
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2? Results 
2.1? Monobodies targeting Src-family kinases (SFKs) 
The aim of this project was to develop and characterize monobodies that disrupt the 
protein-protein interaction between SFKs and their substrates in a kinase-specific 
manner. Active SFKs bind to existing phospho-tyrosine residues in many of their 
substrates via the SH2 domain, enabling the phosphorylation of other critical tyrosine 
residues of the substrate. Small molecule ATP-competitive kinase inhibitors to SFKs are 
poorly selective and suffer from the rapid development of resistance through mutations in 
the binding site.2 Several SH2-domain targeting pY-peptides, peptidomimetics and small 
molecules have been developed, but they are unable to discriminate between the 
individual SFK SH2 domains or have not been tested against all family members.209 
Therefore, selective inhibitors are needed to study the regulation and activity of 
individual SFKs in cellular signaling and to inhibit SFKs involved in oncogenic signaling 
pathways driving cancer cells. Monobodies were developed to bind the SH2 domain of 
different SFKs, due to the central role of this pY-binding domain in substrate 
recognition. Parts of the results of this project have been published in the Journal of 
Molecular Biology, to which I contributed as a co-first author.210 
2.1.1? Selection of monobodies binding the SH2 domains of Src-family 
kinases 
The expression and purification of recombinant SFK SH2 domains and the selection of 
monobody binders was done by Dr. Tim Kükenshöner, a postdoc in our lab, during his 
visit in the laboratory of Prof. Shohei Koide, who has invented monobodies and has 
developed specific binders to a large variety of targets. Monobodies were selected from 
the “loop-only” and “side-and-loop” libraries against the 6 different SH2 domains of Yes, 
Src, Fgr, Hck, Lyn, and Lck, using phage and yeast display. Of each enriched pool of 
binders from the selection, 2 clones were characterized. Monobody clones were named 
Mb(SFK_x) throughout the publication, where x is the clone number. I keep this 
terminology only for this section (2.1.1) and the Figure 2.1 and Figure 2.2. For 
simplicity reasons, Mb(Lck_1) and Mb(Lck_3) will be named ML1 and ML3, 
respectively, the monobodies targeting Src will be named MS2 and MS8 and the 
monobodies targeting Yes will be named MY1 and MY3 in the following sections.  
The binding affinities of the different monobodies were determined using isothermal 
titration calorimetry (ITC) (Figure 2.1) as well as a yeast binding assay (Figure 2.2). Each 
monobody showed a higher affinity for the SH2 domain used in the selection than for 
the other SH2 domains. Moreover, in the yeast binding assay, monobodies selected 
against Yes, Src or Fgr (SrcA family) showed weak or no binding to the members of the 
SrcB family (Hck, Lyn, Lck and Blk) and the monobodies selected against Lyn, Lck or 
Hck did not bind to members of the SrcA family (Yes, Src, Fyn and Fgr). (Figure 2.1) 
For the monobodies selected against Lck, no binding could be measured to Src or Yes by 
ITC either, whereas Mb(Yes_1) is binding to Lck, although with a much weaker affinity 
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than to Yes. (Figure 2.2) These results showed a high sub-family specificity, which had 
previously not been achieved with other SFK inhibitors. 
Figure 2.1 Yeast binding assay of the selected monobodies to the SH2 domain of the different SFKs. 
Each panel shows the mean fluorescence signal of one monobody toward all tested targets at a 
concentration of 250 nM. For clarification, SrcA (Yes, Src, Fgr) and SrcB (Hck, Lyn, Lck, Blk) family 
members are subdivided by a dotted line. Each data point corresponds to the average of two repeats +/− 
SD. The data and graph were generated by Dr. Tim Kükenshöner and are taken from 208. 
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Figure 2.2 ITC measurements of different monobodies with SH2 domains. All calorimetric titrations of 
the monobodies with SH2 domain were performed at 25 °C. Each panel shows (at the top) the raw heat 
signal of an ITC experiment. The bottom panel shows the integrated calorimetric data of the area of each 
peak. The continuous line represents the best fit of the data based on a 1:1 binding model computed from 
the MicroCal software. A representative measurement is shown for each example with KD value and 
stoichiometry (N) calculated from the fit. A: Mb(Lck_1) (70 ?M) titrated to Lck (7 ?M), B: Lck (115 
?M) titrated to Mb(Lck_3) (11 ?M), C: Mb(Src_2) (180 ?M) titrated to Src (12 ?M), D: Blk (142 ?M) 
titrated to Mb(Lck_1) (13 ?M), E: Mb(Lck_3) (150 ?M) titrated to Blk (15 ?M), F: Mb(Yes_1) (215 
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?M) titrated to Lck (15 ?M), G: Mb(Lck_3) (140 ?M) titrated to Yes SH2 domain (15 ?M), H: 
Mb(Lck_3) (150 ?M) titrated to Fyn SH2 domain (15 ?M) and I: Mb(Yes_1) (400 ?M) titrated to Lck 
SH2 domain (40 ?M). The data was generated by Dr. Tim Kükenshöner and the figure is modified from 
210. 
2.1.2? Tandem affinity purification to determine monobody interactors 
In order to assess the selectivity of the monobodies in a complex cellular environment 
containing other SH2-domain containing proteins and other possible unrelated off-target 
proteins, I performed a tandem affinity purification (TAP) followed by tandem mass 
spectrometry of monobodies stably expressed in cell lines.211 
I cloned the cDNAs of monobodies MY1, MY3, MS2, MS8, ML1, ML3 into a vector 
containing the TAP tag, which consists of two copies of the B1 domain of staphylococcal 
protein G (2xProtein G), a TEV protease recognition site, a streptavidin-binding peptide 
(SBP), and a Myc-tag N-terminal to the monobody.211 (Figure 2.3 A) The chronic 
myeloid leukemia cell line K562 as well as the human embryonic kidney (HEK293) cell 
line were chosen to generate cell lines stably expressing the monobodies MY1, MY3, 
MS2 and MS8, and K562 cells as well as the T-cell acute lymphoblastic leukemia cell line 
Jurkat were transduced with the TAP-tagged ML1 and ML3 monobodies. The stable cell 
lines were generated by retroviral transduction and then sorted based on their expression 
of GFP, which is encoded on the same vector separated by an internal ribosome entry site 
(IRES). After confirming the expression of the monobody proteins, I expanded each cell 
line to a total number of 3x109 cells, of which half were taken for each TAP experiment. 
A TAP was then performed with the lysates of the K562 cell lines expressing the 
monobodies MY1, MY3, MS2, MS8, ML1 and ML3 and with the Jurkat cell lines 
expressing ML1 and ML3. The HEK293 cell pellets were frozen and stored for a back-up 
analysis if necessary. An immunoblot analysis against the myc-tag confirmed that the bait 
monobody can be followed throughout the different steps of the TAP and can be 
retrieved after the second purification step. (Figure 2.3 D, E and F). A silver gel analysis 
of the whole elution fraction after the second purification showed only few predominant 
bands, indicating that only the main interactors were pulled down together with the 
monobodies. (Figure 2.3 B and C) The strongest bands correspond to proteins of ~58 
kDa, which is the size of SFKs, as well as a band of 15 kDa, corresponding to the bait 
monobody. Additionally, an immunoblot analysis was performed to confirm the presence 
of the monobody targets in the pull-down. (Figure 2.3 D and F) The total elution 
fraction after the second purification was then separated on an SDS-PAGE gel and in-gel 
digestion with Trypsin was performed prior to analysis by liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS) at the EPFL proteomics core 
facility.  
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Figure 2.3 SFK SH2 monobody interactome analysis by tandem affinity purification (TAP). A: 
Schematic representation of a TAP-tagged monobody and the purification method including two copies of 
the B1 domain of staphylococcal protein G (2xProt.G), TEV protease recognition site, streptavidin-
binding peptide (SBP), and Myc-tag N-terminal to the monobody. B: MS2, MS8, MY1 and MY3 
monobody complexes after TAP (10% of the E1 fractions) from K562 cells, separated by SDS-PAGE and 
visualized with silver staining. C: ML1 and ML3 monobody complexes after TAP (10% of the E1 
fractions) from K562 and Jurkat cells, separated by SDS-PAGE and visualized with silver staining. D: 
Immunoblot analysis of TAP of ML1 and ML3 monobody complexes from Jurkat cells (top) and K562 
cells (bottom) The bait protein and the main target were identified by immunoblotting using an anti-Myc 
or anti-Lck antibody, respectively. E: Immunoblot analysis of TAP of MS2 and MS8 monobody complexes 
from K562 cells. The bait protein was identified by immunoblotting using an anti-Myc antibody. F: 
Immunoblot analysis of TAP of MY1 and MY3 monobody complexes from K562 cells. The bait protein 
and the main target were identified by immunoblotting using an anti-Myc or anti-Yes antibody, 
respectively. TE, total extract; SN1, supernatant IgG beads; TEV, eluate after TEV cleavage; SN2, 
supernatant streptavidin beads; E1, eluate from streptavidin beads; BB, boiled streptavidin beads to control 
the efficiency of elution. TAPs with monobodies ML1 and ML3 in K562 and Jurkat cells were done twice, 
and TAPs with monobodies Mb(Src_2), Mb(Src_8), Mb(Yes_1) and Mb(Yes_3) were done once. The 
figure was modified from 210. 
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We later found that MS2 and MS8 have the same sequence, as all the 8 clones selected 
among the pool of binders to the Src SH2 domain. We therefore continued the analysis 
with only the MS2 sample. Table 2.1 shows a summary of the results of the mass 
spectrometry analysis. The SrcA subgroup members Src, Yes and Fyn were identified 
among the most abundant proteins bound by the monobodies MY1, MY3 and MS2 in 
K562 cell lines. In the cells expressing the Yes-binding monobodies, Lyn, Btk and Tec 
were the only other SH2-domain containing proteins detected to bind to MY1 or MY3, 
although at much lower total spectrum counts than Src, Yes and Fyn. ML1 and ML3 
bound predominantly to Lck in Jurkat cells and to Lyn in K562 cells. In the first 
replicate of the experiment, Lck and Lyn were the only SFKs detected. In the second 
replicate of this experiment, the total number of detected proteins as well as their total 
spectrum counts were much higher. The SFKs Hck and Src were detected along with Lck 
and Lyn, although with total spectrum counts which were more than one order of 
magnitude lower than for Lck in Jurkat and Lyn in K562 cells. For Lck and Src targeting 
monobodies, no other SH2-domain containing proteins were detected which do not 
belong to the Src kinase family. (Table 2.1) 
Cell 
line 
Bait total number 
of proteins 
identified* 
number of 
proteins meeting 
selection 
criteria** 
All identified SH2 domain-containing proteins in 
each sample (in brackets: total spectrum counts, 
rank***) 
  1st 
TAP 
2nd 
TAP 
1st 
TAP 
2nd  
TAP 
1st TAP 2nd TAP 
K562 
ML1 68 252 16 50 Lyn (112, 2); Lck (7, 34) 
Lyn (1523, 1); Hck 
(141, 13); Lck (133, 
15); Src (44, 38) 
ML3 31 335 6 31 Lyn (53, 1) 
Lyn (1614, 1); Hck 
(172, 9); Lck (130, 
15); Src (45, 32) 
Jurkat 
ML1 33 285 3 23 Lck (114, 1); Lyn (1, 22) 
Lck (1811, 1); Src 
(210, 6); Lyn (138, 
13); Hck (131, 16) 
ML3 25 275 6 19 Lck (109, 1); Lyn (1, 19) 
Lck (1930, 1); Lyn 
(177, 6); Hck (162, 
7); Src (159, 9) 
K562 MS2 39  15  Src (35, 7); Yes1 (31, 8); Fyn (31, 8) 
 
MY1 46  13  
Yes1 (101, 4); Fyn (76, 
6); Src (61, 7); Lyn (12, 
20); Tec (6, 27); Btk (1, 
47) 
 
MY3 259  75  
Yes1 (295, 1); Fyn (139, 
6); Src (107, 11); Lyn (32, 
28); Btk (4, 105) 
 
Table 2.1 Overview of mass spectrometry results from the interactome analysis of monobodies MS2, 
MY1, MY3, ML1 and ML3 * Proteins were scored as identified if at least 2 unique peptides were 
detected. The complete list of identified proteins is provided in Supplementary Tables 1-3. ** Selection 
criteria: Proteins with a selectivity score of >0.75 (present in <25% of samples analyzed), with a total 
spectrum count >1% of the most abundant protein in the sample, excluding different isoforms of keratin 
and the bait protein itself. *** All identified proteins, including common contaminants, such as Keratin, 
were sorted by the number of assigned spectra from highest to lowest.  
Together with the very few SH2-domain containing proteins, many other proteins were 
identified by the mass spectrometry analysis, the total number of proteins detected 
ranging from 25 to 335. Most of these proteins were detected in the majority of all the 
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TAP experiments performed in our lab by me or other lab members. These commonly 
found proteins can be contaminants such as keratins or heat-shock proteins, highly 
abundant proteins that are difficult to eliminate completely during the purifications or 
proteins which bind unspecifically to all monobodies, affinity beads or parts of the TAP-
tag. By comparing all the protein lists from our lab database of TAP experiments, I 
calculated for each protein the complement of the percentage of TAP experiments where 
it was detected. We called this number selectivity score because it is a measure of the 
uniqueness of a protein in a given TAP experiment and indicates whether it is likely to be 
a specific interactor of the monobody or its target protein. The following formula was 
used: S=1−(1 ∕ T×P), where T is the total number of TAP experiments and P is the 
number of experiments where the protein is detected. For the analysis, I then only kept 
proteins with a selectivity score >0.75, meaning that it is present in <25% of all TAP 
experiments and with a total spectrum count of ≥10% of the most abundant proteins in 
the sample in order to exclude very low abundant proteins and excluded common 
contaminants such as keratin. Table 2.2 A, B and C contain the complete lists of proteins 
meeting these criteria that were detected and their total spectrum counts in each TAP. 
Identified Proteins Gene Name 
K562 
MS2 
K562 
MY1 
K562 
MY3 
Selectivity 
score 
Proto-oncogene tyrosine-protein kinase Src SRC 40 66 114 0.89 
Non-specific protein-tyrosine kinase Yes YES1 36 111 311 0.96 
Tyrosine-protein kinase Fyn FYN 36 82 147 0.78 
Cilia- and flagella-associated protein 54 CFAP54 21 13 8 0.91 
Monobody 20 0 11 
40S ribosomal protein S3 RPS3 8 16 16 0.88 
Polyubiquitin-B UBB 6 5 75 0.91 
Collagen alpha-1(III) chain COL3A1 6 0 0 0.96 
Collagen alpha-1(I) chain COL1A1 5 1 2 0.84 
Tubulin alpha-1A chain TUBA1A 3 10 38 0.76 
Basement membrane-specific heparan sulfate 
proteoglycan core protein HSPG2 0 0 52 0.99 
Heat shock 70 kDa protein 1-like HSPA1L 0 0 39 0.78 
Hsp90 co-chaperone Cdc37 CDC37 0 11 32 0.89 
Isoform 2 of Tyrosine-protein kinase Lyn LYN 0 13 32 0.8 
Table 2.2 A: Total spectrum counts of the proteins identified by mass spectrometry during the TAP of 
stable K562 cell lines expressing the bait proteins MS2, MY1 or MY3. Only the proteins that met our 
criteria described in the text are shown as well as their selectivity score. Proteins containing an SH2 domain 
are highlighted in bold. 
Identified Proteins Gene Name Jurkat ML1 Jurkat ML3 K562 ML1 
K562 
ML3 
Selectivity 
score 
Tyrosine-protein kinase Lck LCK 112 109 7 0 0.89 
Tyrosine-protein kinase Lyn LYN 1 1 107 44 0.8 
Monobody 11 11 97 59 
CAD protein CAD 2 0 15 0 0.75 
Heat shock 70 kDa protein 1-
like   HSPA1L 0 0 14 0 0.78 
CUB domain-containing CDCP1 0 0 27 6 0.94 
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protein 1 
Talin-1 TLN1 0 0 9 6 0.89 
Diacylglycerol kinase theta DGKQ 0 0 0 4 0.97 
Heat shock 70 kDa protein 1-
like HSPA1L 0 0 14 0 0.78 
B: Total spectrum counts of the proteins identified by mass spectrometry during the 1st TAP of stable 
Jurkat and K562 cell lines expressing the bait proteins ML1 or ML3. Only the proteins that met our 
criteria described in the text are shown as well as their selectivity score. Proteins containing an SH2 domain 
are highlighted in bold. 
Identified Proteins Gene name 
Jurkat 
ML1 
Jurkat 
ML3 
K562 
ML1 
K562 
ML3 
Selectivity 
score 
Tyrosine-protein kinase Lck LCK 1811 1930 133 130 0.89 
Tyrosine-protein kinase Lyn LYN 138 180 1523 1614 0.8 
Non-specific protein-tyrosine kinase Hck HCK 131 162 141 172 0.94 
Proto-oncogene tyrosine-protein kinase 
Src SRC 210 159 44 45 0.89 
Monobody 485 225 1245 1780 0.94 
Tubulin alpha-1B chain TUBA1B 168 122 117 150 0.78 
Tubulin beta-2A chain TUBB2A 0 115 143 152 0.96 
Protein unc-119 homolog A UNC119 114 102 0 0 0.94 
Protein unc-119 homolog B UNC119B 64 69 0 0 0.96 
Hsp90 co-chaperone Cdc37 CDC37 66 52 23 22 0.89 
Sodium/potassium-transporting ATPase 
subunit ?-1 ATP1A1 41 49 4 2 0.94 
Translational activator GCN1 GCN1L1 44 42 62 26 0.81 
Ubiquitin carboxyl-terminal hydrolase 22 USP22 42 38 0 0 0.96 
Tubulin beta-6 chain TUBB6 0 36 51 44 0.92 
4F2 cell-surface antigen heavy chain SLC3A2 20 25 14 11 0.92 
Retinol dehydrogenase 11 RDH11 22 21 0 0 0.97 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 RPN1 21 21 2 1 0.92 
Isoform 2 of Extended synaptotagmin-2 ESYT2 17 21 1 0 0.96 
Transferrin receptor protein 1 TFRC 13 21 15 7 0.94 
Heat shock 70 kDa protein 1A HSPA1A 30 18 113 119 0.88 
Very-long-chain enoyl-CoA reductase TECR 26 18 0 0 0.97 
Exportin-2 CSE1L 17 17 20 14 0.8 
Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, 
mitochondrial MTHFD2 28 15 19 16 0.94 
Exportin-1 XPO1 17 14 51 50 0.89 
RNA-binding protein FUS FUS 18 12 21 10 0.84 
Polyadenylate-binding protein 1 PABPC1 21 11 26 29 0.86 
60S acidic ribosomal protein P0 RPLP0 13 11 33 22 0.88 
Leucine-rich PPR motif-containing 
protein, mitochondrial LRPPRC 11 11 34 20 0.8 
40S ribosomal protein S8 RPS8 11 11 18 10 0.83 
Serine palmitoyltransferase 1 SPTLC1 10 10 19 28 0.94 
60S ribosomal protein L4 RPL4 8 10 30 17 0.94 
60S ribosomal protein L18 (Fragment) RPL18 7 9 25 20 0.94 
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Isoleucine--tRNA ligase, cytoplasmic IARS 1 9 28 11 0.84 
T-complex protein 1 subunit epsilon CCT5 8 7 17 6 0.76 
Trifunctional enzyme subunit alpha, 
mitochondrial HADHA 7 7 26 21 0.86 
Transportin-1 TNPO1 13 6 37 32 0.94 
Isoform B of Phosphate carrier protein, 
mitochondrial SLC25A3 26 5 9 3 0.89 
60S ribosomal protein L6 RPL6 16 4 27 17 0.86 
60S ribosomal protein L3 RPL3 10 4 22 4 0.86 
60S ribosomal protein L7a RPL7A 9 4 13 17 0.83 
Vimentin VIM 2 4 28 42 0.84 
60S ribosomal protein L15 RPL15 6 3 18 11 0.94 
Importin subunit beta-1 KPNB1 4 3 19 14 0.91 
Importin-7 IPO7 0 1 16 14 0.94 
Tubulin beta-3 chain TUBB3 89 0 104 107 0.91 
Heat shock-related 70 kDa protein 2 HSPA2 47 0 42 50 0.88 
ATP-dependent RNA helicase A DHX9 5 0 22 13 0.88 
X-ray repair cross-complementing protein 
6 XRCC6 5 0 16 9 0.96 
Clathrin heavy chain CLTC 1 0 34 26 0.92 
Large proline-rich protein BAG6 BAG6 1 0 35 22 0.88 
Arginine--tRNA ligase, cytoplasmic RARS 1 0 16 11 0.96 
Talin-1 TLN1 0 0 22 62 0.89 
CUB domain-containing protein 1 CDCP1 0 0 106 61 0.94 
Peroxisomal multifunctional enzyme type 2 HSD17B4 0 0 25 18 0.78 
Annexin A1 ANXA1 0 0 17 9 0.83 
Leucine--tRNA ligase, cytoplasmic LARS 0 0 16 6 0.96 
Kinesin-like protein KIF11 KIF11 0 0 16 6 0.92 
Serine/threonine-protein kinase mTOR MTOR 0 0 26 5 0.86 
RNA-binding protein 4 RBM4 0 0 29 3 0.97 
C: Total spectrum counts of the proteins identified by mass spectrometry during the 2nd TAP of stable 
Jurkat and K562 cell lines expressing the bait proteins ML1 or ML3. Only the proteins that met our 
criteria described in the text are shown as well as their selectivity score. Proteins containing an SH2 domain 
are highlighted in bold. 
 
Altogether, the results demonstrate the ability of these monobodies to bind with high 
selectivity to their full-length target protein in cells. They only bind to few other SFK 
SH2 domains and 2 closely related kinases, but no other major off-targets. 
2.1.3? Inhibition of SH2-pY interactions by the selected monobodies 
We next wanted to assess if the monobodies not only bind SH2 domains but also inhibit 
their interaction with pY-containing substrates. We first determined whether they could 
block the binding to a peptide containing the pYEEI motif, a known binding motif of 
SFK SH2 domains. The pY peptide competition assays were performed by Tim 
Kükenshöner using recombinant SH2 domains and monobodies previously purified. All 
the tested monobodies competed with the pYEEI peptide for binding to their on-target 
SH2 domain, except for monobodies ML1, Mb(Lyn_4) and a control non-binding 
34 
monobody HA4-Y87A (HA4_YA)76. (Figure 2.4 A and E) To further study this 
discrepancy between ML3 and ML1, their competition against two additional pY 
peptides with lower affinities for the Lck SH2 domain, pYIIP and pYQPQ, was tested. 
Remarkably, both Lck monobodies displaced these peptides, suggesting that they are 
both able to inhibit protein-protein interactions of the Lck SH2 domain. (Figure 2.4 B) 
ML1 was also not able to compete with the pYEEI peptide binding to any of the other 
purified SH2 domains, while ML3 displaced the pYEEI peptide from all the SrcB family 
SH2 domains but none of the SrcA family SH2 domains. (Figure 2.4 C and D) This 
result is in line with the previous results from the ITC and yeast binding assay and 
underlines the subgroup selectivity of ML3. 
Figure 2.4 Inhibition of pY peptide /SH2 interaction by monobodies as measured by fluorescence 
polarization assay. A: Relative pYEEI peptide binding (in %) to the main target SH2 domain in the 
presence of the indicated monobody. All eight SH2 domains have been measured without and in presence 
of the monobody selected for the respective on-target. The pYEEI peptide in isolation and the SH2/pYEEI 
complex were set to 0% and 100% binding, respectively. Each data point corresponds to the average of at 
least two repeats +/− SD. B: Relative peptide binding (in %) of three different peptides (pYEEI, pYQPQ, 
pYIIP) to the Lck SH2 domain in the presence of each of the two Lck monobodies ML1 or ML3. C: 
Relative pYEEI peptide binding (in %) to the indicated SH2 domains in the presence of ML1. D: Relative 
pYEEI peptide binding (in %) to the indicated SH2 domains in the presence of ML3. E: Relative pYEEI 
peptide binding (in %) to the indicated SH2 domains in the presence of HA4_Y87A. The data was 
generated by Dr. Tim Kükenshöner and the figure is modified from 210. 
I then sought to study the potential of the developed monobodies as functional 
antagonists of SH2 domain mediated protein-protein interactions with full-length 
proteins rather than isolated pY peptides. I therefore did a pull-down assay on T-cell 
receptor-stimulated Jurkat cells with recombinant Lck SH2 domain. Jurkat cells were 
stimulated with a T-cell receptor binding antibody prior to lysis. I then immobilized 
recombinant biotinylated SH2 domain of Lck or Src on Streptavidin-coated beads and 
added either ML3 or the control monobody HA4-Y87A76 prior to incubation with the 
cell lysate. Interacting proteins were analyzed on a silver stained SDS-PAGE gel as well as 
by immunoblotting against tyrosine phosphorylated proteins. (Figure 2.5) Both analyses 
showed a substantially reduced number of interactors when ML3 was added as compared 
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to the SH2 domain alone or after addition of the control monobody HA4_YA. In 
contrast, the Src-SH2 domain bound to the same amount of tyrosine-phosphorylated 
proteins, whether recombinant ML3 was added or not. In particular, the interaction with 
a known interactor of Lck, Zap70, was disrupted by ML3 but not the control 
monobody. ML3 specifically blocks the interaction of the Lck SH2 domain with Zap70 
phosphorylated on Y319, which is known to be responsible for the binding to Lck. These 
results show that ML3 is a selective competitor of SH2 domain mediated protein-protein 
interactions of Lck in a complex cellular lysate. 
 
Figure 2.5 SH2 pull-down assay. A: The monobodies ML3 or HA4-Y87A or buffer alone were added to 
biotinylated Lck or Src SH2 domains immobilized on Streptavidin-coated beads prior to incubation with 
lysate from anti-TCR stimulated Jurkat T cells. Immunoblot analysis after pull-down using an anti-pY 
antibody for a 40% fraction of beads (upper blot), using an anti-Zap70 antibody and an anti-phospho-
Zap70 (pY319) antibody for a 40% fraction of beads (second and third blot from top), and an anti-His-tag 
antibody to detect the recombinant SH2 domains and monobodies for a 10% fraction of beads (lower 
blot). One representative immunoblot is shown out of 5 repeats. B: The remaining 10% fraction of beads 
was separated on an SDS-Page gel and visualized by silver staining. One representative silver stained gel is 
shown out of 5 biological repeats.   
2.1.4? The monobody ML3 inhibits Lck kinase activity in cells 
Finally, our aim was to test if the developed SFK SH2 monobodies can interfere with 
SFK dependent signaling pathways in cells. We focused on the Lck-binding monobodies 
since they showed the most remarkable ability to discriminate between the SrcA and SrcB 
subgroups. Since the Lck SH2 domain is indispensable for the activation of Zap70 kinase 
in the T-cell receptor complex and for T-cell activation, I assessed the effects of ML1 and 
ML3 on Zap70 phosphorylation. 
In a first attempt, I used the same Jurkat cell lines stably expressing the monobodies as 
for the TAP.  However, I did not observe any effect on Zap70 phosphorylation in these 
cell lines, which is probably due to the comparatively low expression of the monobodies 
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using the TAP-tagged vector. I then generated stable Jurkat cell lines expressing Myc-
tagged ML1, ML3, or the control monobody HA4-Y87A using a lentiviral hPGK vector 
obtained from the laboratory of Prof. Jörg Huelsken at EPFL. This vector also contains 
an IRES followed by a GFP and following infection with the lentivirus generated by 
transfection of HEK293T cells with the constructs, the cells were sorted by FACS. I 
could confirm a higher expression of the monobodies using this vector by western blot 
against the Myc-tag (data not shown). 
These cells were then stimulated with an anti-T-cell receptor (TCR) antibody to activate 
the T cell receptor pathway and the phosphorylation of the activation loop of Zap70 
(Y493) as well as of Y319, which is in the Zap70 kinase-SH2 linker, were monitored by 
immunoblotting. (Figure 2.6 A and B) In non-transduced Jurkat cells as well as the cells 
expressing HA4-YA, I observed an increase in Zap70 phosphorylation on both tyrosine 
residues upon stimulation with the TCR antibody. (Figure 2.6 A and B) In contrast, in 
cells expressing ML3, TCR stimulation resulted in much weaker Zap70 phosphorylation, 
which was decreased as compared to the control cells even in non-stimulated cells. ML1 
also reduced Zap70 phosphorylation, but showed milder effects, which is in line with its 
weaker pY competition activity. (Figure 2.6 A and B) This result shows that ML3 and 
ML1 can interfere with Lck-mediated signaling in T-cells and inhibit the activation of 
Zap70.  
Surprisingly, I observed that albeit the more pronounced Lck inhibition by ML3 than by 
ML1, ML3 protein levels were much lower than ML1 or HA4_YA protein levels. I 
observed this effect in several independent experiments where cell lysates prepared on 
different days were immunoblotted with an anti-myc antibody. (Figure 2.6 C) 
Interestingly, the mRNA levels of both ML1 and ML3 were similar, and 5 to 10-fold 
higher in cells transduced with the hPGK vector than with the pRV vector (TAP-tagged 
monobodies). This result suggests that the Jurkat cells may down-regulate protein levels 
of the ML3 monobody that inhibits TCR activation, by an unknown post-translational 
mechanism. 
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Figure 2.6 ML3 or ML1 expression leads to a reduction in Zap70 phosphorylation upon TCR 
activation. A: Jurkat cells expressing no monobody, ML1, ML3 or the control monobody HA4_YA were 
stimulated with an anti-TCR antibody for 5 minutes and lysed. Immunoblot analysis of the cell lysate with 
antibodies against phosphorylated Y319 residue of Zap70 and total Zap70 on the same blot, against 
phosphorylated Y493 residue of Zap70 and total Zap70 on the same blot, against activation loop 
phosphorylated Src-family kinases, against phosphorylated NFAT, phosphorylated ERK and total ERK on 
the same blot and against Actin. (order as displayed, from top to bottom) B: Quantification of the ratio 
between the Y493-phosphorylated Zap70 and total Zap70 signals. The data was transformed by setting the 
pZap70:Zap70 ratio of the unstimulated HA4-Y87A control cells to 1.0 for each experiment. Average 
values and standard deviations from two independent experiments done in two technical replicates were 
used, and p values were calculated using a ratio paired t-test on the untransformed data. *p < 0.05, **p < 
0.01. C: Immunoblot analysis of the expression levels of the myc-tagged monobodies from 2 different 
lysates of the same stable cell lines expressing the hPGK vector constructs. D: RT-PCR analysis of mRNA 
levels of expressed monobodies. The RT-PCR was performed with primers binding to ML1 and ML3 but 
not to HA4_YA. The data was normalized to a GAPDH control run in parallel and the experiment was 
done in triplicates, of which the mean values are shown.  
I also assessed the phosphorylation of proteins that are activated further downstream in 
the TCR activation pathway. The MAP kinase ERK was similarly phosphorylated upon 
TCR stimulation in cells expressing ML1 or ML3 or HA4_YA, and the 
dephosphorylation of the transcription factor NFAT was similar in all cell lines as well. 
(Figure 2.6 A) I then set out to measure the calcium flux in the cells after stimulation 
with the anti-TCR antibody. The cells were loaded with the Ca2+ sensitive Indo-1-AM 
dye, which upon excitation with UV-light displays a different emission spectrum when 
bound to Ca2+ than in the unbound state. The ratio of the two emission maxima of Indo-
1-AM-loaded cells was recorded on a flow cytometer and then the antibody was added to 
elicit the calcium flux response. Ionomycin, a TCR independent stimulant was added 
after the ratio had dropped back to the baseline level as a positive control. No difference 
was observed between the cells expressing ML1 or ML3 or the control monobody. 
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(Figure 2.7 A) Only wild type cells showed a more pronounced calcium flux response 
than the cells expressing a monobody, which is most likely due to the amount of TCR 
expressed on the cell surface, being lower in monobody expressing cells than in wild type 
cells. (Figure 2.7 B) 
 
Figure 2.7 Calcium flux measurement in Jurkat cells expressing no monobody, ML1, ML3 or 
HA4_YA upon TCR stimulation. A: Jurkat cells were loaded with Indo-1-AM, and the ratio between the 
475 nm (Ca2+-bound) and the 400 nm (not bound to Ca2+) signal was measured over time on a flow 
cytometer. The signal was measured for 30 seconds to set the baseline, then an anti-TCR antibody was 
added to the tube and the measurement was continued for 5 minutes, after which Ionomycin was added to 
the tube. One representative plot is shown out of 3 repeats. B: CD3 expression in the same Jurkat cells 
measured by flow cytometry. One representative plot is shown out of 2 repeats. 
2.1.5? VHL-ML3 mediates Lck degradation upon expression in Jurkat cells 
We reasoned that we could use the ML1 and ML3 monobodies for the targeted 
degradation of Lck, and that by this, we could potentially further decrease Lck-mediated 
signaling in T cells. I therefore fused the ML1 and ML3 monobodies as well as the 
negative control monobody HA4-YA to the E3 ubiquitin ligase recruiting Von-Hippel-
Lindau (VHL) protein. I hypothesized that upon binding of the monobody to Lck, the 
fused VHL would recruit the Cullin2 E3 ubiquitin ligase complex, leading to the 
polyubiquitination and proteasomal degradation of Lck.  
The VHL cDNA was fused to the ML3 cDNA and cloned into a lentiviral vector 
containing a Tet-on system for doxycycline dependent expression and a blasticidin 
resistance gene for selection. (pEM24) The Tet-on system in the vector allows to turn on 
the expression and thereby degradation of Lck by addition of doxycycline to the growth 
medium.  
I first determined the minimal lethal concentration of blasticidin to use for the selection 
of the positive cells after transduction. (Figure 2.8 A) Following infection with the 
lentivirus generated by transfection of HEK293T cells with the constructs, the cells 
which had integrated the construct were selected by addition of 5 µg/ml of blasticidin 
and after 4 days of selection, the non-transduced cells were dead, meaning that 100% of 
the remaining transduced cells had integrated the construct. (Figure 2.8 B) The 
expression of the VHL-monobody constructs was induced by addition of doxycycline to 
the medium and the expression of the myc-tagged constructs was tested by 
immunoblotting with an anti-myc antibody. The expression was effectively induced by 
the addition of doxycycline and no leakiness of the constructs could be detected. (Figure 
2.8 C, bottom blot)  
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In order to assess whether the expression of VHL-monobody fusion proteins indeed leads 
to the degradation of the monobody target protein, cell lysates of cells grown in presence 
and absence of doxycycline were immunoblotted with an anti-Lck antibody. I observed 
that indeed, in cells expressing VHL-ML1 or VHL-ML3 fusion proteins, but not in cells 
expressing the control monobody HA4-YA fused to VHL, the protein levels of Lck are 
reduced by 50%, whereas in the same cell lines without addition of doxycycline, the level 
of Lck protein was similar across all the cell lines. (Figure 2.8 C and D) Moreover, when 
looking at total phospho-tyrosine levels, I observed that in doxycycline induced cells 
expressing VHL-ML1 or VHL-ML3, the bands at approximately 55 kD, probably 
corresponding to phospho-Lck and at about 70 kD, which corresponds to Zap70, were 
less strong than in uninduced cells or cells expressing VHL-HA4_YA. This observation 
indicates that the loss of Lck leads to a reduced Zap70 phosphorylation already in 
unstimulated cells. 
 
 
Figure 2.8 VHL-ML1 and -ML3 mediated degradation of Lck in Jurkat cells. A: Wild type Jurkat cells 
were supplemented with blasticidin at the indicated concentration and the cell number was measured for 7 
days. This measurement was done once. B: Jurkat cells were transduced with the PEM24 vector containing 
the indicated VHL-monobody constructs or left untransduced and 5µg/ml blasticidin was added to the 
growth medium 1 day after the second transduction (day 0). The cell numbers were measured on day 2 
and day 4. C: Immunoblot analysis of the lysate of VHL-monobody transduced Jurkat cells grown in 
presence and absence of doxycycline with antibodies against tyrosine-phosphorylated proteins (4G10), Lck, 
Actin and the myc-tag. (Order as displayed from top to bottom) D: Quantification of the ratio between the 
Lck and Actin signals. The data was transformed by setting the Lck:Actin ratio of doxycycline induced 
VHL-HA4_YA transduced cells to 1.0 for each experiment. Average values and standard deviations from 4 
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independent experiments were used, and p values were calculated from the untransformed data using a 
ratio paired t-test. **p < 0.01 
I next stimulated these cells with the anti-TCR antibody, as previously, and assessed 
whether the phosphorylation of Zap70 is reduced in cells where Lck is degraded. I 
observed that indeed, both in unstimulated cells as well as in cells stimulated with an 
anti-TCR antibody for 5 minutes, the phosphorylation of Zap70 is reduced, and that this 
effect is stronger than in cells expressing the monobodies alone without VHL. (Figure 
2.9) 
Figure 2.9 VHL-monobody mediated Lck degradation leads to reduced Zap70 phosphorylation. A: 
Jurkat cells expressing VHL-ML1, -ML3 or -HA4_YA and induced with doxycycline or grown in 
doxycycline-free medium were stimulated with an anti-TCR antibody for 5 minutes and lysed. 
Immunoblot analysis of the cell lysate with antibodies against the myc-tag (upper blot), phosphorylated 
Y319 residue of Zap70 and total Zap70 on the same blot (blots 2 and 3 from top) and against 
phosphorylated Y493 residue of Zap70 and total Zap70 on the same blot (blots 4 and 5 from top). B: 
Quantification of the ratio between the Y319-phosphorylated Zap70 and total Zap70 signals (left) and of 
the ratio between the Y319-phosphorylated Zap70 and total Zap70 signals (right). The data was 
transformed by setting the pZap70:Zap70 ratio of the unstimulated (doxycycline induced) HA4-Y87A 
control cells to 1.0 for each experiment. Average values and standard deviations from 3 independent 
experiments were used, and p values were calculated using a paired t-test. *p < 0.05, **p < 0.01. 
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Collectively, these results demonstrate that the selected monobodies are SFK subgroup 
specific and can interfere with the TCR signaling pathway in cells, leading to the 
degradation of their target protein when coupled to the E3 ubiquiting ligase recruiting 
protein VHL. 
2.2? Monobody delivery using CPPs 
My first attempt at delivering monobodies into cells was to use cell penetrating peptides 
(CPPs). In order to couple monobodies to CPPs, a previous master student in our lab 
had attempted to express and purify recombinant monobody-CPP fusion proteins in E. 
coli. Despite optimization attempts, the resulting proteins were very unstable and prone 
to precipitation, so that no soluble protein could be purified. My attempt at purifying 
monobody-CPP fusion proteins failed for the same reason, and I therefore set out to 
establish a method to chemically ligate monobodies to CPPs. The selected method 
consists of using DTNB (5,5?-Dithiobis(2-nitrobenzoic acid)) or Ellman’s reagent) in 
order to covalently link a monobody to a CPP via a disulfide bond. (Figure 2.10) DTNB 
is normally used as a colorimetric reagent to quantify the number of free thiols in a 
protein, as the reaction product yields TNB, which is yellow. 
Figure 2.10 Covalent binding of a monobody to a CPP by disulfide bond. The CPP is first activated 
with Ellman’s reagent and after purification, reacts with the monobody to form a disulfide bond. 
I added a cysteine residue to the C-termini of 5 monobodies that had previously been 
characterized in our lab. Since monobodies do not contain cysteines, the C-terminal 
cysteine provides the only free thiol in the monobodies to react with DTNB-activated 
CPPs. I then expressed the monobodies, containing a Flag-tag as well as a 10x-His-tag at 
the N-terminus, in the E. coli BL21 strain, allowing for purification on a Ni-NTA 
column. Table 2.3 gives an overview of the 5 monobodies chosen, as well as their target 
and the yield of expression in E. coli.  
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Monobody Target Yield / l of expression medium 
HA4 Abl SH2 domain76 11 mg 
AS25 Abl SH2-kinase interface78 17 mg 
AS27 Abl SH2-kinase interface78 12 mg 
Nsa5 SHP2 N-terminal SH2 domain212 10 mg 
Nsa5 S63K Mutated non-binding form of Nsa575 8 mg 
Table 2.3 Monobodies expressed in the E. coli BL21 strain, their targets, and yields from 1 L of 
expression medium after purification by SEC. Autoinduction medium was used as expression medium, 
cultures were incubated for 20h at 20°C, shaking, prior to lysis. 
Three different CPPs were selected and synthesized with a cysteine in the C-terminus and 
both unlabeled as well as with a tetramethyl-6-carboxyrhodamine (TAMRA) dye label in 
the N-terminus (Table 2.4). 
 
Peptide Origin Sequence Length 
Tat HIV GYGRKKRRQRRRPPQC 16 aa 
CPP44 synthetic, CML- and AML-specific KRPTMRFRYTWNPMKC 16 aa 
Polyarginine synthetic RRRRRRRRRC 10 aa 
Table 2.4 Cell penetrating peptides chosen for coupling to monobodies, their origin and sequence. 
Figure 2.11 A shows a Coomassie-stained gel of all purification steps of AS27 as a 
representative example for all the monobodies. In Figure 2.11 B, the size exclusion 
chromatogram of AS25 is representative for all the monobodies purified. A good yield 
and high purity were obtained for all five monobodies, as shown on a Coomassie-stained 
SDS-PAGE gel of the purified monobodies. (Figure 2.11 C and Table 2.3)  
 
 
Figure 2.11 Monobody purification. The crude bacteria lysate was first purified on a Ni-NTA column 
and then by SEC. A: Coomassie stained SDS PAGE gel with the fractions from the Ni-NTA purification 
of monobody AS27 and the main peak of the SEC after concentration (similar purity was obtained from 
the other monobodies) (L=crude lysate, FT=flow-through, W=wash, E1-3=Ni-NTA elution fractions 1-3) 
B: size exclusion chromatogram of monobody AS25 as an example. (All other monobodies gave similar 
chromatograms). C: Coomassie stained SDS PAGE gel of all the purified monobodies after purification. 
DTNB (or Ellman’s reagent) was then used to covalently link the single cysteine residues 
in the CPPs and the monobodies via a disulfide bridge, as depicted in the scheme in 
Figure 2.11. 
For the first step, activating the CPP with DTNB, different non-denaturing phosphate- 
and TRIS-based buffers as well as pH-values distinct from the pI of the peptides were 
tested. Both Ellman’s reagent and the peptides were soluble in all buffers, but upon 
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mixing, a yellow precipitate formed. The reaction product was contained in the 
precipitate and not the supernatant, as seen by HPLC analysis (data not shown). By 
using a denaturing phosphate buffer containing 6 M guanidinium, a yellow solution was 
obtained, and no precipitation was observed. Ellman’s reagent was used in 5-fold molar 
excess and the reaction was immediate. To monitor the reaction, the initial CPP as well 
as the final product were analyzed by HPLC and mass spectrometry. Figure 2.12 shows 
the HPLC analysis of each peptide and of the reaction product with Ellman’s reagent as 
an overlay. Many of the peptides showed major impurities either in HPLC or in mass 
spectrometry analysis and did not match the data on the quality control sheet of the 
supplier. Even after re-synthesis by the supplier, the quality did not improve and new 
peptides were finally ordered from a different company.  
 
 
Figure 2.12 HPLC chromatograms of 6 CPPs (in blue) and the reaction product of the same peptide 
with Ellman’s reagent (DTNB) (in green). A: CPP44, B: TAMRA-labeled CPP44, C: Tat, D: TAMRA-
labeled Tat, E: polyarginine, F: TAMRA-labeled polyarginine. In each of the chromatograms, the largest 
peak of the green curves corresponds to excess Ellman’s reagent. An analytical scale C-18 column was used 
and the flow rate was constant at 1ml/min. 
In order to establish the coupling of the activated CPPs to monobodies, unlabeled 
CPP44 and Tat were chosen to test the next reaction step. The reaction with Ellman’s 
reagent was repeated at a larger scale and the activated CPP was purified by HPLC on a 
semi-preparative C-18 column, to remove the excess DTNB and the TNB reaction 
product. After lyophilization of the eluate, it was re-dissolved in a sodium phosphate 
buffer at pH 6.5 and the activated peptide remained soluble. To assess the purity of the 
product, an analytical HPLC was run, which gave a single major peak of the expected 
mass for both CPP44 and Tat. (Figure 2.13 A) The DTNB-activated and purified CPPs 
were then mixed with monobody protein. After 30 minutes of incubation on ice, a 
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yellow color formation due to TNB production indicated that the reaction had taken 
place. The analytical HPLC showed that the product eluted in one major peak, which 
was shifted compared to the monobody alone. (Figure 2.13 B) Unfortunately, the 
resulting monobody-CPP product was very unstable and prone to precipitation, similar 
to the recombinant fusion protein. When I replaced the reaction buffer by a sodium 
phosphate buffer containing 6 M guanidinium, the product remained soluble, since the 
protein is denatured. Different attempts to refold the protein by dialysis into a 
guanidinium-free buffer have failed so far, and another coupling method might be 
needed to ligate CPPs to monobodies. 
 
Figure 2.13 CPP-monobody coupling. A: Analytical HPLC chromatogram of purified Tat after activation 
with DTNB. CPP44 resulted in a similarly pure single peak. B: Analytical HPLC chromatogram of AS25 
after coupling to DTNB-activated and purified CPP44 (in green) and of AS25 alone (in blue). 
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2.3? Monobody delivery using Cell Penetrating poly-Disulfides (CPDs) 
Cell penetrating poly-disulfides (CPDs) have been developed by the group of Prof. 
Matile at the University of Geneva, with whom we collaborated on this project. The 
Matile group has shown that CPDs can be used to deliver fluorophores and different 
macromolecules, including peptides, into cells, but protein delivery had not been 
assessed. 113,116 CPDs are synthetic mimics of poly-arginine in which the polypeptide 
backbone is replaced with poly-disulfides. Upon cellular uptake, CPDs are rapidly 
degraded in the cytosol by glutathione (GSH)-mediated reduction of the disulfide bonds. 
2.3.1? Adduct formation and delivery of HPDP-biotin-AS25 
Since the polymerization of CPDs is carried out in organic solvents, proteins cannot be 
used as initiators of the reaction directly. We therefore decided to adopt a different 
strategy to conjugate monobodies to CPDs. We reasoned that since the binding of biotin 
to streptavidin is one of the strongest naturally occurring non-covalent conjugations and 
the reagents are commercially available, we could use streptavidin to couple biotinylated 
monobodies to CPDs grown from a biotinylated initiator. (Figure 2.14 A) 
Tetramethylrhodamine (TMR) coupled to biotin and bearing a free thiol group is used as 
an initiator (I) to form biotinylated and fluorophore-labelled CPDs. The CPD building 
block consists of lipoic acid coupled to arginine (M), as the strained disulfide offers a 
target for nucleophilic disulfide exchange polymerization. The thiol group of the initiator 
reacts with this disulfide, forms a new covalent disulfide bond with the monomer and 
generates a free reactive thiol to react with the next monomer. The polymerization 
reaction can be stopped at different time points by addition of the terminator (T) in 
excess, to yield products with different polymer lengths. (Figure 2.14 A)  
In order to make a biotinylated and fluorophore-labelled monobody, our initial approach 
was to add a cysteine residue to the C-terminus of the monobody by site-directed 
mutagenesis, which could be used to react with the pyridyldithiol-activated, sulfhydryl-
reactive biotinylation reagent Biotin-HPDP, as shown in Figure 2.14 B. We decided to 
use AS25 as a first monobody to test this approach. A bacterial expression plasmid with 
the monobody AS25 with the C-terminal cysteine was expressed in the E. coli BL21 
strain and purified on a Ni-NTA column and by size exclusion. NHS-ester coupled 
Dylight488 was then used to label the free amines in the protein. Since there are 3 lysine 
residues in the monobody in addition to the N-terminus, this would result in up to 4 
Dylight488 molecules per monobody protein. Dylight488 was added to the monobody 
at a 7.5 fold molar excess and incubated for 1 hour at room temperature. After 
purification of the labelled protein from excess dye by dialysis, the ratio of dye molecules 
per monobody was determined to be 3.27 by spectrophotometric absorbance 
measurement.  This labelled monobody was then incubated with Biotin-HPDP for 1 
hour at room temperature. (Figure 2.14 B) 
Streptavidin could then be used to form adducts with this biotinylated and fluorophore 
labelled CPD as well as biotinylated monobodies. (Figure 2.15) Streptavidin is a homo-
tetramer with 4 biotin binding sites, so different stoichiometries could be used to make 
adducts. We reasoned that forming adducts at a 1:2.5:1 (Monobody:CPD:Streptavidin) 
ratio, we would maximize the chance of uptake due to an average of 2.5 molecules of 
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CPD on each adduct. We did not choose a 1:3:1 ratio to avoid having residual free CPD 
in the solution.  
 
Figure 2.14 Synthesis of CPDs and formation of biotinylated and fluorophore coupled monobodies. 
A: TMR-coupled and biotinylated initiator (I) is used to start a nucleophilic disulfide exchange reaction 
with the strained disulfide in the monomer (M), consisting of a lipoic acid coupled to arginine, the reaction 
is stopped by addition of the terminator (T). A schematic representation of the resulting CPD is shown in 
the colored box and will be used throughout the chapter. B: Free amines in a monobody react with NHS-
ester coupled Dylight-488 and after purification of the fluorophore-coupled monobody, reacts with biotin-
HPDP to yield a biotinylated and fluorophore-coupled monobody, as shown schematically in the colored 
box. C: Avi-tagged monobody has been biotinylated by co-expression with BirA enzyme in E. coli and its 
free thiol of the cysteine at the C-terminus reacts with maleimide-coupled Alexa Fluor 488. The resulting 
biotinylated and fluorophore-coupled monobody is shown as a schematic in the colored box. 
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Figure 2.15 Schematic showing adduct formation. Both monobodies and CPDs are biotinylated and 
fluorophore coupled and mixed with streptavidin at a 1:2.5:1 (monobody:CPD:streptavidin) ratio. For 
simplicity, the graph shows resulting adducts at 1:3:1 ratio. 
For the initial testing, we decided to form the adducts by simple mixing at the intended 
ratio, without purifying adducts. This would result in a polydispersed product, with a 
majority of adducts at the intended stoichiometry of 1 monobody and 2.5 CPDs per 
streptavidin and a fraction of adducts with no monobody or more than one monobody 
per streptavidin. Streptavidin was first mixed with CPDs at a 2.5:1 ratio at room 
temperature for 2 hours, and then the biotinylated and labelled monobody was added 
and the mixture was incubated for additional 2 hours at room temperature. As a control, 
a biotin-fluorescein conjugate was added instead of the monobody. Initially, with the 
reaction performed in PBS at pH 7.5, most of the monobody, but not the biotin-
fluorescein, precipitated upon mixing with the streptavidin-CPD. The resulting adducts 
were centrifuged to remove the precipitate and diluted in Leibovitz’s medium to a 
calculated concentration of 500 nM. When considering the precipitation, the actual 
concentration was likely to be lower than 500 nM, however the precise concentration was 
difficult to determine, since the CPDs do not show prominent UV absorption in contrast 
to proteins. Leibovitz’s medium is commonly used for live cell microscopy as it allows 
cells to grow at atmospheric CO2 concentration. The adducts diluted Leibovitz’s medium 
were added to HeLa cells grown in microscopy dishes and incubated at 37°C for 1 hour. 
Figure 2.16 shows images of live HeLa cells after incubation with the adducts for 1 hour 
and a subsequent washing step. Both the adducts with labelled monobody or fluorescein 
seem to be taken up in HeLa cells, since signal from both the TMR on the CPDs and the 
Dylight488 or fluorescein (from the monobody) are detected inside the cells. The TMR 
signal is much stronger in the cells incubated with fluorescein-adducts than the ones with 
monobody-adducts, even though the adducts were prepared in the same way and the 
same number of CPDs are bound to streptavidin on average. This difference is most 
likely due to the precipitation of the monobody-adducts and the resulting lower 
concentration. When the cells were incubated with monobody-adducts at a calculated 
concentration of 1 µM, the intensity of TMR was comparable to the cells incubated with 
fluorescein-adducts. The signal from the fluorescein or Dylight-488 on the monobody is 
largely colocalized with the TMR signal and both signals are mostly coming from distinct 
speckles throughout the cytosol. (Figure 2.16) In some of the cells that were incubated 
with the fluorescein adducts or with the higher concentration of the monobody-adducts, 
signs of apoptosis, such as membrane blebbing, irregular nuclear shapes and cell debris 
were observed. 
Streptavidin
Biotinylation
Polymerisation
biotinylated, fluorophore 
coupled initiator 
fluorophore-labeled 
monobody
    48 
 
Figure 2.16 Adduct delivery in HeLa cells. HeLa cells were incubated with 500 nM CPD-Streptavidin-
CF (A) or 500 nM (B) or 1 µM (C) CPD-Streptavidin-AS25 1h, washed and imaged on a confocal 
microscope. TMR signal is shown in red, CF and Dylight-488 signal in green and nuclei are stained with 
Hoechst and shown in blue. Representative images are shown out of 3 biological experiments where 5 
images were taken from each condition randomly. Scalebars represent 10 µm. 
2.3.2? Buffer and conditions optimization to yield soluble adducts 
Since the adduct formation lead to extensive precipitation of the monobody, I decided to 
optimize the buffer conditions to yield a more soluble product. I tested Tris-HCl, PBS 
and MES buffers at a pH values ranging from 5.5 to 8.5, different salt and glycerol 
concentrations, as well as the addition of polyethylenglycol (PEG) of different sizes. The 
best condition was found to be MES buffer at pH 5.5 with 150 mM NaCl and 10% 
glycerol, as it yielded less precipitation than all the other conditions. The addition of 
PEG did not result in any change as compared to the same buffers without PEG. In 
addition, by reducing the concentration of both the monobodies and the CPDs to 15 
µM prior to mixing, I was able to further improve the solubility. The conditions for the 
formation of adducts were also slightly changed to favor the protein stability and 
solubility. The reaction of Biotin-HPDP with monobody was performed at 4°C and the 
biotinylated monobody was added to the streptavidin-CPD adducts at 4°C drop by drop 
and with gentle mixing, then left to complete the reaction for 1 hour at 4°C. Using this 
new buffer and reaction conditions, the final product appeared to be soluble with no 
visible precipitate. Any invisible precipitated material was removed by centrifugation and 
the resulting soluble adducts were diluted in Leibovitz’s medium to the required 
concentration for the respective experiment. The incubation with HeLa cells was 
performed on the same day of adduct formation to avoid any precipitation due to freeze-
thaw cycles or prolonged storage at 4°C. 
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2.3.3? Adduct formation and delivery of Avi-tagged and in vivo biotinylated 
monobody 
Since the addition of several Dylight488 molecules on the monobody could interfere 
with its binding to the target protein, we also decided to test another biotinylation and 
labeling approach. By adding an Avi-tag to the N-terminus of the monobody, we 
reasoned that we could use this to attach a biotin, thereby freeing the C-terminal cysteine 
for reaction with a maleimide coupled dye. This method has the advantage that the 
reaction with the maleimide coupled dye is site-specific, since there is no other cysteine 
residue in the monobody. I co-expressed Avi-tagged monobody with BirA enzyme in 
presence of biotin in the E. coli BL21 strain. BirA is a bacterial enzyme specifically 
recognizing the Avi-tag sequence (GLNDIFEAQKIEWHE) and attaching one biotin 
molecule to the lysine residue. The co-expression of both proteins yielded a monobody 
that was biotinylated to about 90% according to a streptavidin bead pulldown assay. 
After purification by Ni-NTA and SEC, the monobody was labeled on the single C-
terminal cysteine using maleimide-AlexaFluor488 and purified from excess dye using a 
PD-10 sephadex G25 column. (Figure 2.14 C) The formation of adducts was done in 
the same way as for the HPDP-biotinylated and NHS-ester labelled monobody with the 
improved buffer and reaction conditions. 
I incubated HeLa cells for 1 hour with adducts with either HPDP-biotinylated, NHS-
ester labelled (AS25-Dylight488) or Avi-tag-biotinylated, maleimide labelled (Avi-AS25-
AF488) monobody and observed their uptake in live cells. As shown in Figure 2.17, both 
the TMR signal from the CPDs and the 488 nm signal from the monobody can be seen 
in speckles in the cytosol, but not all the cells take up the same amount of adducts, as 
already observed before. The 488 nm signal partially colocalizes with the TMR signal, 
and the Avi-AS25-AF488 adducts seem to be localized closer to the cell membrane after 
uptake than the AS25-Dylight488 adducts. No 488 nm signal can be observed when the 
cells are incubated with adducts containing an unlabeled monobody, or with CPD alone. 
Since no major differences were observed between the two labelling and biotinylation 
protocols of the monobodies, I used the in vivo biotinylated AS25 with only one 
fluorescent dye on the C-terminus for all the subsequent experiments. In all the 
conditions, except for the control cells which were incubated with labelled monobody 
only, signs of apoptosis, such as membrane blebbing, irregular nuclear shapes and cell 
debris were observed. These effects were most clearly observed in cells incubated with 
500 nM CPD only, indicating that the observed toxicity stemmed from the CPD and 
not the monobody. The experiment was repeated with different batches and sizes of 
CPDs with the same result. The observed toxicity was surprising, since results from of 
similar adducts containing the same CPDs at concentrations up to 1 µM have been 
published and shown to have no toxic effects on HeLa cells in an MTT assay by the 
Matile group.113 
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Figure 2.17 Adduct delivery and comparison between in vivo biotinylated and HPDP-biotin 
conjugated monobodies. HeLa cells were incubated with adducts or controls at 500nM for 1h, washed 
and imaged using a confocal microscope. A: Adduct with HPDP-biotinylated, NHS-ester labelled AS25 
(AS25-Dylight488); B: Adduct with Avi-tag-biotinylated, maleimide labelled AS25 (Avi-AS25-AF488); C: 
Adduct with Avi-tag biotinylated, unlabeled AS25; D: Avi-AS25-AF488 alone; E: TMR-labelled, 
biotinylated CPDs alone. TMR signal is shown in red, CF and Dylight-488 signal in green and nuclei are 
stained with Hoechst and shown in blue. Representative images are shown out of 2 biological experiments 
where 5 images were taken from each condition randomly. Scalebars represent 10 µm. 
2.3.4 CPD containing adducts have cytotoxic effects on HeLa cells 
In order to test whether the adducts were indeed inducing cytotoxic effects, I stained the 
cells with Sytox Green after the incubation with adducts containing only streptavidin and 
CPDs at an average 1:2.5 ratio. Sytox Green is a DNA intercalating dye, which is 
impermeable in healthy cells but can penetrate the cell membrane as well as the nuclear 
envelope in cells undergoing apoptosis due to membrane permeabilization. As shown in 
Figure 2.18 A, the nuclei of cells incubated with adducts for 1 hour indeed become 
positive for Sytox Green staining, at adduct concentrations of 250 nM and 500 nM but 
TMR Dylight-/AF-488 TMR + 488 + Hoechst Overlay with brightfield
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E
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not at 125 nM or lower concentrations. When Streptavidin alone is added to the cells at 
500 nM, the cells remain negative for Sytox Green. This result clearly indicates that 
concentrations of adducts of 250 nM or above cause membrane permeabilization in 
HeLa cells. We reasoned that this permeabilization could also be due to the cell 
penetrating nature of the CPDs and a byproduct of the uptake of the adducts into the 
cytosol. I therefore repeated the same experiment including a 24-hour incubation time in 
adduct free medium after the incubation with the adducts as well as several washing 
steps, in order to allow the cells to recover from the membrane permeabilization. When 
subsequently staining the cells with Sytox Green, I also observed the Sytox Green signal 
in the nuclei, showing that even when the cells are left to recover from the delivery, their 
membranes remain permeabilized which is a clear sign of occurring cell death. (data not 
shown) 
I additionally performed a CellTiter Glo assay to test if the number of viable cells is 
decreasing in response to the incubation with CPD adducts. CellTiterGlo is a cell 
viability assay measuring the amount of ATP in a well. Since only healthy cells produce 
and contain high amounts of ATP, this is a direct measure of the number of viable cells. 
In the wells with 500 nM adduct concentration, the luminescent signal and thereby the 
number of viable cells was significantly decreased as compared to the control with 
streptavidin only. (Figure 2.18 B) The cytotoxic effects observed were independent of the 
CPD length, as two different CPD sizes as well as preparation batches were tested and 
gave similar results. Incubation of the cells with adducts at 250 nM or 125 nM had much 
less effect on cell viability in the CellTiter Glo assay. (Figure 2.18 B) 
Based on these results, I decided to work with adducts at 100 nM concentration for 
subsequent experiments, as this concentration did not induce any cytotoxic effect in 
either the CellTiter Glo or the Sytox Green assay.  
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Figure 2.18 CPDs have cytotoxic effects on HeLa cells. A: Sytox Green stain of live HeLa cells after 1h 
incubation with Streptavidin-CPD adducts at indicated concentrations. TMR signal is shown in red and 
Sytox Green signal in green. Scalebars represent 10 µm. Representative images are shown out of 2 
biological repeats. B: CellTiter Glo assay on HeLa cells which were incubated with Streptavidin-CPD 
adducts of different CPD lengths for 1 h, then washed and incubated in growth medium for 24 h before 
adding the CellTiter Glo reagent. This experiment was done once in triplicates. 
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2.3.4? CPD-AS25 adducts are taken up into HeLa cells without cytotoxic 
effects at a lower concentration 
In order to assess if the monobodies can also be delivered to the cytoplasm after 
incubation at a lower concentration, I performed live cell imaging on HeLa cells after 
incubation with adducts at 100nM and subsequent washing. After 1 hour of incubation 
with the adducts at 100 nM, a TMR signal can be observed in the cytosol of the cells, 
and a very weak 488 nm signal from the monobody is detectable, which is absent in cells 
incubated with CPD adducts without monobody as a control. (Figure 2.19 A) Longer 
incubation times with the adducts, as well as in medium after a shorter incubation with 
adducts were tested in a subsequent experiment to assess whether more adducts are taken 
up over time. (Figure 2.19 B) When the cells are incubated for 1 hour in medium after 
the incubation with adducts, the 488 nm signal becomes more visible in the cytosol. This 
suggest that the fraction of adducts not containing any monobody might be taken up 
faster than the monobody-adducts. Both the 488 nm and the TMR signal are mostly 
localized in distinct speckles throughout the cytosol. After incubating the cells for 24 
hours with the adducts, both the TMR and the 488 nm signals become much stronger. 
When incubating the cells for 1 hour with the adducts and then for 24 hours in medium, 
the signal was weaker than in cells incubated with adducts for 24 hours, but still 
remained. However, even after prolonged incubation, the signal remains mainly in 
distinct speckles, which possibly represent vesicles, in most of the cells. Cells incubated 
with control adducts containing only CPDs but no monobody do not display any 488 
nm signal, showing that the observed signal in the monobody-adduct incubated cells is 
indeed coming from the AF488 label on the monobody. No cytotoxic effects could be 
observed in these cells, even after prolonged incubation with the adducts and a Sytox 
Green stain remained negative. (data not shown) 
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Figure 2.19 100 nM adducts are taken up in HeLa cells without having cytotoxic effects. A: HeLa cells 
were incubated with 100 nM AS25-streptavidin-CPD adducts or streptavidin-CPD adducts for 1h, washed 
and imaged on a confocal microscope. Representative images are shown out of one experiment where 5 
images were taken from each condition randomly. B: HeLa cells were incubated with 100 nM AS25-
streptavidin-CPD adducts for 1h (upper left) or for 24h (lower left), or with streptavidin-CPD control 
adducts for 1h (upper right) or for 24h (lower right) washed, then imaged or incubated for 1h with AS25-
streptavidin-CPD adducts, washed and incubated for 1h (upper middle) or for 24h (lower middle) in 
growth medium before imaging. Live cell images were taken on a confocal microscope, TMR signal is 
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shown in red, AF-488 signal in green and nuclei are stained with Hoechst and shown in blue (only in A). 
Representative images are shown out of one experiment where 5 images were taken from each condition 
randomly. Scalebars represent 10 µm.  
2.3.5? Immunofluorescence and colocalization analyses reveal an endocytic 
uptake route for CPD-monobody adducts 
Since the observed speckles were moving when observed in live HeLa cells, we 
hypothesized that they could be endosomes, suggesting an endocytic uptake route for 
CPD adducts at this concentration. We also wanted to assess whether the endocytosed 
adducts are translocated to the cytosol or degraded in lysosomes. I therefore performed 
colocalization experiments with antibodies against the early endosomal marker EEA1 as 
well as the lysosomal marker Lamp1. HeLa cells grown on coverslips were incubated with 
adducts for different durations and subsequently washed, fixed and permeabilized. The 
coverslips were then incubated with an antibody either against EEA1 or Lamp1, a 
secondary anti-mouse antibody coupled to Cy5 and the nuclear stain Hoechst. The 
coverslips were mounted on glass slides and analyzed using a confocal microscope. Images 
of 5 sections at the mid-nuclear plane were taken and analyzed using ImageJ and the 
JaCOP plugin developed by the BIOP at EPFL. I chose to measure the colocalization 
between CPDs and the antibody stain, since the 488 nm signal from the monobodies was 
not detectable at incubation times below 1 hour and fainter than the TMR signal at later 
timepoints. The 488 nm signal was much fainter in the fixed cells than in the previous 
experiments where live cells were observed.  
Briefly, cells were defined as regions of interest (ROIs) and throughout the 5 z-slices of 
each individual ROI, the Mander’s overlap coefficient was calculated between the TMR 
and the Cy5 channel. The results were plotted as single dots, each representing a single 
cell and showing the incidence of the antibody colocalized with the CPDs (Mander’s 
overlap coefficient 1) on the x-axis and the incidence of the CPDs colocalized with the 
antibody (Mander’s overlap coefficient 2) on the y-axis. Both coefficients range from 0 to 
1, 1 on the y-axis meaning that all the pixels of the TMR channel colocalize with pixels 
from the Cy5 channel.  
As shown in Figure 2.20, the speckles corresponding to the TMR signal partially 
colocalize with the EEA1 signal after 20 minutes and up to 2 hours of incubation with 
the adducts, reaching its maximum after 30 minutes. This suggests that CPD adducts are 
taken up in early endosomes where they can be seen from 20 minutes to 2 hours after 
addition of the adducts to the cells. From there, they then translocate to a different 
compartment as the colocalization decreases between 30 minutes and 4 hours after 
addition of the adducts. (Figure 2.20) 
In cells stained with the antibody against Lamp1, we observed an increasing 
colocalization between the TMR and the Cy5 channels with a maximum at 4h after 
addition of the adducts, which is the longest time-point analyzed. (Figure 2.21) This 
result indicates that the adducts are following a lysosomal degradation route, as the 
localization in lysosomes increases over time. 
Collectively, these results suggest that CPDs coupled to monobodies mediate an 
endocytic uptake route, meaning that CPD-coupled monobodies are first taken up in 
endosomes, which fuse with lysosomes to promote their degradation. These results are in 
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contradiction to previously published data arguing that CPDs induce a direct 
translocation over the membrane, called thiol-mediated uptake. The idea is that CPDs 
bind to thiols on the cell surface by dynamic covalent disulfide exchange, upon which 
they translocate through micellar pores and get released into the cytosol by disulfide 
exchange with glutathione.114 
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Figure 2.20 Colocalization analysis between CPDs and the early endosomal marker EEA1. A: Confocal 
images of fixed HeLa cells after incubation with adducts for the indicated time-points, and staining with a 
primary antibody against EEA1 and a secondary Cy5-coupled antibody. TMR signal is shown in green, 
Cy5 signal in red and Hoechst staining in gray. Scalebars represent 10 µm. Representative images are 
shown out of one biological experiment where 15 images were taken from each condition randomly. B.: 
Colocalization analysis using JaCOP tools and Fiji ImageJ software. Each dot represents a single cell and 
the Manders coefficient 1 is plotted on the x axis and 2 on the y axis. 
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Figure 2.21 Colocalization analysis between CPDs and the lysosomal marker Lamp1. A: Confocal 
images of fixed HeLa cells after incubation with adducts for the indicated time-points, and staining with a 
primary antibody against Lamp1 and a secondary Cy5-coupled antibody. TMR signal is shown in green, 
Cy5 signal in red and Hoechst staining in gray. Representative images are shown out of one biological 
experiment where 15 images were taken from each condition randomly. Scalebars represent 10 µm. B.: 
Colocalization analysis using JaCOP tools and Fiji ImageJ software. Each dot represents a single cell and 
the Mander’s coefficient 1 is plotted on the x axis and 2 on the y axis. 
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2.4? Monobody delivery using Bacterial Toxins 
The lab of Prof. Hak-Sung Kim has developed an effective and receptor-specific protein 
delivery system by fusing the B-subunit of Shiga-like toxin (Stx2B) from E. coli to the 
translocation domain or domain II of Exotoxin A (TDP) from P. aeruginosa.191,199,213 
They have shown that functional enzymes and short peptides can be delivered into the 
cytosol using this bacterial toxin fusion construct. However, a small number of the 
delivered molecules are likely to be sufficient to elicit a cellular response when reaching 
the cytosol. The delivery of functional stoichiometric binders to endogenous proteins 
into the cytosol has not yet been demonstrated with this toxin construct. Moreover, the 
precise uptake mechanism and intracellular trafficking route of proteins delivered using 
the Stx2B-TDP fusion construct still remains to be fully elucidated. The authors 
hypothesized that they follow the same retrograde uptake route after endocytosis as Shiga 
toxin on its own, a quantitative analysis however remains to be done to fully answer this 
question. We therefore wanted to assess if this system could be used to deliver 
monobodies to the cytosol of cells, in sufficient amounts to have an inhibitory effect on 
their target protein. This project was done with the help of Katyayanee Neopane, who 
did her master’s thesis in our lab and whom I supervised. For simplicity reasons, the 
STx2B-TDP fusion protein is named Toxin in all the fusion constructs throughout this 
thesis. 
2.4.1? Cloning and expression of Toxin-Monobody fusion proteins 
In this project, we used the monobodies AS25, targeting the Bcr-Abl kinase, and ML3, 
targeting the Lck kinase, to study the efficiency of the delivery system as well as the 
consequences of the monobody delivery on signaling. In addition, we used the green 
fluorescent protein emGFP and the non-binding HA4_Y87A monobody76 as control 
proteins. 
In a first step, we tested if recombinant fusion proteins composed of the two toxin 
subunits and a monobody can be expressed and purified. We genetically fused a 
monobody followed by a KDEL sequence to the C-terminus of the TDP. KDEL is an 
ER retention motif which is thought to facilitate the retrograde transport since it is 
required for the cytotoxicity of Exotoxin A and constructs comprising a C-terminal 
KDEL motif have shown enhanced cytosolic uptake.191,199,213 In order to visualize the 
uptake of the monobody proteins, we used two different labelling techniques. A cysteine 
residue was introduced C-terminal to the monobody and N-terminal to the KDEL motif 
by site-directed mutagenesis, to allow the site-specific labelling of the recombinant 
protein using thiol-reactive maleimide-coupled fluorescent dyes. In addition, we 
generated a construct containing a SNAP-tag N-terminal to the monobody, allowing the 
labelling with benzylguanine (BG) as a substrate for the SNAP-tag. We also introduced a 
6x-Histidine-tag (6xHis) N-terminal to the KDEL motif to allow the purification of the 
protein using Ni-NTA beads. In addition to these constructs, we generated constructs 
bearing a nuclear localization sequence C-terminal to the monobody and constructs with 
an the E3 ubiquitin ligase recruiting protein VHL in addition N-terminal to the 
monobody. The purification of these constructs as well as the experiments they were used 
for will be discussed in section 2.4.7 and 2.4.11, respectively. Figure 2.22 shows an 
overview of all the constructs generated. 
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Figure 2.22 Schematic of all the constructs generated for the project with their size as monomeric 
proteins 
The resulting constructs were transformed into the E. coli strain Origami, which bears a 
mutation in a thiol reductase, helping to conserve the disulfide bonds necessary for the 
correct folding of the toxin subunits. Upon expression, the proteins were purified using a 
Ni-NTA gravity flow column and size exclusion chromatography (SEC). Since the Stx2B 
is forming pentamers, we expected our recombinant proteins to be pentameric in native 
conditions. Indeed, we could confirm the pentameric nature of the native proteins by 
SEC, where the largest peak corresponds to the molecular weight of the pentamer, 
according to the column calibration. (Figure 2.23 A-E) The purified fractions 
corresponding to the largest peak were analyzed on a Coomassie stained SDS-PAGE gel, 
where the denatured proteins appeared as a single band corresponding to the size of the 
monomeric fusion protein. (Figure 2.23 F-J) The integrity of the obtained proteins was 
further confirmed by an immunoblot using an anti-penta-His antibody. (Figure 2.23 K-
O) All constructs were solubly expressed with reasonable yield (between 2 and 10 mg per 
liter of culture) and could be purified to good homogeneity (>90%). 
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Figure 2.23 Stx2B-TDP-Monobody fusion protein purification. The crude bacteria lysate was first 
purified on a Ni-NTA column and then by SEC. A-E: Size exclusion chromatograms, F-J: Coomassie 
stained SDS-PAGE gels with the fractions from the Ni-NTA purification (L=crude lysate, FT=flow-
through, W=wash, E=elution) and the main peak of the SEC after concentration, as well as in some gels the 
shoulder fraction from the SEC. K-O: Corresponding immunoblots with an antibody recognizing penta-
His. Purified proteins: Stx2B-TDP-emGFP (A, F, K), Stx2B-TDP-ML3 (B, G, L), Stx2B-TDP-AS25 (C, 
H, M), Stx2B-TDP-SNAP-ML3 (D, I, N), Stx2B-TDP-SNAP-AS25 (E, J, O). 
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2.4.2? Uptake of fluorescently labelled Toxin-monobody fusion proteins in 
HeLa cells 
 
In order to assess the uptake efficiency of the purified proteins, we chose HeLa cells as a 
model cell type since they grow as adherent cells, have a large cytoplasm compared to the 
nucleus, and subcellular compartments can be distinguished. We determined whether 
they express the receptor for Stx2B - Gb3 - on their surface by staining them with a 
FITC coupled anti-Gb3 (CD77) antibody for flow cytometry analysis. Most of the HeLa 
cells are CD77 positive, but the amount of CD77 expression is broadly distributed. 
(Figure 2.24 A)  
We first tested the uptake of Toxin-emGFP in HeLa cells, to verify that the recombinant 
toxin subunits are well folded and functional. Upon incubation with HeLa cells, 
fluorescent signal from the emGFP could be observed in the cytoplasm already after 15 
minutes of incubation. (Figure 2.24 C) However, independently of the time of 
incubation, some cells did not display any measurable fluorescence, and some cells were 
brighter than others. This is in line with the broad distribution of the Gb3 expression 
level on the surface within a population of HeLa cells observed by flow cytometry. 
(Figure 2.24 A) In order to quantify the number of cells taking up protein over time, 
individual cells from each timepoint were categorized into either “no fluorescence”, 
“faint” or “bright”, according to the fluorescence intensity measured across the cell. 
(Figure 2.24 B) This categorization shows that the percentage of cells taking up protein 
increases by 20% between 15 and 30 minutes of incubation, and marginally between 30 
minutes and 1 or 2 hours of incubation. 
Recombinant Toxin-AS25 with a cysteine at the C-terminus of the monobody was 
labelled using maleimide-coupled Alexa488 fluorescent dye and purified using a desalting 
column to remove excess dye. We then incubated the labelled proteins with HeLa cells at 
different concentrations and for different time periods to assess the efficiency of uptake 
by confocal microscopy. 
When incubating the cells with 1 µM protein for different times, we observed an increase 
in the mean fluorescence over time. (Figure 2.24 D) Similarly, when increasing the 
concentration of the protein, the fluorescence intensity increased in most cells. While 0.1 
µM protein was hardly detectable in the cytosol, in cells incubated with 2.5 µM protein, 
the fluorescence intensity was on average higher when compared to cells incubated with 1 
µM protein. (Figure 2.24 E) However, in line with the heterogenous uptake efficiency of 
Toxin-emGFP, also with Toxin-AS25, we observed differences in fluorescence intensity 
within a population treated for the same time and with the same concentration of 
protein.  
Collectively, these results show the uptake of both emGFP and monobodies in cells 
which express the Shiga toxin receptor Gb3, and that the uptake is both concentration 
and time dependent. 
    63 
 
Figure 2.24 Toxin-monobody delivery in HeLa cells. A: Flow cytometry plot of HeLa cells stained with 
CD77-FITC. B: HeLa cells were incubated for different durations with AF488-labelled Toxin-AS25 and 
categorized based on the average fluorescence throughout the cell. The number of cells analyzed is 
indicated below each bar. C: HeLa cells were incubated with 1µM Toxin-emGFP for different times. D: 
HeLa cells were incubated with 1 µM AF488-labelled Toxin-AS25 for different durations. E: HeLa cells 
were incubated with 0.1 µM or 1 µM or 2.5 µM Toxin-AS25 for 1h. Scale bars correspond to 10 µM. 
Representative images are shown out of one experiment where 10 images were taken from each condition 
randomly. 
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2.4.3? Uptake and labeling of SNAP-tagged Toxin-monobody fusion 
proteins in HeLa cells  
In order to test the labeling of SNAP-tagged proteins inside cells using BG-coupled 
fluorophores, HeLa cells were transiently transfected with a plasmid driving the 
expression of SNAP-AS25 under a CMV promoter and incubated with 500 nM (cell-
permeable) BG-Silicorhodamine (BG-SiR) 2 days after the transfection. The cells were 
observed by confocal microscopy and the transfected cells showed an evenly distributed 
fluorescence, already after 30 minutes of incubation with BG-SiR, whereas cells 
transfected with AS25 alone and incubated with BG-SiR did not show any fluorescence. 
(Figure 2.25 A) We next labelled recombinant Toxin-SNAP-AS25 with the cell-
impermeable SNAP substrate BG-Alexa-Fluor-647 (BG-647) and purified the labelled 
protein using a desalting column. We then incubated HeLa cells with this labelled 
protein for different durations and observed them by confocal microscopy. In some cells 
we already observed a weak fluorescent signal after only 15 or 30 minutes of incubation, 
which became stronger after 1 hour of incubation with the protein. (Figure 2.25 B) The 
staining pattern and signal intensities at different incubation times are similar as with the 
AF-488-labelled Toxin-monobody and the Toxin-emGFP constructs, suggesting that the 
uptake mechanism and duration are similar. 
We next incubated the cells with unlabeled Toxin-SNAP-monobody constructs and 
added the cell-permeable BG-SiR after a washing step. The BG-SiR effectively stained 
the monobody inside the cells, resulting in a similar staining pattern as with the pre-
labeled SNAP-tagged constructs. Control experiments with cells incubated with Toxin-
SNAP-monobody and the cell-impermeable SNAP substrate BG-647 did not show any 
staining, and cells incubated only with BG-SiR but no proteins showed a very weak 
signal. (Figure 2.25 C) These experiments show that we can use the SNAP-tag as an 
alternative means to label recombinant toxin-monobody fusions. 
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Figure 2.25 Delivery of SNAP-tagged Toxin-monobody constructs in HeLa cells. A: HeLa cells were 
transfected with SNAP-AS25 (left) or AS25 (right) and incubated with BG-SiR for 30 minutes 2 days post 
transfection. B: HeLa cells were incubated with Toxin-SNAP-AS25 prelabelled with BG-647 for the 
indicated durations. The lower right image shows HeLa cells incubated with the same unlabeled construct 
for 1h, washed and subsequently incubated with BG-647 for 1h. C: HeLa cells were incubated with 
unlabeled Toxin-SNAP-ML3 for the indicated durations, washed and incubated with BG-SiR for 30 
minutes. The upper right image shows HeLa cells incubated with the same construct followed by an 
incubation with BG-647. The lower right image shows HeLa cells incubated only with BG-SiR, but no 
protein. All images were taken of live cells on a confocal microscope. Scalebars correspond to 10 µM. 
Incubation with BG-647-labelled Toxin-SNAP-AS25
15 min
30 min
1 h
Unlabelled Toxin-AS25, wash, BG-647
Transfection and staining with Bg-SiR
SNAP-AS25 AS25
A
B
C Incubation with unlabelled Toxin-SNAP-ML3
staining with BG-SiR
1 h
1 h
30 min
no protein, staining with BG-SiR
staining with BG-647
1 h
0
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Representative images are shown out of one (A) or two (other panels) biological repeats where 10 images 
were taken from each condition randomly. 
We next wanted to assess whether the staining pattern we observed in the previous 
experiments changes with longer incubation times. Since most of the signal was seen in 
distinct speckles and not evenly distributed throughout the cytosol when we incubated 
cells with Toxin-monobody constructs for up to 4 hours, we wanted to test if the signal 
becomes more distributed when the cells are incubated with the protein for longer 
durations. We therefore labelled Toxin-SNAP-AS25 with BG-647 and incubated it with 
HeLa cells for 1, 2.5, 9 or 24 hours or we incubated the cells with the same protein for 1 
hour, followed by a washing step and further incubation in growth medium for 1, 2.5, 9 
or 24 hours. (Figure 2.26) 
We observed the same staining pattern for each duration of incubation, and even after 
prolonged incubation, the strongest fluorescent signal came from distinct speckles, with 
only a very faint signal which was dispersed throughout the cells. (Figure 2.26) The 
signal intensity increased with longer incubation times with the labelled protein. 
However, when the cells were washed and then further incubated in growth medium, the 
signal strength stayed the same for up to 24 hours. (Figure 2.26) This result indicates that 
the protein stays within the cells for at least 24 hours after it has been removed from the 
medium and is not degraded or exported out of the cells. 
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Figure 2.26 SNAP-tagged Toxin-monobody constructs remain in cells for 24h after delivery. HeLa 
cells were incubated for the indicated durations with BG-647-labelled Toxin-SNAP-AS25 (left column) or 
washed after 1h of incubation with the protein and incubated in medium for the indicated duration (right 
column). Live cells were imaged on a confocal microscope. Scale bars correspond to 10 µm. Representative 
images are shown out of one experiment where 10 images were taken from each condition randomly. 
 
2.4.4? Little colocalization between the delivered protein and Lysotracker 
In order to test if the delivered proteins employ a retrograde trafficking route to reach the 
cytosol, like native Shiga toxin and Exotoxin A, we set out to do a colocalization analysis 
with markers for different endocytic compartments in the cell.  
 
Since we observed most of the fluorescent signal in distinct speckles, we first tested if 
these speckles could correspond to lysosomes, meaning that the protein would be 
1 h
2.5 h
9 h
24 h
continue incubation with protein wash and incubate in growth medium
incubate with BG-647-labelled Toxiin-SNAP-AS25
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endocytosed and degraded in lysosomes instead of translocating to the TGN and ER via 
the retrograde trafficking route. 
We stained HeLa cells with the live cell marker Lysotracker Red for 30 minutes, after 
having incubated them for different periods with AF488-labelled Toxin-AS25. Figure 
2.27 shows that at the analyzed time-points, little of the AF488 signal colocalizes with 
the lysotracker signal, indicating that most of the lysosomes do not contain the delivered 
protein. (Figure 2.27)  
 
 
Figure 2.27 The majority of delivered Toxin-AS25 does not colocalize with the Lysotracker Red 
marker. HeLa cells were incubated with AF-488-labelled Toxin-AS25 for the indicated time periods and 
subsequently with Lysotracker red for 30 minutes. Images were taken with a confocal microscope. Scalebars 
correspond to 10 µm. Representative images are shown out of one experiment where 15 images were taken 
from each condition randomly. 
2.4.5? Toxin-AS25 partially colocalizes with ER-tracker 
We next wanted to test whether the delivered monobodies are taken up into the ER via 
the retrograde trafficking pathway. We therefore incubated HeLa cells with the live cell 
marker ER-tracker Red after incubation with AF-488-labelled Toxin-AS25 for 30 
minutes or for 1, 2 or 4 hours. 
 
15 min
30 min
1 h
2 h
LysotrackerAF-488 488 + Lysotracker Overlay with brightfield
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Figure 2.28 Toxin-AS25 partially colocalizes with ER-tracker Red. HeLa cells were incubated for the 
indicated durations with 1 µM AF488-labelled Toxin-AS25 and subsequently washed and incubated with 
ER-tracker for 20 minutes. Arrows indicate particularly visible areas where the AF488 and ER-tracker 
labels colocalize. Scale bars correspond to 10 µm. Representative images are shown out of one experiment 
where 15 images were taken from each condition randomly. 
Figure 2.28 shows that after 30 minutes as well as 1 hour of incubation with the protein, 
most of the AF-488 signal does not colocalize with the ER-tracker signal. However, after 
2 and 4 hours of incubation, some of the green signal colocalizes with ER-tracker, which 
is particularly visible where the ER structures are thin. (Figure 2.28, indicated by arrows) 
The ER-tracker stained almost the whole cytoplasm in most cells, making it difficult to 
assess whether the AS25 really colocalizes with the ER or is in close proximity. 
Nevertheless, the images taken after 2 and 4 hours indicate that the delivered protein 
30 min
1h
2h
4h
ER-Tracker RedAF-488 ER-tracker + 488 Overlay with brightfield
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could indeed be partially localized in the ER, showing that it is translocated via the 
retrograde trafficking route. 
2.4.6? Immunofluorescence imaging and quantitative colocalization analysis 
between the delivered monobody and endocytic compartments 
Both the live cell markers ER-tracker and Lysotracker resulted in a high background 
signal, which made it difficult to quantify the colocalization between the respective live 
cell marker and the signal of the delivered protein. We additionally wanted to test 
whether the protein is taken up into early endosomes, for which no live cell marker exists. 
We therefore decided to do immunofluorescence experiments with fixed cells after 
protein delivery, to be able to perform a quantitative colocalization analysis thereafter. 
We set out to do a pulse chase experiment, where HeLa cells were incubated at 37°C with 
BG-647-labelled Toxin-SNAP-AS25 for 10 minutes, after which they were washed to 
stop any further uptake and incubated in growth medium. The cells were fixed at 
different time points thereafter, with one hour being the longest time point, based on the 
finding that Toxin-emGFP can be observed in the ER after 30 minutes by the group of 
professor Hak-Sung Kim.199 
The cells were subsequently fixed and permeabilized to allow the penetration of specific 
antibodies against EEA1 to stain early endosomes (Figure 2.29 A), Lamp1 for lysosomes 
(Figure 2.30 A), Golgin97 to stain the Trans-Golgi-network (TGN) (Figure 2.31 A) and 
the ER resident protein Calreticulin (Figure 2.32 A). All antibodies used were first tested 
using different fixation and permeabilization reagents and then titrated to determine the 
optimal concentration for the staining. Controls with the FITC or AF-488-coupled 
secondary antibodies alone were performed to determine the background staining from 
the secondary antibodies, which was negligible in all cases. 
The samples were imaged using a confocal microscope and 5 sections were taken at the 
nuclear plane. Images were thereafter analyzed using ImageJ and the JaCOP plugin 
developed by the BIOP at EPFL. Briefly, cells were defined as regions of interest (ROIs) 
and a threshold algorithm was applied to distinguish true signal from background noise 
for both the delivered protein signal and the subcellular compartment marker antibody 
signal. The Mander’s overlap coefficient was then calculated between the signal of the 
647 nm channel corresponding to the delivered protein and the signal of the 488 nm 
channel corresponding to the compartment marker stain after application of the 
threshold algorithm. Representative images showing the result of each threshold 
algorithm are shown in the panel B of the Figure 2.29 to Figure 2.32. The results were 
plotted as single dots, each representing a single cell and showing the incidence of the 
delivered protein colocalized with the marker (Mander’s overlap coefficient 1) on the x-
axis and the incidence of the marker colocalized with the delivered protein (Mander’s 
overlap coefficient 2) on the y-axis. Both coefficients range from 0 to 1, 1 on the x-axis 
meaning that all the pixels of the 647 nm channel colocalize with pixels from the 488 nm 
channel. (Figure 2.29 to Figure 2.32, panel C)  
Figure 2.29 A shows that there is a colocalization of part of the signal from the antibody 
against EEA1 (green) with the AF-647 signal from the delivered protein (red). The 
quantitative analysis indicates that the colocalization increases after 10 and 30 minutes of 
incubation after the protein delivery and decreases again after 1 hour of incubation in 
growth medium. (Figure 2.29 C) This result indicates that the delivered proteins are 
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indeed endocytosed and leave the early endosomes again between 30 minutes and 1 hour 
after their internalization. 
There is very little colocalization of the protein with the signal form the Lamp1 antibody, 
suggesting that the early endosomes containing the proteins do not fuse with lysosomes 
and that the delivered monobodies are thus not degraded by lysosomal proteases. (Figure 
2.30) 
The marker for the TGN, Golgin97, produces a high background signal, despite 
optimization attempts, and a careful evaluation of the threshold algorithm was needed to 
remove all the cells from the analysis, where part of the background signal was selected by 
the algorithm. In the remaining cells, only the strongest signal was selected as true signal. 
(Figure 2.31 B) A colocalization of the Golgin97 signal with the protein was observed in 
part of the cells 10 minutes after the protein uptake, whereas 30 minutes or 1 hour after 
the delivery, very little colocalization between the two signals was observed, suggesting 
that the protein did not reach the TGN at the studied timepoints. (Figure 2.31 C) 
The staining with the antibody against Calreticulin resulted in a strong signal throughout 
almost the whole cytoplasm, which made it difficult to find an algorithm capable of 
distinguishing between the ER and the rest of the cytosol. (Figure 2.32 Figure 2.19 A) 
The selected threshold algorithm only selected the pixels with the strongest signal (Figure 
2.32 figure 2.19 B) and almost no colocalization was measured between the antibody and 
protein signals at any of the timepoints. (Figure 2.32 Figure 2.19 C) Another antibody 
against Calnexin was also tested and resulted in a very similar staining pattern than the 
Calreticulin antibody. This result indicates that the protein does not reach the ER at the 
studied timepoints, which is in line with the previous analysis using ER-tracker, with 
which the delivered protein only partially colocalized after 2 to 4 hours of incubation. 
However, the results need to be evaluated carefully, since the staining pattern of the 
antibody is not sufficiently distinct to allow a precise colocalization analysis. 
 
Collectively, the results of this colocalization analysis show that the delivered protein is 
taken up in early endosomes, after which it is not degraded in lysosomes but presumably 
translocated to a different endocytic compartment. The analysis does not allow any 
conclusions about the question, if the delivered proteins follow a retrograde trafficking 
route after their uptake, as the protein is not observed to be localized in the TGN or ER 
for up to one hour after the delivery, and longer timepoints might be needed to answer 
this question. 
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Figure 2.29 Colocalization of BG-647 labelled Toxin-SNAP-AS25 with early endosomes in HeLa 
cells. A: HeLa cells were incubated with the protein for 10 minutes, washed, incubated in growth medium 
and fixed after 0, 10 or 30 min or 1h. The cells were permeabilized and stained with a primary antibody 
against EEA1, a secondary anti-mouse antibody coupled to FITC and the nuclear stain Hoechst. Scale bars 
represent 10µm. Representative images are shown out of one experiment where 15 images were taken from 
each condition randomly. B: Result of the applied threshold algorithm, showing the fluorophore signal in 
the upper panel and the corresponding pixel selection by the threshold algorithm in the lower panel for one 
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representative ROI. C: Result of the colocalization analysis showing the average of 5 slices for each ROI, 
represented as a single dot.  
 
 
Figure 2.30 Colocalization of BG-647 labelled Toxin-SNAP-AS25 with lysosomes in HeLa cells. A: 
HeLa cells were incubated with the protein for 10 minutes, washed, incubated in growth medium and 
fixed after 0, 10 or 30 min or 1h. The cells were permeabilized and stained with a primary antibody against 
Lamp1, a secondary anti-mouse antibody coupled to FITC and the nuclear stain Hoechst. Scale bars 
represent 10µm. Representative images are shown out of one experiment where 15 images were taken from 
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each condition randomly. B: Result of the applied threshold algorithm, showing the fluorophore signal in 
the upper panel and the corresponding pixel selection by the threshold algorithm in the lower panel for one 
representative ROI. C: Result of the colocalization analysis showing the average of 5 slices for each ROI, 
represented as a single dot.  
 
Figure 2.31 Colocalization of BG-647 labelled Toxin-SNAP-AS25 with the TGN in HeLa cells. A: 
HeLa cells were incubated with the protein for 10 minutes, washed, incubated in growth medium and 
fixed after 0, 10 or 30 min or 1h. The cells were permeabilized and stained with a primary antibody against 
Golgin97, a secondary anti-rabbit antibody coupled to Alexa Fluor 488 (AF-488) and the nuclear stain 







































































































































0 min 10 min 30 min 1 h
0 0.5 10 0.5 10 0.5 10 0.5 1
0.0
0.5
1.0
Colocalization of BG-647 with Golgin97
Co
lo
ca
liz
at
io
n 
of
G
ol
gi
n9
7 
w
ith
 B
G
-6
47
A
B
BG-647 FITC (Golgin97) BG-647 + FITC BG-647 + FITC + Hoechst
0
10 min
30 min
1 h
C
    75 
Hoechst. Scale bars represent 10µm. Representative images are shown out of one experiment where 15 
images were taken from each condition randomly. B: Result of the applied threshold algorithm, showing 
the fluorophore signal in the upper panel and the corresponding pixel selection by the threshold algorithm 
in the lower panel for one representative ROI. C: Result of the colocalization analysis showing the average 
of 5 slices for each ROI, represented as a single dot.  
 
Figure 2.32 Colocalization of BG-647 labelled Toxin-SNAP-AS25 with the ER in HeLa cells. A: HeLa 
cells were incubated with the protein for 10 minutes, washed, incubated in growth medium and fixed after 
0, 10 or 30 min or 1h. The cells were permeabilized and stained with a primary antibody against 
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Calreticulin, a secondary anti-rabbit antibody coupled to Alexa Fluor 488 (AF-488) and the nuclear stain 
Hoechst. Scale bars represent 10µm. Representative images are shown out of one experiment where 15 
images were taken from each condition randomly. B: Result of the applied threshold algorithm, showing 
the fluorophore signal in the upper panel and the corresponding pixel selection by the threshold algorithm 
in the lower panel for one representative ROI. C: Result of the colocalization analysis showing the average 
of 5 slices for each ROI, represented as a single dot.  
2.4.7? Delivery of NLS-tagged fusion proteins into HeLa cells 
We next wanted to assess if part of the delivered monobody protein reaches the cytosol. 
We hypothesized that the fluorescent signal from proteins located in the cytosol could be 
masked by the much stronger signal from vesicles and therefore difficult to detect. The 
same amount of protein in vesicles than in the cytosol would also result in a weaker signal 
from the cytosol as the volume is bigger and the protein more dilute. We therefore added 
a nuclear localization signal (NLS) to our proteins, so that after reaching the cytosol, they 
would be transported to the nucleus, where we could easily distinguish them from 
vesicles in the cytoplasm. Since NLS-containing proteins are recognized in the cytosol by 
importins, to be translocated through nuclear pores, the delivery of protein to the nucleus 
means that this protein must have reached the cytosol after delivery. 
 
We cloned the NLS sequence PKKKRKVED to the C-terminal of the monobodies, N-
terminal of the KDEL sequence and expressed and purified the encoded protein in E. coli 
Origami cells as for the other toxin-monobody fusions, obtaining similar yields and 
purity. We then labelled the resulting proteins using the cysteine-reactive maleimide 
coupled Alexa Fluor 488 and purified the labelled protein as described previously. The 
protein was incubated with HeLa cells for 2.5 hours, then the cells were washed to 
remove any protein that was not internalized, and live HeLa cells were observed using the 
confocal microscope. The cells were further incubated in growth medium thereafter and 
observed again after a total of 7 hours and 24 hours of incubation. Images of 5 nuclear 
plane sections were taken for each position and processed using Fiji ImageJ. Figure 2.33 
shows a representative image for each condition.  
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Figure 2.33 Uptake of NLS-tagged Toxin-monobody proteins in the nucleus. HeLa cells were 
incubated with AF-488 labelled NLS-Toxin-AS25 or NLS-Toxin-ML3 or Toxin-AS25 without NLS for 
2.5h, washed and incubated in growth medium, so that the total incubation time was 7h or 24h. The cells 
were then stained with Hoechst and imaged using a confocal microscope. Scalebars correspond to 10 µm. 
Representative images are shown out of one experiment where 15 images were taken from each condition 
randomly. 
In order to quantify the fluorescence intensity in the nucleus of each cell, I wrote a macro 
script in Image J, measuring the intensity of the 488 nm signal in each nucleus defined 
by the Hoechst signal. A description as well as the entire macro code can be found in 
section 4.20.2. The results of this analysis are represented in Figure 2.34. 
The fluorescent signal of the labelled protein in the nucleus after 24 hours of incubation 
is significantly higher in the cells incubated with Toxin-ML3-NLS or Toxin-AS25-NLS 
than with Toxin-AS25. (Figure 2.34) This result demonstrates that part of the delivered 
proteins must have reached the cytosol. After 2.5 or 7 hours of incubation, no difference 
can be seen between the three different proteins, suggesting that the translocation to the 
2.5 h
7 h
24 h
Toxin-AS25-NLS Toxin-ML3-NLS
Toxin-AS25
AF-488 Hoechst Overlay AF-488 Hoechst Overlay
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cytosol followed by nuclear import of the proteins occurs between 7 and 24 hours after 
the initial uptake in endosomes. 
 
 
Figure 2.34 Quantification of the fluorescence intensity in the nucleus after the delivery of NLS-
tagged Toxin-monobody proteins. HeLa cells were incubated with the indicated AF-488-labelled proteins 
for 2.5h, washed, and incubated in medium for the indicated durations, prior to nuclear staining with 
Hoechst and imaging on a confocal microscope. Each dot represents the mean 488 nm fluorescence in the 
nucleus of a single cell, as measured in 5 z-planes through the nucleus and normalized to the mean of the 
control cells incubated with unlabeled Tox-AS25-NLS. P-values were calculated using a Welch two-sample 
t-test. 
2.4.8? Gb3 expression in K562 and Jurkat cells 
We next set out to assess if the delivered monobodies remain correctly folded and 
functional during the uptake, and whether the amount reaching the cytosol is sufficient 
to inhibit endogenous proteins and signaling pathways. 
Since we wanted to analyze the effect of the delivery of AS25 into K562 cells and of ML3 
into Jurkat cells, we set out to measure the expression of the Shiga-toxin receptor Gb3 in 
these cell lines. K562 and Jurkat cells were stained using an antibody against Gb3 
(CD77) and analyzed by flow cytometry. The analysis revealed that both cell lines do not 
have Gb3 on their surface and thus we would not expect any uptake of the Toxin-
Monobody fusion proteins in these cell lines. 
The formation of Gb3 and its presence in the cell membrane is dependent on the 
expression of Lactosylceramide 4-alpha-galactosyltransferase (A4GALT) or Gb3 synthase, 
which catalyzes the transfer of galactose to lactosylceramide to form Gb3. We therefore 
reasoned that expressing this enzyme could lead to the presence of Gb3 on the surface 
and render the cells susceptible for delivery using our toxin construct. The A4GALT 
cDNA encoding for Gb3 synthase was cloned into a lentiviral vector containing a 
blasticidin resistance gene for selection as well as a Tet-on system for doxycycline 
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dependent expression of Gb3 synthase. The dependence on doxycycline for the 
expression would provide us with an internal control cell line, which in absence of 
doxycycline would carry the same transgene but not express Gb3 on the cell surface. 
Stable Jurkat and K562 cells were generated by lentiviral transduction. We determined a 
minimal lethal dose of blasticidin in K562 cells of 7.5 µg/ml, in the same way as 
described in section 2.1.5 for Jurkat cells. We then supplemented the growth media of 
the K562 cells with 7.5 µg/ml and that of the Jurkat cells with 5 µg/ml blasticidin to 
select for the transduced cells. After one week of selection, all the non-transduced cells in 
a control dish were dead, meaning that the selection has resulted in a pure population 
where 100% of the cells carry the transgene. We treated the surviving cells with 
doxycycline for 24 hours to test for the presence of Gb3 on the cell surface by 
immunostaining and flow cytometry. Both cell lines expressed high levels of Gb3 
compared to HeLa cells when doxycycline was added to the growth medium but not 
when left untreated. (Figure 2.35 A) In K562 cells, a small amount of Gb3 positive cells 
were also observed in the untreated cells, showing some degree of leakiness of the plasmid 
in this cell line. We next assessed the ability of these cell lines to take up the monobodies 
fused to the toxin construct. We induced the expression of Gb3 synthase with 
doxycycline in both the transduced Jurkat and K562 cell lines and incubated the K562 
cells with 1 µM of recombinant BG-AF647 labelled Toxin-SNAP-AS25 and the Jurkat 
cells with the respective concentration of labelled Toxin-SNAP-ML3 for 1 hour. After 
washing the cells, they were observed using flow cytometry to detect the BG-647 signal. 
97% of both the doxycycline induced Jurkat and K562 cells which had been incubated 
with the labelled proteins were BG-647 positive, whereas the intensity of the signal from 
uninduced cells incubated with the same proteins was much lower. (Figure 2.35 B) To 
confirm that the proteins are indeed internalized into the cells and not only binding to 
the cell surface, doxycycline treated cells were incubated with unlabeled Toxin-SNAP-
ML3 or Toxin-SNAP-AS25, washed with PBS to remove surface-bound proteins and 
then incubated with the cell impermeable SNAP substrate BG-AF647. A fluorescent 
signal of much lower intensity than in cells incubated with labelled proteins was 
observed. (Figure 2.35 B) These results suggest that the cells have internalized the 
proteins and that the signal does not come from surface-bound proteins. 
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Figure 2.35 Gb3 expression in stable Jurkat and K562 cell lines and uptake of Toxin-monobody 
contructs. A: Jurkat (left) and K562 (right) cells were transduced with a doxycycline inducible A4GALT 
gene, to express Gb3 on their surface. The cells were treated with doxycycline for 24h, stained with an anti-
Gb3 (CD77) antibody and analyzed by flow cytometry. B: Transduced Jurkat cells (left panel) were treated 
with doxycycline for 24h (blue, orange and purple lines) or left untreated (red and green lines) and then 
incubated with BG-647 labelled Toxin-SNAP-ML3 (green and purple lines) or in medium alone (red and 
blue lines) or with unlabeled Toxin-SNAP-ML3, washed and subsequently incubated with BG-647 (orange 
line). K562 cells (right panel) were treated in the same way, but with Toxin-SNAP-AS25 instead of Toxin-
SNAP-ML3. One representative plot is shown out of 2 biological repeats. 
2.4.9? AS25 inhibits the growth of K562 cells upon delivery 
We next wanted to assess whether the amount of AS25 monobody delivered to the 
cytosol of K562 cells is sufficient to have an inhibitory effect on Bcr-Abl signaling. AS25 
has been shown to induce apoptosis upon retroviral transduction in K562 cells, which are 
dependent on Bcr-Abl signaling for their growth and survival.78 
 
We set out to measure cell survival of K562 cells after the delivery of Toxin-AS25 protein 
using the RealTime Glo MT cell viability assay, which is composed of the NanoLuc 
luciferase and a cell permeable substrate, which, when reduced in the cytosol, reacts with 
the enzyme to produce a luminescent signal. Since only metabolically active cells have a 
reducing potential, the signal intensity is directly proportional to the number of viable 
cells present. 
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Doxycycline induced K562 cells were seeded in a 96-well assay plate, and recombinant 
Toxin-AS25, or control proteins were added. Uninduced K562 cells which do not 
express Gb3 on the surface were used as a control. The cells were incubated for 4 days 
and luminescence signal was measured every 24 hours. Figure 2.36 A shows a 
representative time-course and Figure 2.36 B shows the luminescence signal at the 48-
hour and 72-hour timepoint comparing all the proteins added. All the experiments were 
done in triplicates and 6 biological repeats were done of the same experiment, whereas 
not all the control proteins were included in each repeat. 
Figure 2.36 A shows that, whereas the cell number increases with time when doxycycline 
induced cells were treated with AS25 alone or left untreated, but it decreases when the 
cells are treated with Toxin-AS25 or Toxin-SNAP-AS25. In uninduced cells not 
expressing Gb3, the addition of Toxin-AS25 or the SNAP-tagged version have no effect 
on cell growth, showing that the growth inhibitory effect of the Toxin-conjugated AS25 
is dependent on uptake via the receptor Gb3. Nilotinib is a small molecule Bcr-Abl 
kinase inhibitor and is used as a positive control. Figure 2.36 B shows that in uninduced 
cells which were not treated with doxycycline, none of the added proteins has an effect 
on cell growth. However, the incubation of doxycycline induced K562 cells with Toxin-
AS25 or Toxin-SNAP-AS25 leads to a reduction of viable cells as compared to 
uninduced cells. When 2 µM Toxin-AS25 or Toxin-SNAP-AS25 are added, the number 
of viable cells is further decreased than with 1 µM of the same proteins, indicating that 
the effect is concentration-dependent. AS25 alone has no effect on the growth of K562 
cells, showing that the inhibitory effect of AS25 is dependent on its uptake. The delivery 
of an unrelated protein, such as emGFP has no effect either, which indicates that protein 
delivery on its own has no inhibitory effect on cell growth. However, when adding 
Toxin-ML3 or Toxin-SNAP-ML3, the cells are also growing less, even though the effect 
is less pronounced than with AS25. This could be explained by the binding of ML3 to 
the Lyn kinase, which is expressed in K562 cells and the inhibition of which could have 
an effect on cell growth, in line with reports in the literature.214-219 The delivery of the 
non-binding control monobody Toxin-HA4_YA also mildly reduces cell growth as 
compared to the control. This might be due to a weak residual binding of the HA4_YA 
mutant monobody to Abl. On the other hand, the effect of the other monobodies on cell 
growth could also be due to a general toxicity of monobodies when delivered to K562 
cells using the bacterial toxin construct.  
Taken together, these results demonstrate that the uptake of AS25 in K562 cells has an 
inhibitory effect on cell growth and is dependent on the toxin construct and Gb3 on the 
surface of the target cells. 
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Figure 2.36 Realtime Glo assay after AS25 delivery in K562 cells. K562 cells were incubated with the 
indicated amounts of proteins and Relatime Glo reagents for 96h. A: Time course of one representative 
experiment. Error bars indicate the SD of 3 technical replicates. B: 48h (upper panels) and 72h (lower 
panels) timepoints comparing the different conditions with each dot representing one assay point. The 
experiment was done in technical triplicates with between 2 and 6 biological repeats, depending on the 
protein and concentration. All the technical and biological repeats are shown and p-values are calculated by 
averaging the technical replicates of each biological repeat, using a one-way ANOVA without correcting for 
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multiple comparisons. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) Error bars indicate the SD of all the 
repeats. 
2.4.10? The delivery of AS25 into K562 cells leads to apoptosis 
Small molecule kinase inhibitors targeting Bcr-Abl lead to apoptosis in CML cells by 
inhibiting Bcr-Abl mediated signaling pathways which are necessary for their growth and 
survival. We thus analyzed whether the effect on cell growth of the delivered AS25 is also 
due to apoptosis. We stained the cells with fluorophore coupled annexin V and the 
nuclear stain 7AAD. Annexin V binds to phosphatidylserine, which, in healthy cells is in 
the inner leaflet of the plasma membrane but flips to the outer leaflet when cells undergo 
apoptosis. The cells thus become positive for annexin V staining as soon as they enter 
apoptosis. 7AAD is a cell impermeable DNA binding dye, which can only enter cells that 
have a permeable cell membrane because they are apoptotic. As membrane 
permeabilization occurs only in late apoptosis, the double staining allows to distinguish 
between early (only annexin V positive) and late (double positive) apoptotic cells. 
 
The cells were stained and analyzed 24, 48 or 72 hours after incubation with Toxin-AS25 
or control proteins. Figure 2.37 shows the flow cytometry plots from one representative 
experiment with the gating strategy to separate early and late apoptotic cells. Figure 2.38 
and Figure 2.39 show the fractions of cells in early and late apoptosis, respectively, from 
all the biological replicate experiments. About 3 to 5% of the cells are in early apoptosis 
and 1-2% in late apoptosis, when no protein or treatment is added, which is expected for 
a healthy cell population. When treated with nilotinib, about 30% of the cells are found 
in early apoptosis after 24 hours of treatment, and after 48 or 72 hours, this percentage 
increases to about 40%. About 10% of the nilotinib treated cells are in late apoptosis 
after 24 hours of treatment, 38% after 48 hours and more than 50% after 72 hours of 
treatment. In the Gb3 expressing cells incubated with Toxin-AS25 or Toxin-SNAP-
AS25, 20 to 25% are in early apoptosis after 24 hours of incubation, and this fraction 
stays the same also after longer incubation. (Figure 2.38) 10% of these cells are in late 
apoptosis after 24 hours of treatment, similar to the nilotinib treated cells, and after 48 or 
72 hours, this percentage increases to about 20% for the Toxin-AS25 treated cells. 
(Figure 2.39) Cells treated with AS25 alone, and uninduced cells treated with Toxin-
AS25 or Toxin-SNAP-AS25 do not undergo apoptosis, demonstrating that the effect is 
dependent on the expression of Gb3 on the surface as well as the presence of the toxin 
construct, leading to the uptake of AS25. The delivery of Toxin-ML3 and Toxin-SNAP-
ML3 also leads to apoptosis in Gb3 expressing K562 cells, indicating that ML3 might 
indeed inhibit Lyn in these cells lines and thereby induce apoptosis. When delivering 
emGFP, no increase in apoptosis is observed as compared to untreated cells and with the 
Toxin-conjugated non-binding monobody HA4_YA, also only a small fraction of cells 
undergoes apoptosis, which is marginally higher than in untreated cells after 48 and 72 
hours of incubation.  
These results collectively show that AS25 specifically induces apoptosis in K562 cells after 
toxin mediated delivery, as in absence of Gb3 or the toxin construct, no increased 
apoptosis is observed.   
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Figure 2.37 Flow cytometry plots of annexin V-7AAD-staining after protein delivery. K562 cells were 
incubated with the indicated proteins for 24, 48 or 72 hours, washed and stained with a Cy5-coupled 
antibody against annexin V and with 7AAD, which are plotted on the x and y axis, respectively. The gates 
indicate the early and late apoptotic populations. Representative plots are shown out of 1 (Toxin-HA4_YA) 
to 4 (other samples) biological repeats. 
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Figure 2.38 Fractions of cells in early apoptosis according to the annexin V-7AAD stain after protein 
delivery. K562 cells were incubated with the indicated proteins, washed and stained with a Cy5-coupled 
antibody against annexin V and with 7AAD and analyzed by flow cytometry. The percentages of early 
apoptotic cells correspond to the gates shown in Figure 2.37 figure 2.24. Each dot corresponds to a 
biological repeat of the experiment. P-values are calculated using a one-way ANOVA without correcting for 
multiple comparisons. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) Error bars indicate the SD of all the 
repeats. 
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Figure 2.39 Fractions of cells in late apoptosis according to the annexin V-7AAD stain after protein 
delivery. K562 cells were incubated with the indicated proteins, washed and stained with a Cy5-coupled 
antibody against annexin V and with 7AAD and analyzed by flow cytometry. The percentages of late 
apoptotic cells correspond to the gates shown in Figure 2.37 figure 2.24. Each dot corresponds to a 
biological repeat of the experiment. P-values are calculated using a one-way ANOVA without correcting for 
multiple comparisons. (*p<0.05, **p<0.01) Error bars indicate the SD of all the repeats. 
2.4.11?The delivery of a VHL-ML3 fusion protein in Jurkat cells targets Lck 
for degradation 
I chose the VHL-ML3 fusion protein studied in section 2.1.5 to study protein delivery 
using the bacterial toxin construct in Jurkat cells. As the degradation of Lck is easy to 
assess by immunoblotting, without the need of T cell receptor stimulation, it is a suitable 
readout to investigate whether functional VHL fusion proteins can be delivered using the 
bacterial toxin construct.  
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We first cloned the VHL-ML3 and VHL-HA4_YA constructs shown in Figure 2.22 into 
the expression vector containing the bacterial toxin and expressed and purified the 
resulting fusion proteins in E. coli Origami cells as described previously for the other 
proteins. The expression of these proteins containing the VHL gave much lower yields 
and purity after the Ni-NTA column purification than the previously purified proteins. 
We therefore performed a series of small-scale expression trials to test different expression 
media as well as lysis buffers in order to find conditions better suited for these proteins. 
According to the results of this screen we decided to use TB medium for expression and 
HEPES buffer supplemented with Triton-X-100 as a lysis buffer. With these conditions, 
we still obtained a low, but acceptable yield of about 2 mg from 1 liter of bacteria 
culture. 
Figure 2.40 A and B show size exclusion chromatograms of Toxin-VHL-ML3 and 
Toxin-VHL-HA4_YA, respectively. The shoulder eluting just after the main peak was 
collected after the size exclusion, corresponding to the correct size of the pentamer 
according to the column calibration. Figure 2.40 C shows a Coomassie-stained gel of the 
different fractions from the Ni-NTA column and SEC purification of Toxin-VHL-ML3 
and Toxin-SNAP-VHL-ML3. The SNAP-tagged version was purified at the same time 
because we reasoned that the SNAP-tag might stabilize the protein and lead to a better 
yield, which was not the case.  
 
 
Figure 2.40 Stx2B-TDP-VHL-Monobody fusion protein purification. The crude bacteria lysate was first 
purified on a Ni-NTA column and then by SEC. A and B: Size exclusion chromatograms, the shoulder of 
the first peak corresponds to the right size of the pentamer and was purified. C: Coomassie stained SDS 
PAGE gel with the fractions from the Ni-NTA purification (L=crude lysate, FT=flow-through, W=wash, 
E=elution) and the shoulder of the main peak of the SEC after concentration. 
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We next incubated the purified proteins with Jurkat cells for 48 hours before washing 
and lysing the cells to study their effect on Lck protein levels. We observed a decrease of 
the Lck protein level in the Toxin-VHL-ML3-treated cells of more than 50%, as 
compared to cells where no protein was added. (Figure 2.41 A and B) When the cells 
were incubated with Toxin-emGFP, Toxin-VHL-HA4_YA or Toxin-VHL-AS25, we did 
not observe such a drop in Lck protein levels. The incubation with Toxin-ML3, without 
the VHL protein resulted in a very mild reduction of Lck levels in 2 out of 3 repeats. In 
the cells where the expression of Gb3 had not been induced with doxycycline, we did not 
observe any decrease of Lck protein levels after adding Toxin-VHL-ML3. On the 
contrary, Lck levels even increased slightly. On the anti-His immunoblots, we observed 
that the bands corresponding to the delivered VHL-fusion constructs were much fainter 
than of the proteins not bearing a VHL sequence. (Figure 2.41, lower blot) This indicates 
that the VHL-tagged proteins are indeed recruited to the CUL2-E3 ubiquitin ligase 
complex and degraded. Moreover, we observed an additional smaller band in the lanes 
corresponding to Toxin-ML3 and Toxin-emGFP, which correspond to the size of the C-
terminal, His-tagged parts of the proteins after cleavage by the protease furin. (Figure 
2.41 A, lower blot) This indicates that the protein is indeed internalized and cleaved by 
furin along the endocytic or retrograde pathway. In the lane corresponding to ML3, no 
band can be seen, because the protein without the toxin-construct is not taken up into 
the cells. In the lane corresponding to uninduced cells treated with Toxin-VHL-ML3, no 
band can be seen either, showing that Gb3 needs to be present on the cell surface for 
protein uptake. When uninduced cells were incubated with Toxin-SNAP-ML3, a band 
of the same strength than with doxycycline induced cells can be seen, which is surprising, 
as the cells should not be able to take up this protein without the expression of Gb3 
either. (Figure 2.41 A, lower blot) The same observation was made in the other repeats of 
the experiment, and only Toxin-SNAP-ML3 but no other proteins resulted in a band in 
the anti-His immunoblot when incubated with uninduced cells, indicating that this 
protein might bind to the cell membrane through a protein-protein interaction which is 
independent of Gb3. 
Collectively, these results demonstrate that the delivery of VHL-ML3 into Jurkat cells is 
dependent on the binding of the toxin to Gb3 on the cell surface. Furthermore, the VHL 
protein is necessary to induce Lck degradation, indicating that the VHL-ML3 protein 
recruits Lck to the CUL2-E3 ubiquitin ligase complex after its delivery to the cytosol in a 
correctly folded state.  
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Figure 2.41 Delivery of Toxin-VHL-ML3 in Jurkat cells. Jurkat cells were incubated for 48 hours with 
the indicated proteins, washed and lysed. The cell lysate was immunoblotted with antibodies against Lck, 
Actin and the His-tag. A: One representative set of western blots form the same experiment. B: 
Quantification of the Lck immunoblot normalized to Actin and to the control where no protein was 
added. Each dot represents an individual biological repeat of the experiment. P-values are calculated using a 
two-tailed t-test, comparing the values for Toxin-VHL-ML3 with the values where * are shown. (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001) Error bars indicate the SD of all the repeats. 
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3? Discussion 
3.1? Monobodies targeting SFKs 
The aim of this project was to develop monobodies that are able to discriminate between 
different SFKs and to inhibit their function in cells. Since off-target binding is a major 
challenge when developing selective protein binders, I first set out to characterize the 
selectivity of the SFK SH2 domain binding monobodies in cells. The TAP coupled to 
LC-MS/MS analysis is a rigorous way of determining monobody selectivity, as it assays 
the selectivity of monobodies on a proteome-wide scale instead of concentrating on a 
particular protein family. The TAP-MS protocol has been developed with the goal to 
keep protein complexes intact during the pull-down and to obtain a comprehensive list of 
proteins which might directly or indirectly interact with the monobodies.211  
We observed large differences in the total number of identified proteins and in their total 
spectrum counts between the first and the second repeat of the analysis of Lck binding 
monobodies. (Table 2.1 and Table 2.2) This is most probably due to differences in TAP 
efficiency, sample handling and possibly the analysis itself carried out by the proteomics 
core facility. Still, the ranking and list of the most abundant monobody binders was very 
similar between both repeats, which demonstrates the accuracy and reproducibility of the 
method. One major drawback of this type of mass spectrometry analysis is the large 
number of contaminant proteins that are typically detected, despite the two consecutive 
affinity purification steps, which makes it difficult to distinguish them from true 
interactors. The online contaminant repository for affinity purifications (CRAPome) 
database has been created in an attempt to list these common contaminators from 
affinity-purification experiments and to facilitate their identification. 
(http://crapome.org) Although very useful when doing analyses with similar purification 
tags than the ones listed in the database, a comparison with data obtained by the same 
protocol is in our case certainly more reliable. I therefore compared my results with all 
the protein lists already generated by our lab using exactly the same protocol. This 
approach allowed me to calculate a selectivity score for each protein, and to distinguish 
between true interactors and contaminants.  
When analyzing the resulting protein list, one has to consider, that the amount of a given 
protein seen by mass spectrometry analysis is determined by a combination of its cellular 
abundance and its affinity for the bait. We therefore have to take into account the cell-
type specific expression of potential monobody off-targets, especially for the different 
SFKs. Even though the SrcA family members Yes, Src and Fyn are constitutively 
expressed across cell types, Lck might for example be much more abundant in T cells, 
and therefore lead to higher spectral counts, independently of monobody binding 
affinity. However, the fact that Yes, Src and Fyn were almost completely lacking in the 
MS analysis strongly supports the findings of the yeast binding assay (Figure 2.1), ITC 
(Figure 2.2) and pY peptide competition assays (Figure 2.4), all demonstrating the 
subgroup specificity of the Lck binding monobodies.  
 
Most of the selected monobodies bind with nanomolar affinity to their respective targets, 
and especially ML3 is one of the strongest binders and most potent pY peptide displacing 
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monobodies. (Figure 2.4) However, in a functional assay, it only showed a relatively mild 
effect at inhibiting Zap70 phosphorylation upon T cell receptor activation. Despite the 
decreased Zap70 phosphorylation, there was no effect on downstream signaling 
processes, such as calcium flux and NFAT dephosphorylation. (Figure 2.6 and Figure 
2.7) This lack of signal propagation could be due to redundancies in the signaling 
pathway that are not entirely dependent on Lck or may still be functional despite 
blockade of the SH2 domain by a monobody. Fyn kinase has been reported to contribute 
to proximal TCR signaling, albeit it is less important than Lck.220 Some reports indicate 
that Fyn can directly bind to the T cell receptor221,222 and that it can partially compensate 
for the loss of Lck, especially during T cell development.223 Experiments with the Lck-
deficient Jurkat cell line JCaM1 suggest that Fyn alone is sufficient to activate the 
MAPK-ERK signaling pathway, via a PLC?1 independent pathway by recruiting Grb2-
SOS complexes directly to phosphorylated ?-chains in the TCR.224,225 Since ML1 and 
ML3 are subgroup specific and only bind Lck but not Fyn, this might be the reason for 
the relatively mild reduction in Zap70 phosphorylation. Moreover, a process known as 
kinome reprogramming, which consists in the activation of alternative signaling pathways 
in response to kinase inhibition has been frequently observed in different types of 
cancer2,226 and could also occur in response to Lck inhibition. Unlike classical kinase 
inhibitors, ML1 and ML3 do not inhibit the kinase domain of Lck, but the SH2 
domain. Albeit inhibiting certain protein-protein-interactions of Lck with its substrates, 
the activity of the kinase domain is not altered by the monobodies, and Lck might still be 
able to bind substrates via its SH3 domain and/or phosphorylate substrates 
independently of the SH2 domain. An alternative explanation for the reduced Zap70 
phosphorylation in ML1 or ML3 expressing cells could be that the monobodies are 
binding directly to Zap70 as an off-target. However, we detected only very low spectral 
counts for Zap70 in the second repeat of the TAP experiment in Jurkat cells expressing 
ML1 and ML3, with total spectrum counts (TSC) of less than 1% of the TSC for Lck. 
Moreover, the addition of ML3 to lysates from activated T cells blocked the binding of 
Zap70 to recombinant Lck SH2 domain, (Figure 2.5) providing further evidence that 
ML1 and ML3 inhibit the binding of Zap70 to Lck and do not bind Zap70 directly.  
A puzzling observation was that, despite the very similar binding mode to the Lck SH2 
domain, ML1 is not able to compete with a pYEEI peptide while ML3 is, whereas both 
monobodies competed with two other pY peptides having a lower affinity for the Lck 
SH2 domain. (Figure 2.4) In line with this, the inhibition of Zap-70 phosphorylation by 
ML1 was less pronounced than by ML3. The crystal structures of ML1 or ML3 in 
complex with the Lck SH2 domain, that were obtained during the study,210 show that 
both monobodies bind to the +3-specificity pocket, which is most likely responsible for 
their capacity to distinguish between the SrcA and SrcB subgroups. In contrast, the pY 
binding pocket of the SH2 domain is less occluded by the CD loop of ML1 than ML3, 
which could be the reason why ML3 shows more potent binding inhibition in several 
assays. 
We repeatedly observed lower protein levels of ML3 than ML1 in Jurkat cells transduced 
with the respective plasmids, even when using a different expression vector. (Figure 2.6) 
However, we observed the same mRNA levels in both cell lines suggesting that protein 
levels are regulated post translationally, and that the cells might be able to adapt to the 
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inhibitory effects of the monobodies by reducing their protein levels, or that ML3 is a less 
stable protein as ML1 in cells and therefore has a shorter half-life. 
 
The degradation of Lck by ML1 or ML3 fused to VHL resulted in a more pronounced 
reduction in Zap70 phosphorylation upon TCR activation, as compared to the 
expression of ML1 or ML3 alone. (Figure 2.9) This observation is consistent with reports 
from the group of Prof. Craig Crews, that lower IC50 values can be reached when 
conjugating kinase inhibiting drugs to a small molecule VHL-ligand (PROTAC concept) 
than with the drug on its own.227,228 They rationalize this finding with the fact that 
degradation of the target protein inhibits downstream signaling in a more sustained way 
than the binding of an inhibitor which needs to continuously bind at saturating 
concentrations.205 
Experiments measuring Ca2+-flux and phosphorylation of downstream proteins in these 
cells would clarify whether this more pronounced reduction in Zap70 phosphorylation 
could have consequences on downstream signaling in contrast to cells expressing ML1 or 
ML3 alone. Another approach would be to use a reporter cell line for one of the 
downstream transcription factors, for example NFAT. 
 
Conclusively, we showed that the monobodies ML1 and ML3 inhibit proximal T-cell 
signaling and that this effect can be increased by coupling them to the E3-ubiquitin ligase 
VHL, inducing Lck degradation. They could be further used to study T cell receptor 
signaling or other signaling pathways involving Lck, Lyn, Blk or Hck, and to inhibit 
deregulated signaling in cancer cells or autoimmune disease.  
3.2? Monobody delivery using CPPs 
Since CPPs have been the first method of delivering proteins into cells, and many of 
them are of natural origin, we first chose to test their applicability to monobodies. We 
chose Tat because it is a naturally occuring peptide and the first discovered CPP,87 and 
CPP44 because it has been proposed to be homing specifically to AML and CML cells.100 
Polyarginine has been proposed to be the simplest sequence still able to deliver proteins, 
which is why we included it into our study. We ordered all peptides with and without a 
red fluorescent TAMRA, because this fluorophore is pH-independent and thus still 
visible in the acidic compartment of lysosomes.  
I established a protocol to activate these cysteine-modified CPPs using DTNB and 
thereby making them reactive towards free thiols, allowing to covalently ligate them to 
cysteine-containing proteins by a disulfide bond. However, even though the ligation of 
the activated CPPs to monobodies appeared to be effective, as demonstrated by the 
colorimetric reaction as well as analytical HPLC, the resulting protein was almost entirely 
lost through precipitation. Different attempts to dilute the protein in guanidinium-
containing buffers and to then refold it have all failed. This apparent tendency of CPP-
coupled monobodies to aggregate or precipitate is in line with our previous difficulties to 
express and purify them as fusion proteins in E. coli. Highly positively charged CPPs 
might form electrostatic interactions with negatively charged amino acids in the 
monobodies that could have a destabilizing effect. Therefore, an unfolded linker between 
the CPP and the monobody might help improving the solubility of the fusion proteins 
and could be assessed in a future attempt. It would be very interesting to test the cellular 
effects of monobody delivery using CPPs, if a stable construct can be generated. 
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On the other hand, CPPs have been shown to lead to endosomal entrapment of the 
majority of the protein cargo by an increasing number of groups.94,229,230 In order to 
overcome this limitation, different strategies to enhance the endosomal escape have been 
proposed.109,231 The combination of endosomal-escape enhancing mechanisms with CPPs 
might be useful also for the delivery of monobodies and would be interesting to assess. 
However, by comparing CPPs to the other two protein delivery approaches that I have 
worked on during my PhD, I think that CPPs alone are less promising for the delivery of 
functional proteins to the cytosol, even though they might be used in combination with 
other methods. 
3.3? Monobody delivery using CPDs 
As CPDs have been proposed as cellular delivery agents for certain macromolecules, 
which can circumvent the endosomal escape problem frequently encountered with CPPs 
and other methods, I chose to test if I could use them to deliver functional monobodies 
into cells. The first attempts of coupling biotinylated monobodies to CPDs via 
streptavidin were hampered by extensive precipitation of the adducts. However, rigorous 
and systematic testing of different buffer conditions led to an optimized protocol, which 
allowed me to avoid major precipitation issues. When performing the first tests in HeLa 
cells, I could observe a fluorescent signal inside the cells, demonstrating that the adducts 
were indeed taken up. (Figure 2.16 and Figure 2.17) However, I also observed signs of 
cytotoxicity, such as membrane blebbing, irregular nucleus shapes and cell debris in a 
large fraction of cells. When I counterstained the cells with Sytox Green, a DNA-
intercalating dye which does not penetrate healthy cells, the nuclei became green 
fluorescent, demonstrating that the cells were permeabilized. Even when I washed the 
cells after having incubated them with adducts for one hour, and then incubated them in 
growth medium for another 24 hours, the cells remained permeabilized, as indicated by 
the Sytox Green staining. (Figure 2.18 A) I additionally performed a Cell Titer Glo assay, 
which also showed that the adducts at a concentration of 500 nM are toxic to HeLa cells. 
(Figure 2.18 B) Since I also did the same tests with adducts which did not contain any 
monobodies, the cytotoxic effects must stem from the CPDs, and not from the 
monobodies. 
These results clearly demonstrate that CPDs are toxic to HeLa cells when added at 
concentrations of 500 nM. Cells incubated with 250 nM adducts were also positive for 
the Sytox Green staining but did not show cytotoxicity in the CellTiter Glo assay. These 
results are contradicting previous studies from the group of Prof. Stefan Matile, claiming 
no cytotoxicity of the CPDs for concentrations up to 2.5µM and negligible cytotoxic 
effects at 10µM, as measured by an MTT assay.113 The reasons for these observed 
differences are unclear to us. 
I nevertheless decided to continue the study with a lower concentration of 100 nM of the 
adducts as no cytotoxicity was observed with this concentration. Since endosomal 
entrapment is a common challenge for protein delivery, I set out to assess whether CPDs 
could overcome this limitation and deliver monobodies to the cytosol of HeLa cells.  
A fluorescent signal from the labelled monobodies was observed in the cells after 
incubation, showing that even at lower concentrations, CPDs were effective at promoting 
the cellular uptake of the adducts. (Figure 2.19) However, most of the fluorescent signal 
originated from distinct speckles within the cell and no dispersed signal was observed, 
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also in contrast to delivery experiments with different cargoes, which have been published 
by the group of Prof. Matile.113,116 When observed in live cells, these speckles were in part 
moving in the cell, indicating that they could be intracellular vesicles.  
I hypothesized that these speckles could be endosomes and therefore performed 
immunofluorescence experiments with antibodies against the early endosomal marker 
EEA1 as well as the lysosomal marker Lamp1. (Figure 2.20 and Figure 2.21) First of all, I 
observed a much less intense fluorescent signal from the labelled monobodies in these 
fixed cells as when observing live cells. This could be due to a quenching of the signal by 
the fixation and permeabilization method, or to a less efficient monobody delivery in this 
set of experiments, as compared with the live cell experiments. Since a new batch of 
CPDs was used, there could also be a variation in the coupling or delivery efficiency 
between different batches of CPDs. Because the intensity of the monobody signal was 
very low, especially at early time points of the delivery, I chose to analyze the 
colocalization between the signal from the CPDs with the signal from the antibodies. I 
observed an increasing colocalization between early endosomes and the CPDs for up to 
30 minutes, after which it decreased again. (Figure 2.20) This observation suggests that 
CPDs coupled to proteins are at least in part taken up via endocytosis. I also observed an 
increasing colocalization of the CPDs with lysosomes, starting as early as 20 minutes after 
addition of the adducts. (Figure 2.21) 
These results collectively show that CPD-monobody adducts are at least partially taken 
up by endocytosis, which fuse with lysosomes along the endocytic route, leading to a 
degradation of the adducts. I did not address whether the adducts are degraded over time, 
and further experiments including longer time points as well as a quantitative analysis 
would be needed to answer this question. The fact that the fluorescent signal from the 
CPDs was lower after incubation with adducts for one hour followed by medium for 24 
hours, than after incubation with adducts for 24 hours indicates that the adducts might 
be degraded when they are removed from the medium and are not taken up any longer. 
Further experiments would be needed to test this hypothesis. 
 
These results do not agree with the model proposed by the group of Prof. Stefan Matile, 
by which CPDs are delivered into cells through a thiol-mediated uptake mechanism, and 
not through endocytosis.113,114 They observe very strong fluorescent signals from cells 
incubated with fluorescent CPDs, including fluorescence in the nucleoli already after a 
few minutes of incubation.113 However, the thiol-mediated uptake model is a theoretical 
hypothesis and remains to be confirmed experimentally. On the other hand, CPDs could 
behave differently and follow a different cellular uptake route when coupled to proteins 
than when coupled to fluorophores or other small molecules, which were used in the 
studies of the Matile group. It has been shown that CPPs can be taken up into cells by 
different mechanisms depending on the cargo that they are coupled to, as well as the cell 
type.93,94 Therefore, and because streptavidin together with the monobody is 
approximately 65 kD in size, it is very likely that the uptake is not following the same 
route as when a smaller cargo is attached to the CPDs. CPDs have also been shown to at 
least partially colocalize with the live cell marker for lysosomes, Lysotracker, by Fu et al., 
who also studied protein delivery using CPDs.115 They have shown PARP1 cleavage upon 
the delivery of CPD-conjugated Caspase 3 as well as a decrease in cell viability upon 
delivery of the small molecule doxycycline using CPDs. However, they incubate cells 
with adducts at concentrations below 100 nM, which is probably sufficient since low 
amounts of caspase 3 as well as of doxycycline already elicit a biological response. 
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In a later publication, the Matile group reported the delivery of streptavidin reaching the 
nucleoli after delivery.116 They used the same protocol for the formation of streptavaidin-
CPD adducts and HeLa cells were incubated for 1 hour with 1 µM of the resulting 
adducts of a size of approximately 77kD. The cells show a strong fluorescent signal from 
both the CPDs as well as a fluorophore coupled to streptavidin, mostly in large speckles 
in the nuclei. However, even though the cells are rounded up and show signs of 
cytotoxicity, no toxicity test was done, and no explanation is given, on the mechanism, 
by which these large adducts can rapidly enter cells and even accumulate in nucleoli.  
 
In order to reduce the cargo size, a different way of coupling monobodies to CPDs 
without the need of streptavidin could be envisaged, such as native chemical ligation, 
which is commonly used to ligate peptides. On the other hand, a combination of CPDs 
with peptides promoting endosomal escape could be used to avoid the endosomal 
entrapment observed after the delivery of monobody-CPD-adducts. Several endosomal 
escape promoting peptides have been described and are listed in the introduction. 
In conclusion, I demonstrated that low, subtoxic concentrations of CPDs can be used to 
deliver monobodies into cells. However, this method might benefit from a combination 
with peptides promoting endosomal escape, or other methods to avoid endosomal 
entrapment. 
3.4? Monobody delivery using bacterial toxins 
To enable the development of monobodies and potentially other protein binders as 
protein-based therapeutics, we were able to validate the use of bacterial toxins for the 
cellular delivery of monobodies. Different bacterial toxins have been proposed and tested 
for protein delivery, and differences in their efficacy, which might be dependent on both 
the cargo and the cell type have been identified. The anthrax toxin pore has for example 
been shown to be effective at delivering proteins which are able to unfold in order to 
translocate through the pore into the cytosol, whereas more stable proteins will remain 
trapped in endosomes.140 Endosomal entrapment is a common drawback for many 
protein delivery approaches, including for bacterial toxin-mediated delivery as it has been 
observed with Diphtheria toxin and in some cases Anthrax toxin.168 Toxins which 
employ the host cell’s retrograde trafficking route to reach the cytosol could overcome 
this limitation. We therefore chose to study the delivery of monobodies by a fusion 
construct between Shiga-like toxin and Pseudomonas Exotoxin A, which has been 
introduced by the group of Prof. Hak-Sung Kim.199 
 
For monitoring the uptake of the proteins into cells, we used two different labelling 
strategies. In the first approach, a maleimide coupled dye was covalently attached to free 
thiol groups on cysteine residues. Since the fusion protein is purified and kept in a non-
reducing buffer, we assumed that the four cysteines present in the toxin part would 
remain in their disulfide state, which is essential for their native structure, and that the 
dye would only be coupled to the C-terminal cysteine. The fluorescent signal observed 
within the cells after incubation with labelled Toxin-monobody fusion proteins 
demonstrates that the toxin part remains correctly folded and functional after labelling. 
(Figure 2.24) The second labeling strategy, using the SNAP-tag has several advantages 
over labelling with cysteine-reactive dyes. First, it allows the site-specific labelling of a 
specific tag which is far away from the toxin subunits essential for the uptake. Second, 
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since cell-permeable as well as -impermeable SNAP substrates are commercially available, 
it enabled us to distinguish between surface-bound and internalized proteins, providing 
an additional control for the cellular uptake of the delivered proteins. Third, the SNAP-
tag helped stabilizing the recombinant toxin-monobody fusion proteins, leading to 
higher protein purification yields, as well as less precipitation upon labelling as compared 
to labelling with the maleimide-coupled dye. The staining patterns we observed after 
incubating HeLa cells with the labelled proteins were similar with cysteine-labelled 
proteins as with SNAP-tag-labelled proteins, suggesting that Stx2B is in both cases able 
to bind Gb3 and that neither of the two strategies hinder the protein uptake. (Figure 
2.25) 
 
Live cell imaging demonstrated the uptake of the fusion proteins into cells and no 
reduction in fluorescence intensity was observed for up to 24 hours after the uptake. 
(Figure 2.26) The strongest fluorescent signal however came from distinct speckles of 
which some were moving in live cells, suggesting that the delivered proteins were at least 
partially located in vesicles. A strong fluorescent signal coming from vesicles could also 
mask a fainter signal from proteins which are dispersed in the cytosol, as the much bigger 
volume of the cytosol would lead to a dilution of the protein and a less intense signal 
than in vesicles. In order to determine the nature of these vesicles and the uptake route 
followed by the monobody, we performed a colocalization analysis with markers for 
different endocytic compartments. Our first attempt using live cell imaging and markers 
proved challenging due to the lack of specific live cell markers for different types of 
endosomes and the high background signal of the existing markers for lysosomes 
(Lysotracker) and ER (ERtracker). (Figure 2.27 and Figure 2.28) We therefore set out to 
do immunofluorescence experiments, allowing the use of antibodies against proteins 
specifically expressed in different subcellular compartments. The colocalization analysis 
with EEA1 suggested that the proteins first enter early endosomes, from which they 
appear to escape between 30 minutes and 1 hour after the uptake. (Figure 2.29) 
Immunofluorescence with an anti-Lamp1 antibody showed only little colocalization 
between the delivered proteins and the antibody, suggesting that the proteins do not 
undergo lysosomal degradation, or only to a small extend. (Figure 2.30) The presence of 
fluorescent protein in live cells for up to 24 hours further supported this hypothesis. 
(Figure 2.26) The antibodies used as markers for the TGN and for the ER both resulted 
in high background signal despite efforts of optimization and testing a second antibody 
(anti-Calnexin) as a marker for the ER, which hampered the application of a threshold 
algorithm to distinguish true signal from background. Very little colocalization between 
the delivered proteins and either the markers of the TGN or the ER was detected at any 
of the analyzed time points, suggesting that the proteins do not reach these 
compartments within one hour after their uptake. (Figure 2.31 and Figure 2.32) The 
studied time points were chosen based on the publication from the group of Prof. Hak-
Sung Kim, showing that EGFP delivered using this toxin fusion construct already 
reached the ER after 30 minutes of incubation.199 However, this hypothesis is based on a 
qualitative evaluation of cells incubated with the live cell marker ER-tracker, which gave 
the same diffuse background signal as in our experiments and therefore might be partly 
unspecific. Early studies of the retrograde transport of Shiga-toxin report the presence of 
Shiga-toxin B subunit in the Golgi apparatus as early as 20 minutes after the 
internalization, and its colocalization with a KDEL-tagged fluorescent protein only 2 to 5 
hours after the uptake.147 When coupled to the TDP subunit and a protein to be 
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delivered, we would therefore maybe expect even longer trafficking times as for the B-
subunit alone. Further experiments including longer time points might therefore be 
needed to show a localization of the delivered proteins in the TGN or ER, demonstrating 
their uptake via the retrograde trafficking route.  
 
In order to determine the nature of the vesicles in which at least part of the delivered 
proteins remain for up to 24 hours, further experiments will be needed. Retrograde 
trafficking can occur at different stages along the endocytic route and originate from 
different types of endosomes, early, late or recycling endosomes.184,232 Which of these 
compartments are involved in the trafficking of Stx2B-TDP-monobody fusion proteins 
remains to be elucidated. This question could be answered by immunofluorescence 
experiments with antibodies against proteins which localize to these compartments, for 
example Rab9 for late endosomes and Rab11 for recycling endosomes.  
In order to elucidate whether the delivered proteins are at least in part reaching the 
cytosol, we added an NLS sequence to their C-terminus. Nuclear localization is easier to 
measure than cytoplasmic localization, due to the smaller volume of the nucleus as 
compared to the cytosol and the absence of vesicles which might mask the fainter 
fluorescent signal in the cytosol. The NLS sequence is bound by importins in the cytosol, 
which enable its translocation through the nuclear pore. In the nucleus, GTP bound 
form of the small GTPase Ran binds to this complex, reducing the affinity of importin to 
the protein and thereby releasing the protein into the nucleus.233 Thus, if proteins are 
transported to the nucleus, they must have reached the cytosol, as they can only be 
recognized by importins in the cytosol. We have found an increase in fluorescence in the 
nucleus after 24 hours of incubation with two different monobodies, as compared to a 
control construct of the same sequence which is lacking the NLS. (Figure 2.33 and 
Figure 2.34) This result demonstrates that the delivered proteins reach the cytosol at least 
partially, as the fluorescent signal from the nuclei from cell incubated with the NLS-
tagged constructs was about 2.5 to 3 times higher than with the control construct. 
However, this experiment does not allow a quantitative analysis to determine the exact 
amount of protein taken up in the cytosol.  
The lack of precise quantification methods for protein delivery is a common problem in 
the field, which has been addressed by subcellular fractionation methods. There are 
numerous different protocols for this technique, which is however prone to artifacts. Our 
attempts to do a subcellular fractionation of HeLa cells have failed, because we were 
unable to completely avoid any contamination between the cytosolic and the different 
endosomal compartments. Besides, this technique requires a large number of cells, as 
some of the fractions are of very small volumes, which would require large amounts of 
recombinant proteins to study their subcellular localization using this technique.  
In order to overcome these limitations, the group of Prof. Andreas Plückthun has 
proposed a biotin ligase-based assay to objectively quantify cytosolic delivery, which is 
independent of protein function.140 The bacterial BirA enzyme is expressed in the studied 
cell line and biotinylates delivered proteins carrying an Avi-tag. Since the enzyme is only 
expressed in the cytosol, the amount of biotinylated versus non-biotinylated protein then 
gives a measure of the fraction of the protein which has reached the cytosol.  
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It would be interesting to assess the amount of monobodies delivered using the bacterial 
toxin construct using this approach, in order to test how effectively the delivered 
monobodies are translocated to the cytosol.  
Another way of showing that the monobodies are reaching the cytosol is by testing their 
function. Since monobodies interfere with their target in a 1:1 stoichiometry, monobody 
concentrations above the KD of the target binding are required in order to effectively 
inhibit the target protein.  
 
We have demonstrated that the growth of K562 cells, which are dependent on Bcr-Abl 
activity for their survival, is inhibited after the delivery of AS25. Moreover, the delivery 
and growth inhibiting effect of AS25 is dependent on both the presence of Gb3 on the 
cell surface and the bacterial toxin subunits fused to the monobody. (Figure 2.36) In a 
second step, we could also demonstrate that K562 cells undergo apoptosis upon delivery 
of AS25, again in a Gb3- and toxin-dependent manner. (Figure 2.37) We did not 
observe any growth arrest or apoptosis when replacing the monobody with emGFP, 
whereas ML3 or the non-binding control monobody HA4_YA also affected the cell 
growth and apoptosis, albeit the percentage of cells undergoing apoptosis was lower than 
with AS25. (Figure 2.38 and Figure 2.39) 
The growth-inhibiting effect of ML3 could be explained by the high affinity of ML3 for 
Lyn, which has been shown to be required for the proliferation of Bcr-Abl dependent 
cells.214 In addition, Lyn has been implicated in the survival of drug resistant CML 
cells.216,217,219 HA4_YA however, which also showed mild inhibition, is not binding to 
either Lyn210 or Abl kinase76 and should thus not influence the survival of K562 cells. We 
cannot exclude that HA4_YA might bind to another protein involved in K562 cell 
survival, which we have missed so far. On the other hand, these results could also be 
explained by a general toxicity of monobodies when delivered into cells. Testing Bcr-Abl 
negative cell lines could help to resolve this issue. 
 
Shiga toxin and Pseudomonas Exotoxin A both hijack the cellular ER-associated protein 
degradation pathway (ERAD), responsible for the translocation of misfolded proteins 
from the ER to the cytosol.144,150,172 Following furin cleavage, the A subunit of Shiga toxin 
is released from the B-subunit by disulfide bond reduction and then binds to chaperones, 
which unfold and direct the protein to the translocon channel in the ER membrane for 
retrotranslocation to the cytosol.172 The PE domain-II is also recognized by the 
translocon, leading to the export of the PE domain-II and -III from the ER to the cytosol 
via the same mechanism.144 Proteins thus need to unfold to pass through the translocon 
channel, and the failure of proteins to unfold and exit the ER leads to their 
accumulation. It has been shown that the accumulation of unfolded or misfolded 
proteins can cause ER-stress and the activation of the unfolded protein response (UPR) 
pathway leading to a more rapid protein clearance or apoptosis of the cell.234,235 This 
mechanism has been identified as one of the reasons for neuron degeneration in 
Alzheimer’s disease in response to amyloid-? accumulation236 and can also be induced by 
the expression of recombinant proteins.237 Monobodies are thermodynamically very 
stable238 and might unfold less readily than the effector domains of the bacterial toxins. 
After furin cleavage and disulfide reduction of the TDP, part of the TDP protein remains 
covalently attached to the monobody. A stable monobody could possibly prevent the 
complete unfolding of the cleaved TDP-monobody fusion protein, leading to its 
accumulation in the ER. This would explain the apoptosis observed to a varying extend 
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in the cells incubated with different Toxin-monobody constructs. To test this hypothesis, 
we incubated HeLa cells with the same proteins and measured their growth with the 
Realtime Glo assay. Although the number of HeLa cells was slightly reduced (15% as 
compared to the control) after 72 hours of incubation with Toxin-AS25, this effect was 
much less pronounced than with K562 cells, and we did not observe any decrease of cell 
numbers upon incubation of the cells with Toxin-SNAP-AS25, Toxin-HA4_YA or 
Toxin-emGFP. (data not shown) These results indicate that monobodies do not cause 
any cytotoxicity related to their accumulation in the ER upon delivery, but rather that 
AS25 is specifically cytotoxic to K562 cells. On the other hand, HeLa cells could also be 
less susceptible to ER stress caused by unfolded proteins, or they could take up less 
protein than K562 cells. Given that the expression of Gb3 in the cell membrane is similar 
in HeLa cells as in A4GALT-expressing K562 cells, I think that this latter explanation is 
unlikely. (Compare Figure 2.24 A and Figure 2.35 A) 
 
Kinase inhibitors against Bcr-Abl, such as Imatinib and Nilotinib, bind the kinase 
domain and thereby inhibit the phosphorylation of downstream targets, including of the 
transcription factor Stat5, leading to apoptosis.239-241 When measuring Stat5 
phosphorylation in the K562 cells which we incubated with the toxin-AS25 constructs, I 
could not detect a reduction in Stat5 phosphorylation. (data not shown) In the original 
publication describing AS25, the authors observed that the percentage of GFP-positive 
cells after transduction with AS25 decreased over time, indicating that they undergo 
apoptosis due to Bcr-Abl inhibition by AS25.78 Even though a reduction of phospho-
Stat5 levels has been shown in response to HA4, another Bcr-Abl targeting monobody, 
that blocks the pY pocket of the SH2 domain, it has not yet been demonstrated that Bcr-
Abl inhibition by AS25 also has an effect on Stat5 phosphorylation.76 A strong effect of 
the Bcr-Abl SH2-kinase interface on STAT5 activation was demonstrated in Bcr-Abl 
transduced Ba/F3 and UT-7 cells77, but dependence of K562 cell survival on STAT5 
activation has not been demonstrated. It therefore remains possible, that Bcr-Abl 
inhibition by AS25 in K562 cells leads to apoptosis via a different mechanism that is 
independent of STAT5, or that AS25 is killing K562 cells by an off-target effect. The 
rapid cell death of K562 cells transduced with AS25 did not allow a selectivity study by 
affinity purification and it thus remains an open question, whether AS25 has off-targets 
in K562 cells. Another way of testing if AS25 inhibits Bcr-Abl would be to directly 
measure the activation loop phosphorylation of Bcr-Abl, which has been shown to be 
reduced in cells transduced with the tandem monobody HA4-7c12.77 
 
Further evidence, that proteins coupled to the Stx2B-TDP toxin construct can reach the 
cytosol following uptake, is provided by the delivery of VHL-ML3 into Jurkat cells. 
In the previous section, I have discussed the degradation of Lck induced by the 
expression of VHL-ML3 in Jurkat cells. VHL can only actively recruit the Cullin2 E3 
ubiquitin ligase complex when in the cytosol, providing a direct way of testing whether 
the amount of delivered monobodies reaching the cytosol is sufficient to induce the 
degradation of a target protein. We could demonstrate that indeed, Lck protein levels are 
reduced in cells expressing Gb3 that were incubated for 48 hours with the Toxin-VHL-
ML3 fusion protein. (Figure 2.41) We did not observe this effect in cells lacking Gb3 or 
when incubating them with VHL-ML3 alone, demonstrating that the degradation of Lck 
is dependent on the delivery of VHL-ML3 by the bacterial toxin construct. We moreover 
did not observe the effect when replacing ML3 with HA4_YA or with AS25, which 
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shows that ML3 must be folded and fully functional to be able to bind Lck and to lead to 
its degradation. In order to demonstrate that Lck is degraded following its ubiquitination 
by the Cullin2 ubiquitin ligase complex, it would be interesting to measure ubiquitinated 
Lck upon delivery of VHL-ML3. 
 
In summary, we have demonstrated that proteins can be delivered into the cytosol of 
different cell types by the Stx2B-TDP bacterial toxin fusion construct. The lack of Gb3 
expression on Jurkat and K562 cells was used to demonstrate the dependence of the 
delivery on the binding of Stx2B to Gb3. This provides the delivery system with cell-
selectivity that could be used to specifically target certain cancer cell types that 
overexpress Gb3, such as Burkitt’s lymphoma cells, gastric adenocarcinoma, colorectal 
cancer cells and others.194,242-244 On the other hand, the receptor specificity might also be 
altered in order to target other cell types. Efforts to replace Stx2B by a, EGFR targeting 
repebody or by human EGF have been made by the group of Hak-Sung Kim.155,199 Albeit 
less efficient for cellular delivery than the constructs with Stx2B, these approaches are 
promising and further development could lead to an even more versatile bacterial toxin 
based delivery system.  
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4? Materials and methods 
4.1?  Cloning 
4.1.1? Gateway cloning 
The Gateway cloning system was used to clone all the monobodies into the pRV 
expression vector for the TAP experiments and to clone the SNAP-AS25 and Toxin-
monobody-NLS constructs into the pCS2 vector for transient transfection. The monobody 
genes were first amplified by PCR from the pHFT vector using primers compatible with 
gateway cloning. The amplified DNA was then introduced into the pDONR201 vector 
using the BP clonase mix (Invitrogen) and then from there into the destination vector 
pRVNTAP-GS-Gw using LR clonase mix (Invitrogen), prior to transformation in the E. 
coli strain DH5?. The hPGK vector was obtained from the laboratory of Prof. Jörg 
Huelsken (EPFL), and the monobodies ML1, ML3 and HA4_YA were introduced using 
Gateway cloning, using the same protocol as for the pRV vector. 
All DNA preparations were made using the QIAGEN Miniprep kit and all the resulting 
constructs were confirmed by sequencing.  
4.1.2? Site-directed mutagenesis 
A C-terminal cysteine way introduced by site directed mutagenesis using the Quik-
change site directed mutagenesis kit (Stratagene) at the C-terminus of the monobodies 
AS25, AS27, HA4, Nsa5, and Nsa5_S63K for the CPP project as well as the monobodies 
AS25 and ML3 for the bacterial toxin project. 
4.1.3? Conventional cloning 
The toxin-monobody, Toxin-SNAP-monobody constructs and the constructs with 
nuclear localization sequence (NLS) were generated by conventional cloning. The Stx2B-
TDP construct was obtained from the laboratory of Prof. Hak-Sung Kim (KAIST, 
Korea), and the original insert was replaced by the monobodies using HindIII and NheI 
restriction enzymes.  
The monobodies AS25, AS27, HA4, Nsa5, and Nsa5_S63K had already previously been 
cloned in the pHFT2 vector containing a 10x-His-tag and a Flag-tag and were obtained 
from the laboratory of Prof. Shohei Koide (University of New York, USA). 
4.1.4? InFusion cloning 
The A4GALT gene was obtained from the Gene expression core facility at EPFL and 
amplified using primers with 15bp overhangs complementary to the PEM24 vector and 
compatible with InFusion recombinase. The PEM24 vector was obtained from the 
laboratory of Prof. Etienne Meylan (EPFL). The vector was linearized using HpaI and 
PacI restriction enzymes and the A4GALT sequence was introduced using the InFusion 
recombinase kit according to the manufacturer’s instructions (In-Fusion® HD Cloning 
Kit User Manual, Clontech. (2012)). The VHL sequence was obtained from the 
laboratory of Prof. Sapkota (Dundee University, UK) and was introduced into the 
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PEM24 vector containing ML3 using InFusion cloning after linearizing the vector using 
the HpaI restriction enzyme. All constructs in the PEM24 vector were transformed in the 
E. coli strain HB101.  
All constructs were confirmed by sequencing and are shown in Table 4.1. 
 
Cloning 
method 
Constructs Restriction 
enzymes 
N-terminal Tags C-terminal 
Tags 
Conventional 
cloning 
pHFT2-AS25  10x-His, Flag  
pHFT2-AS27  10x-His, Flag  
pHFT2-HA4  10x-His, Flag  
pHFT2-Nsa5  10x-His, Flag  
pHFT2-Nsa5_S63K  10x-His, Flag  
pET21a-Stx2b-TDP-
AS25/ML3 
HindIII, 
NheI 
 6X His, 
KDEL 
pET21a-Stx2b-TDP-
SNAP-AS25/ML3 
NotI, NheI SNAP 6X His, 
KDEL,  
pET21a-Stx2b-TDP-
AS25/ML3-NLS 
HindIII, 
XhoI 
 6X His, 
KDEL, NLS 
pET21a-Stx2b-TDP-
SNAP-AS25/ML3-NLS 
NotI, XhoI SNAP 6X His, 
KDEL, NLS 
InFusion 
cloning 
pEM24-A4GALT PacI, HpaI   
pEM24-VHL-ML3 NdeI, NheI 6X Myc, Flag  
pEM24-VHL-
HA4_Y87A 
NdeI, NheI 6X Myc, Flag  
pET21a-Stx2b-TDP-
VHL-ML3 
HindIII  6X His, 
KDEL 
pET21a-Stx2b-TDP-
VHL- HA4_Y87A 
HindIII  6X His, 
KDEL 
pET21a-Stx2b-TDP-
SNAP-VHL-ML3 
NotI SNAP 6X His, 
KDEL  
Gateway 
cloning 
pRV-N-TAP(GS 
2xT)_MS2 
 2x-Protein G, 
TEV site, SBP, 
Myc 
 
pRV-N-TAP(GS 
2xT)_MS8 
 2x-Protein G, 
TEV site, SBP, 
Myc 
 
pRV-N-TAP(GS 
2xT)_MY1 
 2x-Protein G, 
TEV site, SBP, 
Myc 
 
pRV-N-TAP(GS 
2xT)_MY3 
 2x-Protein G, 
TEV site, SBP, 
Myc 
 
pRV-N-TAP(GS 
2xT)_ML1 
 2x-Protein G, 
TEV site, SBP, 
Myc 
 
pRV-N-TAP(GS 
2xT)_ML3 
 2x-Protein G, 
TEV site, SBP, 
Myc 
 
hPGK-ML1  6x-myc, Flag  
hPGK-ML3  6x-myc, Flag  
hPGK-HA4_Y87A  6x-myc, Flag  
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pCS2-SNAP-AS25  6X Myc  
pCS2-Stx2b-TDP-
AS25/ML3-NLS 
 6X Myc  
pCS2-Stx2b-TDP-
SNAP-AS25/ML3-NLS 
 6X Myc, SNAP  
Table 4.1 Expression constructs used for this thesis. 
4.2?  Expression and purification of recombinant proteins 
E. coli cells of the BL21(DE3) strain were transformed with the plasmids of all constructs 
except the toxin constructs, which were transformed in the E. coli strain Origami.  A 
preculture was grown over night in 5 ml Luria Bertani (LB) medium containing the 
appropriate antibiotics Ampicillin for all constructs and additionally Tetracycline for the 
expression in the Origami strain. The preculture was used to inoculate 1 l Auto 
Induction Medium (AIM) with the same antibiotics which was incubated for 72 hours at 
20°C shaking at 200 rpm. For the constructs bearing a VHL, Terrific Broth (TB) was 
used instead of AIM, the cells were grown at 37°C until their OD595 nm had reached 
between 0.8 and 1, 1 mM IPTG was added and the culture was further incubated at 
18°C shaking at 200 rpm for 15 to 18 hours. 
 
4.3?  Ni-NTA gravity flow purification 
The cells were harvested by centrifugation at 6000g for 15 minutes and the pellet was 
resuspended using Buffer A (50mM Tris-HCl pH 7.5, 500mM NaCl, 10% glycerol, 
20mM Imidazole). 1mM DTT was added to the Buffer A for all the constructs except 
the ones bearing the Stx2b-TDP construct. For the constructs bearing a VHL, Hepes-
based Buffer A was used (50mM Hepes pH 7.5, 500mM NaCl, 10% glycerol, 0.1% 
Triton-X-100, 20mM Imidazole). DNAse was added before the cells were lysed using the 
Avestin Emulsifex C3. The lysates were centrifuged at 14000g for 45 minutes. The 
supernatant containing protein was filtered through 0.45?m filter. The protein samples 
were incubated with 1.5 ml Nickel agarose resin equilibrated with Buffer A for 1 hour at 
4°C on a rotor. The lysates were then transferred into a 20mL plastic body column and 
the flow-through was allowed to pass completely. The column was washed with 50 
column volumes of Buffer A prior to elution with 6mL of Buffer B (the same as the 
buffer A but with 400 mM Imidazole). 50ul each of the lysate, flowthrough, wash and 
elution fractions were kept for SDS-PAGE analysis later. The concentration of the eluted 
protein was measured using the Nanodrop spectrophotometer. 
 
4.4?  Size exclusion chromatography 
Ni-NTA purification was followed by size-exclusion chromatography (SEC). The 
samples were first filtered through 0.22?m syringe filters before loading onto a Superdex 
size exclusion column attached to the Akta Avant system (GE) and pre-equilibrated with 
Gel filtration (GF) buffer (25mM Tris-HCL, pH 7.5, 150mM NaCl, and 5% Glycerol, 
(+1mM DTT, only for monobodies, not for Stx2B-TDP constructs)). A Superdex200 
16-600 column was used for purification of Stx2B-TDP constructs, and a Superdex75 
26-600 was used for purification of monobodies. The elution fractions corresponding to 
the molecular weight of the protein were collected and concentrated using Amicon 
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centrifugal filters. The concentration of the protein was measured using the Nanodrop 
spectrophotometer.  
 
4.5?  SDS-PAGE and Coomassie staining 
The expression of the protein was analyzed by Sodium dodecyl sulphate Polyacrylamide 
Gel electrophoresis (SDS-PAGE). The flow-through, wash and elution fractions from 
Ni-NTA purification and elution fraction from SEC were mixed with (4X) sample buffer 
(0.2M Tris-HCL, 8% SDS, 400mM DTT, 40% glycerol and 0.02% bromophenol 
blue), boiled at 95°C and loaded in the pockets of a 12% polyacrylamide gel. The gel was 
run at 100V constant in SDS running buffer (0.25M Tris, 1.92M glycine, 1% (w/v) 
SDS). SDS-PAGE gels were either used for western blotting or stained in coomassie 
staining solution (10% acetic acid, 50% absolute ethanol and 0.025% coomassie brilliant 
blue G-250) for 1-2 hours at room temperature after boiling for few seconds, and 
destained using destaining solution (10% acetic acid and 20% ethanol). The membranes 
were imaged using the Odyssey infrared imaging system (Li-Cor) and analysed using 
ImageStudio software (Li-Cor). 
 
4.6?  Monobody labelling 
Two strategies were applied to label the Toxin-monobody constructs. The first strategy 
was to label the free cysteine in the monobody with maleimide coupled to AlexaFluor488 
(ThermoFisher) and the second strategy was to use the fluorogenic benzylguanine (BG) 
substrates to label the SNAP tag.  
4.6.1? Maleimide labelling 
The concentration of the protein was measured using the Nanodrop spectrophotometer. 
A ten fold molar excess of the required protein amount was used for labelling. Maleimide 
was added in a 1:10 molar ratio (Protein:dye) and the labelling reaction was left to 
proceed in dark overnight at 4°C with mild shaking.  
4.6.2? SNAP tag labelling 
The concentration of the protein was measured using the Nanodrop spectrophotometer. 
A ten-fold molar excess of the required protein amount was mixed with the cell 
impermeable fluorogenic SNAP substrate (BG-Cy5 or BG-547) in a 1:5 molar ratio 
(Protein:dye) and the reaction was left to proceed in dark for 2 hours at room 
temperature with mild shaking. For in-cell labelling, 500nM permeable SNAP substrate 
(BG-Sir) was added to the cells previously incubated with the SNAP-protein for 30 
minutes. The cells were then washed with PBS and imaged. 
 
4.6.3? Purification of the labelled protein 
For the recovery and purification of the labelled protein, PD SpinTrap G-25 or PD 
MidiTrap G-25 (GE Healthcare) columns prepacked with Sephadex G-25 resin were 
used depending on the sample size.  The columns were first equilibrated with the 
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equilibration buffer (25mM Tris-HCl pH7.5, 150mM NaCl, 5% glycerol). The sample 
was slowly allowed to pass through the equilibrated resin and the purified labelled protein 
was eluted in the same buffer.  
 
4.7?  Mammalian cell culture 
The adherent cell lines HeLa (human cervical carcinoma), HEK293 (Human Embryonic 
Kidney), HEK293gp and HEK293T were cultured in Dulbecco’s Modified Eagle 
Medium, DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) and 
1% penicillin/streptomycin (P/S, Amimed). K562 cells and Jurkat cells, which grow in 
suspension, were cultured in RPMI (Gibco), supplemented with 10% FBS and 1% P/S. 
All the cells were cultured in flat, round cell culture dishes of 10 or 15 cm diameter at 
37°C in 5% CO2. Adherent cells were split 3 times per week by washing with PBS, 
followed by incubation with 1-2 ml Trypsin-EDTA (Gibco) at 37°C, and resuspension 
by pipetting in growth medium. 10-20% of the cell suspension was added to a new dish 
containing growth medium. Suspension cells were split 3 times per week. Cells were first 
centrifuged at 400g for 3 minutes, resuspended in fresh growth medium and counted 
using the CASYton cell counter. The concentration was adjusted to 1x105 cells/ml and 
the cells were transferred to a new culture dish. Blasticidin at the experimentally 
determined concentrations of 5 µg/ml for Jurkat (acute T cell leukemia) cells and 7.5 
µg/ml for K562 (chronic myeloid leukemia) cells were continuously added to the growth 
medium of cells after lentiviral transduction with a PEM24 vector containing a 
blasticidin-resistance.  
 
4.8?  Transfection 
Cells were transiently transfected with plasmids using the Polyfect transfection reagent 
(QIAGEN), according to the manufacturer’s protocol. Briefly 1.5ug plasmid DNA was 
diluted in serum-free DMEM to a total volume of 100?l per dish with 12?l polyfect 
transfection reagent per dish. The mixture was then vortexed for 10 seconds and 
incubated for 10 minutes at room temperature. While complex formation occurred, the 
medium was removed from HeLa cells in the dishes and replaced with 7ml warm 
complete DMEM. 600?l of complete DMEM was added to the transfection complexes. 
712?l of the mixture was added slowly and dropwise to the cells. The plates were swirled 
and incubated at 37°C in 5% CO2. 
 
4.9?  Cell lysate preparation 
Adherent cells were washed twice with cold PBS and then lysed by addition of cold lysis 
buffer (50mM Tris-HCl, pH7.5, 150mM NaCl, 5mM EDTA, 5mM EGTA, 1% NP-
40, 50mM NaF, 1mM orthovanadate, 1 mM PMSF (Sigma), 1mg/ml TPCK 
(Applichem), 10µg/ml protease inhibitor cocktail (Roche)). For 10 cm dishes, 400 ?l 
lysis buffer (recipe below) was used. The cells were detached using a rubber scraper and 
transferred into an Eppendorf tube by pipetting.  
Suspension cells were centrifuged for 5 minutes at 500g at 4°C. The pellet was 
resuspended in 10 ml cold PBS. In case of the delivery experiment, the cells incubated 
with protein in Leibovitz medium were directly transferred into 10 ml cold PBS. After 
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centrifugation for 5 minutes at 500g at 4°C, the pellet was washed once with 1 ml PBS, 
transferred into a cold Eppendorf tube and resuspended in 50 µl lysis buffer.  
After 10 minutes incubation on ice, the lysate was cleared by centrifugation for 10 
minutes at 20000g at 4°C. The supernatant (lysate) was transferred into fresh cold tubes. 
Protein concentrations in lysates were determined using Bradford solution (Bio-Rad) 
diluted 1:5 in water and measuring the OD595 nm and comparing to a standard curve 
determined by measuring known amounts of a ?-globulin solution. 
 
4.10? Immunoblotting 
Protein lysate samples were diluted in Laemmli buffer containing 1mM DTT to contain 
100 µg protein per 20 µl and then boiled at 95°C for 5 minutes. The samples were 
separated by SDS-PAGE (as described in section 4.5) and transferred to a nitrocellulose 
membrane using a semi-dry blotting system (Bio-Rad) or transferred to a nitrocellulose 
membrane using the iBlot dry blotting system (ThermoFisher). For using the semi-dry 
blotting system, a nitrocellulose membrane (Whatman, Protran BA85, GE Healthcare) 
was placed on top of three Whatman cellulose chromatography papers presoaked in 1x 
western blot buffer (25 mM Tris-HCl, pH 7.5, 192 mM glycine, 10% v/v methanol) 
and the SDS-PAGE gel was placed on top, followed by another 3 presoaked Whatman 
papers. The transfer was done in 30 minutes using 300 mA constant current per minigel. 
For the iBlot system, materials provided by the manufacturer and specified for the iBlot 
were used and the transfer was done using program 4, according to the manufacturer’s 
protocol. 
The membrane was blocked for 1h in a blocking buffer consisting of either 5% w/v non-
fat dry milk powder (Bio-Rad) or 5% w/v BSA or Li-Cor blocking buffer diluted 1:5 in 
either PBS-T or PBS-T (PBS or TBS supplemented with 0.1% Tween20). The buffers 
used for the individual antibodies are listed in table. The membrane was then incubated 
with the appropriate antibody (Table 4.2) diluted 1:1000 in blocking buffer at 4°C 
overnight with gentle shaking. After washing 3x for 5 minutes with either PBS-T or 
TBS-T, the membrane was incubated with a secondary IRDye680 or IRDye800 or 
HRP-coupled antibody diluted 1:10000 in wash buffer for 1 hour at room temperature 
with gentle shaking. The membrane was again washed 3x for 5 minutes and then imaged 
using the Odyssey fluorescent imaging system (Li-Cor) for IRDye coupled secondary 
antibodies and analysed using ImageStudio software (Li-Cor). For HRP-coupled 
secondary antibodies, Amersham ECL Prime Western Blotting Detection reagent (Ge 
Healthcare) was used for development according to the manufacturer’s protocol. 
Membranes were imaged using the FluorChem IS-8900 (Alpha Innotech). 
 
Primary antibody  Blocking buffer Wash 
buffer 
Secondary Antibody 
Rabbit Yes, CST (3201) 5% BSA in PBS-T TBS-T Anti-rabbit HRP, Jackson 
Immunoresearch (111-
035-003) 
Mouse penta-His, Qiagen 
(34610) 
5% BSA in TBS-T TBS-T Anti-mouse IRDye 680, 
Li-Cor (926-32210) 
Mouse Myc, ThermoFisher 
(MA1-2-1316-0800) 
5% BSA in TBS-T TBS-T Anti-mouse IRDye 680, 
Li-Cor (926-32210) 
Mouse Lck, CST (2657) 5% BSA in TBS-T TBS-T Anti-mouse IRDye 680, 
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Li-Cor (926-32210) 
Mouse Zap70, CST (2709) 5% BSA in TBS-T TBS-T Anti-mouse IRDye800, 
Li-Cor (925-32210) 
Rabbit pZap70(Y493), 
CST (2704) 
5% BSA in TBS-T TBS-T Anti-rabbit IRDye680, 
Li-Cor (925-68071) 
Rabbit pZap70(Y319), 
CST (2701) 
5% BSA in TBS-T TBS-T Anti-rabbit IRDye680, 
Li-Cor (925-68071) 
Mouse tubulin, Sigma (T-
9026) 
5% BSA in PBS-T PBS-T Anti-mouse IRDye680, 
Li-Cor (926-32210) 
Mouse pY 4G10, Millipore 
(05-1050) 
1:5 Li-Cor buffer 
in PBS-T 
PBS-T Anti-mouse-HRP, 
Jackson Immunoresearch 
(115-035-003) 
Mouse pERK 
(T202/Y204), CST (9106) 
5% BSA in PBS-T PBS-T Anti-mouse IRDye680, 
Li-Cor (926-32210) 
Rabbit ERK, CST (9102) 5% BSA in PBS-T PBS-T Anti-rabbit IRDye800, 
Rockland (611-732-127) 
Rabbit pSrc-family 
(activation loop), CST 
(D49G4) 
5% BSA in TBS-T TBS-T Anti-rabbit IRDye800, 
Rockland (611-732-127) 
Rabbit pNFAT (S54), 
ThermoFisher (44-944G) 
1% milk + 1% 
BSA in TBS-T 
TBS-T Anti-rabbit IRDye680, 
Li-Cor (925-68071) 
Mouse beta-Actin, 
ThermoFisher (MA1-140)  
5% BSA in PBS-T PBS-T Anti-mouse IRDye800, 
Li-Cor (925-32210) or 
Anti-mouse IRDye 680, 
Li-Cor (926-32210) 
Table 4.2 List of antibodies used for immunoblotting 
4.11?Retroviral transduction 
Stable cell lines expressing monobodies for TAP experiments were generated by retroviral 
transduction with the pRV vector constructs, which carry a GFP gene following an IRES 
site, for selection. HEK293gp cells stably expressing MLV gag and pol proteins were used 
to produce the virus. They were co-transfected with the VSV-G cDNA and the pRV 
vector plasmid DNA by calcium phosphate transfection. 4 µg VSV-G DNA and 12 µg 
pRV plasmid DNA were mixed with 330 µl 0.1x Tris-EDTA, 55 µl 2.5 M CaCl2 and 
with water to a total volume of 550 µl. 550 µl 2x Hepes Buffered Saline (HBS) were added 
dropwise while vortexing. The transfection complexes were incubated at room 
temperature for 20 minutes, then added dropwise to the HEK293gp cells in 10 cm 
dishes. 
The cells were incubated for 16 hours at 37°C in 5% CO2 and then the medium was 
replaced with 6 ml fresh growth medium and the cells were incubated for another 24 
hours.The supernatant was removed, filtered through a 0.22µm filter and added to the 
target cells, after having removed their medium and incubated them with 2µl Polybrene 
for 5 minutes. The supernatant of the HEK293gp cells was again replaced with 6 ml 
fresh medium and the infection of the target cells was repeated 24 hours later. After 
incubating again for 24 hours, the medium of the target cells was replaced, and 2 days 
later, they were analyzed on a flow cytometer for GFP fluorescence, indicating the 
integration of the gene. 
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4.12?Lentiviral transduction 
Stable cell lines expressing the PEM24 vector with the A4GALT gene, with the VHL 
fused to the monobodies ML1, ML3 or HA4_YA, and the hPGK vector with the 
monobodies ML1, ML3 or HA4_YA were generated by lentiviral transduction. The 
hPGK vector carries a GFP gene following an IRES site and the PEM24 vector carries a 
blasticidin resistance gene for selection. 
HEK293T cells were co-transfected with a plasmid encoding the viral envelope, a 
packaging plasmid and the construct of interest to produce lentivirus by calcium 
phosphate transfection. For a 10-cm dish, 11.25 ?g construct DNA , 3.95 ?g envelope 
plasmid and 7.3 ?g packaging plasmid DNA were mixed with 330 µl 0.1x Tris-EDTA, 
55 µl 2.5 M CaCl2 and with water to a total volume of 550 µl. 550 µl 2x Hepes Buffered 
Saline (HBS) were added dropwise while vortexing. The transfection complexes were 
incubated at room temperature for 20 minutes, then added dropwise to the HEK293gp 
cells in 10 cm dishes. 
The cells were incubated for 16 hours at 37°C in 5% CO2 and then the medium was 
replaced with 7 ml fresh growth medium and the cells were incubated for another 8 
hours. The supernatant was removed, filtered through a 0.22µm filter and transferred to 
a tube for overnight storage. The supernatant of the HEK293T cells was again replaced 
with 7 ml fresh medium and harvested again in the same way 16 hours later. The 
medium was removed from the target cells and replaced with half of the pooled and 
filtered HEK293T supernatant containing the virus. A second infection was performed 
24 hours later in the same way. After incubating them for 24 hours, the medium of the 
target cells was replaced, and 2 days later, they were either analyzed on a flow cytometer 
for GFP fluorescence (hPGK constructs), or blasticidin was added to the culture medium 
to select for cell having integrated the gene of interest. 
 
To induce the expression of the gene of interest of cells transduced with the pEM24 
vector, 100 ng/ml Doxycycline was added to the medium in a dropwise manner and 
replaced every 2-3 days. The effective concentration for doxycycline was previously 
determined. The expression of the protein of interest was determined by lysis and western 
blot (previously described). 
 
4.13?T cell stimulation 
Jurkat cells were stimulated with anti-TCR antibody (clone C305, Millipore) at a 
concentration of 100 ng/ml for 5 min at 37°C. The cells were cooled to 4°C immediately 
after stimulation by addition of ice-cold PBS and centrifugation at 4°C at 500g for 5 
minutes. Cell lysates were prepared as described in section 4.9. 
 
4.14?Recombinant SH2 domain pull-down 
Jurkat cells were stimulated with the anti-TCR antibody as described in section 4.13 and 
lysed as described in section 4.9 and the protein content was quantified using Bradford 
reagent. Recombinant Lck and Src SH2 domains were biotinylated in vitro using 
recombinant BirA enzyme. Magnetic beads coated with streptavidin were incubated with 
either biotinylated Lck or Src SH2 domain for 2 hours at 4°C, washed 3 times with TBS 
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and then incubated for 30 minutes with ML3 or the non-binding HA4_Y87A control 
monobody. After washing 3 times with TBS, the beads were incubated for 2 hours with 3 
mg of lysate from stimulated Jurkat cells. After another 3 washing steps, the beads were 
boiled for 5 minutes in SDS-PAGE loading buffer prior to separation on an SDS-PAGE 
gel. 
 
4.15?Tandem affinity purification 
The cells stably expressing the monobodies in the pRV-vector were expanded to 
approximately 3x109 cells in 300 ml shaker flasks for mammalian cells at 37°C in 5% 
CO2 and while shaking at 180 rpm. The cells were first grown up to a concentration of 
106 cells/ml in 20 ml growth medium a 15-cm dish and then diluted with growth 
medium to 100 ml and transferred into a 300 ml shaker flask with a conical bottom after 
addition of 1x Pluronic-F-68 (Gibco) (100x stock diluted 1:100) to reduce the shear 
stress during shaking. The cells were then grown while shaking at 180 rpm for 2 days, 
before diluting the culture medium 1:3 with growth medium supplemented with 
Pluronic-F-68. The cells were diluted 1:3 every 2 days until reaching a total volume of 
1800 ml of cell culture. The cells were then pelleted by centrifugation at 500g for 5 
minutes in mammalian cell centrifugation bottles of 150 ml and the pellets were 
resuspended in 10 ml PBS each, pooled and centrifuged again. The pellet was 
resuspended in 50 ml PBS and the cells were counted. Between 2.2 and 3.4 x109 cells 
were obtained from 1800 ml cell culture medium. The 50 ml cell suspension in PBS was 
divided into 2 tubes, centrifuged again, the supernatant was removed and the pellets were 
frozen in liquid N2 and stored in the -80°C freezer. 
 
During the TAP, all the steps were performed with cold buffers, at 4°C while working in 
the cold room. The cell pellets were thawed by resuspension in 25 ml cold TAP buffer 
(50mM Tris-HCl, pH 7.5, 100 nM NaCl, 5% glycerol, 0.2% NP-40, 1.5 mM MgCl2 
and 25 mM NaF, 1mM orthovanadate, 1 mM PMSF (Sigma), 1mg/ml TPCK 
(Applichem), 10µg/ml protease inhibitor cocktail (Roche)) and incubated on ice for 15 
minutes for lysis to proceed. The lysate was first centrifuged at 4500g for 15 minutes and 
the supernatant was transferred into ultracentrifuge tubes (polycarbonate thick walls, 38 
ml, Beckman-Coulter). The lysates were centrifuged for 1 hour at 4°C at 100,000g in the 
ultracentrifuge using the rotor SW32Ti (Beckman Coulter).  
The supernatant was transferred to a 50-ml tube while avoiding the lipid layer (total 
extract, TE) and an aliquot of 50µl was saved. IgG beads (Sigma, A2909) were washed 
and equilibrated with TAP buffer and then 200µl of the beads diluted 1:1 in TAP buffer 
were added to the lysate and incubated on a rotating wheel at 4°C for 2 hours.  
The 50µl TE sample was used to calculate the protein concentration using a Bradford 
assay. The beads were recovered by centrifugation at 600 rpm for 3 minutes at 4°C, an 
aliquot of the supernatant was saved (SN1) and the rest discarded and the beads were 
transferred into a Bio-Spin column (Bio-Rad, 732-6008). The beads were washed with 
10 ml TAP buffer and then with 5 ml TEV-NP-40 buffer (10 mM Tris-HCl, pH7.5, 
100 mM NaCl, 0.5 M EDTA, pH8.0, 0.2% NP-40). 50µg of TEV protease were diluted 
to a final volume of 400µl in TEV buffer (10 mM Tris-HCl, pH7.5, 100 mM NaCl, 0.5 
M EDTA, pH8.0) and added to the beads after closing the bottom of the column. The 
beads were incubated for 1h at 16°C while shaking at 800rpm. The TEV eluate was 
collected from the column into an Eppendorf tube and another 400µl of TEV-NP-40 
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buffer were added to the beads and eluted by gravity flow into the same tube. 30µl were 
saved (TEV). 
Streptavidin UltraLink Resin beads (PierceThermo, 53114) were washed 3 times with 
TEV buffer and 150µl of the beads diluted 1:1 in TEV buffer were added per sample and 
incubated for 1h on a rotating wheel at 4°C. The Streptavidin beads were transferred into 
a Bio-Spin column, the eluate was discarded except for a 50µl sample which was saved 
(SN2) and the beads were washed with 10 ml TEV-NP-40 buffer. The proteins were 
eluted from the column with 2x 250 µl 150 mM HCl into tubes containing 125 µl 
TEAB. A 30 µl sample was saved (E1). The beads were boiled with 75µl 4x sample buffer 
for 5 minutes at 95°C and a sample was saved (BB). The eluate was frozen in liquid N2, 
lyophilized overnight and resuspended in 50 µl 4x Laemmli sample buffer (Bio-Rad) 
containing 0.5% ?-mercapto-ethanol. A 10% fraction of the sample was separated on an 
SDS-PAGE gel and protein bands were visualized by silver staining. The saved samples 
(TE, SN1, TEV, SN2, E1 and BB) were separated by SDS-PAGE and immunoblotted 
with the indicated antibodies. The 90% fraction of the final eluate was separated by 
SDS-PAGE (any kD gel, Bio-Rad, 456-9033), stained with R-250 Coomassie Blue 
solution and submitted for mass spectrometry analysis by the EPFL proteomics core 
facility. Gel lanes were cut into pieces and subjected to in-gel digestion with trypsin. 
Extracted peptides were separated by reversed-phase chromatography on a Dionex 
Ultimate 3000 RSLC nano UPLC system (Dionex) on-line connected in-line either with 
an Orbitrap Elite or an Orbitrap Q-Exactive Mass Spectrometer (Thermo Fischer 
Scientific). Raw data were processed with Proteome Discoverer software and searched 
with Mascot against a human database (UniProt). The data was obtained from the 
facility in a Scaffold3 software file format and was analyzed as described in the results 
section. 
 
4.16?Flow cytometry 
4.16.1? GFP expression analysis 
Flow cytometry was used to assess the DNA integration of the pRV and hPGK vectors by 
measuring the 488 nm signal from the GFP. 1 ml of cell suspension with 105 to 106 cells 
were taken, washed 2 times with PBS, resuspended in PBS supplemented with 0.5% BSA 
(FACS buffer) and then analyzed on the BD LSRII flow cytometer (Beckman-
Dickinson) using the 488nm laser and a 525/40nm bandpass filter.  
 
4.16.2? Cell sorting 
Cell sorting was performed on a FACS AriaII device at the EPFL Flow cytometry core 
facility. 107 cells washed with PBS and resuspended in FACS buffer, before sorting them 
according to their 488 nm fluorescence into tubes containing FBS. Afterwards, the cells 
were centrifuged at 500g for 5 minutes and resuspended in growth medium. 
4.16.3? Gb3 expression analysis 
Flow cytometry was used to assess the expression of Gb3 receptor (CD77) on the surface 
of different cells. HeLa cells were first trypsinized and resuspended in 5mL fresh DMEM. 
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5x105 cells per sample were centrifuged for 3 minutes at 500g and washed once with PBS. 
The cell pellet was resuspended in 100 ?l FACS buffer containing human FITC-
conjugated anti-CD77 antibody (Biolegend, 357103) diluted 1:20 and the tube was 
incubated at dark on ice for 20 minutes. The cells were washed with 3 ml PBS and the 
pellet was resuspended in 400?l FACS buffer for analysis on the BD LSRII flow 
cytometer (Beckman-Dickinson) using the 488nm laser and a 525/40nm bandpass filter. 
4.16.4? Protein delivery 
Flow cytometry was used to assess the delivery of the proteins in suspension cells. 
5x105 K562 and Jurkat cells transduced with the A4GALT gene and induced with 100 
ng/ml doxycycline or uninduced were collected after centrifugation at 500g for 3 minutes 
and resuspension in fresh buffer. After one washing step with PBS, the supernatant was 
aspirated and pellet was resuspended in Leibovitz medium containing the AlexaFluor488 
or SNAP-substrate or unlabeled protein to be delivered. The cells were incubated in a 48-
well plate for 30 minutes at 37°C. The cells were collected in 15ml tubes, centrifuged and 
washed three times with PBS. The cell pellets were then resuspended in 400 µl FACS 
buffer for analysis. The samples were analyzed on an LSRII flow cytometer (Beckman-
Dickinson) using the 488nm laser and a 525/40nm bandpass filter for the delivery of 
AF488-labelled proteins or using the 640nm laser and a 670/14nm bandpass filter for the 
delivery of SNAP-tagged proteins.  
4.16.5? AnnexinV/7AAD staining 
K562 cells either induced with 100 ng/ml doxycycline for 24h or uninduced were 
pelleted by centrifugation at 400g for 3 minutes and resuspended in Leibovitz’s medium 
supplemented with 10% FBS, 1% P/S and 7.5 µg/ml blasticidin. The cells were counted 
on the CASYton cell counter and their concentration was adjusted to 4x105 cells/ml for 
the 24-hour timepoint, 2x105 cells/ml for the 48-hour timepoint and 1x105 cells/ml for 
the 72-hour timepoint. 100ng/ml doxycycline was added to the cells previously induced 
with doxycycline.250 µl of cell suspension were transferred in each well of a 24-well plate 
and 250 µl of recombinant protein diluted in Leibovitz’s medium and sterile filtered were 
added. The cells were incubated for 24, 48 or 72 hours at 37°C in 5% CO2.  
AnnexinV binding buffer was prepared by diluting the 10x AnnexinV binding buffer 
(BD) 1:10 in sterile water. The AnnexinV/7AAD staining solution was prepared by 
diluting Cy5-coupled AnnexinV (BD) 1:50 and 7AAD (BD) 1:20 in 1x AnnexinV 
binding buffer. The cells were transferred from the wells of the 24-well plate into 15-ml 
tubes with 10 ml PBS and centrifuged at 500g for 5 minutes. The pellets were 
resuspended in 100µl AnnexinV staining solution and transferred to FACS tubes. After 
15 minutes of incubation at room temperature in the dark, 200µl of AnnexinV binding 
buffer was added without washing the cells and the cells were analyzed on the LSRII flow 
cytometer (Beckman-Dickinson) using the 640nm laser and a 670/14nm bandpass filter 
for detection of Cy5 and the 561nm laser and a 670/30nm bandpass filter for detection 
of 7AAD. Unstained and single stained controls were included in each experiment and 
used for compensation between the Cy5 and 7AAD signals. Analysis and compensation 
were done using FlowJo software. 
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4.17?CellTiter-Glo luminescent cell viability assay 
The cells were seeded in a 96-well plate and incubated with adducts for 1h, and then in 
adduct-free medium for 24h after 3 washing steps with PBS. The cells were then lysed by 
addition of the CellTiter Glo reagent (Promega), according to the manufacturer’s 
protocol. The luminescent signal was measured using the M5 plate reader (Molecular 
devices). 
 
4.18?Realtime-Glo luminescent cell viability assay 
The Realtime-Glo assay kit (Promega) was used to monitor cell viability of K562 cells 
after protein delivery. For this, K562 cells transduced with A4GALT were induced with 
100 ng/ml of doxycycline, which was added to the medium 24 hours before the 
experiment, or were left uninduced. The cells were pelleted by centrifugation at 400g for 
3 minutes and the pellets were resuspended in Leibovitz’s medium supplemented with 
10% FBS, 1% P/S and 7.5 µg/ml blasticidin. After counting the cells using the CASYton 
cell counter, they were diluted to 1x105 cells/ml and the NanoLuc enzyme (Promega) as 
well as the MT cell viability substrate were added to the cell suspension at a 1:1000 
dilution as indicated in the manufacturer’s protocol. The cells were then seeded in an 
opaque white 96-well plate at a density of 5x103 cells in 50µl per well. The proteins 
diluted at 2x the indicated end concentration in Leibovitz’s medium supplemented with 
10% FBS, 1% P/S and 7.5 µg/ml blasticidin were sterile filtered and 50µl were added per 
well. The plates were incubated at 37°C in 5% CO2. After 24, 48, 72 and 96 hours of 
incubation, the plates were inserted into the M5 plate reader (Molecular devices) and 
luminescence was measured. 
4.19?Microscopy 
4.19.1? Live cell microscopy 
8x104 cells were seeded 24 hours before incubation with the protein in 35 mm glass-
bottom dishes. Before protein incubation, the medium was aspirated and the cells were 
washed once with 1 ml sterile PBS. The protein was diluted in Leibovitz medium 
supplemented with 10% FBS and 1% P/S and the cells were incubated in 1 ml of the 
protein dilution at the indicated concentration for the indicated time. For incubation 
times longer than 1 hour, the protein dilutions were sterile filtered prior to addition to 
the cells. Before imaging, the cells were washed twice with PBS and fresh Leibovitz’s 
medium was added. The dishes were imaged using a spinning disk confocal microscope 
(Yokogawa Spinning-Disk “CSU-W1”) at the BIOP, EPFL with the 60x oil objective 
using appropriate laser settings. For AF488 labelled proteins, the 488nm laser was used. 
For BG-Cy5 and BG-Sir labelled SNAP tagged proteins, 640nm laser was used. For each 
sample, individual z-slices were imaged at the nuclear plane. The same laser settings were 
used for each sample of the same experiment.  
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4.19.2? Immunofluorescence 
8 x104 cells were seeded 24 hours before incubation with the protein in a six-well plate 
with 18mm sterile round coverslips. Before protein incubation, the medium was 
aspirated and the cells were washed once with 1 ml PBS. The protein was diluted in 
Leibovitz medium supplemented with 10% FBS and 1% P/S and the cells were 
incubated in 1 ml of the protein dilution at the indicated concentration for the indicated 
time. The cells were washed once with PBS and then fixed in 4% Paraformaldehyde 
(PFA) at room temperature for 15 minutes (all antibodies except for anti-Calreticulin) or 
in ice-cold 100% Methanol for 5 minutes at -20°C. (anti-Calreticulin antibody) The cells 
were rehydrated three times in PBS supplemented with 0.01% Triton-X-100 (PBS-TX). 
The coverslips were incubated for 1h in permeabilization solution (PBS, Saponin 0.1%, 
BSA 5%) at room temperature and then washed 3 times with PBS-TX. The coverslips 
were placed on the parafilm-coated and labelled lid of a 6-well plate in a humidity 
chamber. PBS-TX was added on top to prevent drying. PBS-TX was aspirated and 50µl 
of primary antibody solution diluted 1:500 in PBS-TX supplemented with 1% BSA was 
added. The coverslips were incubated overnight at 4°C in the humidity chamber.  
The coverslips were washed with PBS-TX once, then 3 times with 5 minutes incubation 
between washes, each time by aspirating the solution form the coverslips and pipetting 
fresh solution immediately to the rim of the coverslip to prevent coverslips from drying. 
50µl of secondary antibody diluted 1:1000 in PBS-TX supplemented with 1% BSA was 
added on each coverslip and incubated for 45 minutes in the humidity chamber at room 
temperature. The cells were washed once with PBS-TX, then 3 times with 5 minutes 
incubation between washes. 100µl of 1:1000 dilution of Hoechst in PBS was added on 
each coverslip and incubated for 10 minutes at room temperature in the humidity 
chamber. The cells were washed 3 times with PBS. For each coverslip, 2µl Fluoromount-
G mounting medium was put on a microscopy slide just before mounting. Each coverslip 
was taken up with tweezers, dipped into a becher with water and the excess water was 
removed with a paper tissue. It was then placed upside down on the slide on top of the 
mounting media. Excess media was removed with a paper tissue and the slides were 
allowed to dry in the dark.  After drying, the cells were imaged on the spinning disk 
confocal microscopy (Yokogawa Spinning-Disk “CSU-W1”) at the BIOP, EPFL with the 
60x oil objective using appropriate laser settings.  
 
Primary antibodies Organelle stained Secondary antibodies 
Mouse EEA1 (Sigma 
BD610547) 
Early Endosomes Anti-Mouse FITC (Sigma 
F0257) and anti-Mouse 647 
(Biolegend 405322) Mouse Lamp1 (Sigma 
BD555798) 
Lysosomes 
Rabbit Golgin-97 (Abcam 
Ab84340) 
Golgi bodies Anti-Rabbit 488 (Abcam 
Ab15007) and anti-Rabbit Cy5 
Rabbit Calnexin (Abcam 
Ab22595) 
Endoplasmatic 
Reticulum  
Rabbit Calreticulin (Abcam 
Ab92516) 
Table 4.3 List of antibodies used for immunofluorescence 
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4.20? Image processing and analysis 
After image acquisition, the images were processed and analysed in Fiji/ImageJ software. 
The Common Tools Plugin (written by the BIOP, EPFL) was used to process all the 
images. First, Look Up Tables (LUTs) were selected for each channel in the image. Then, 
brightness and contrast (B/C) for each channel was adjusted. The image without protein 
labelling was used as a reference to subtract background signal from the true signal. The 
same settings were applied to all the images from one experiment. 
4.20.1? Colocalization analysis 
For colocalization analysis, Regions of Interest (ROIs) were selected from the processed 
images with correct LUTs and B/C. This was done using the MultiManualSelect tool 
(written by the BIOP, EPFL). ROIs were drawn for each cell in each image using 
polygon selection tool. At least 15-20 images per experimental condition were analyzed 
with 1-4 cells per image. After selecting ROIs, a threshold algorithm was selected for each 
channel, which was appropriate to selects true signal and omit the background noise for 
each image in a similar way. In contrast to using a fixed threshold value, this method 
allowed to correct for overall intensity differences between the images. The images were 
then all processed in the same way using the selected threshold for the individual 
channels. Using the JaCOP tools (written by PTBIOP, EPFL) in ImageJ, the Mander’s 
overlap coefficients between the channels of the protein signal and the antibody signal 
were calculated for each cell (ROI) individually by averaging over the different z-stacks.  
4.20.2? Nuclear localization analysis  
After acquiring images as described in section 4.19.1 from cell incubated with NLS-
tagged proteins, the following ImageJ script was used to process all the images and 
quantify the signal from the 488nm channel in the nucleus. It loops through all the 
images in a chosen folder, and for each image, it loops through the 5 slices taken in the 
nuclear plane. The Hoechst stained nuclei of each slice are first defined as regions of 
interest (ROIs), by setting a threshold selecting pixels with a Hoechst signal above a 
certain value. Each distinct area with a minimum number of pixels is then saved as a 
ROI, discarding small speckles that might result from noise or artifacts. The mean 
intensity of the 488 nm signal of each ROI is measured, corresponding to the signal from 
the delivered proteins. The mean intensity values of the 5 slices corresponding to the 
same ROI are matched and the average is calculated. This gives a measure for the average 
488 nm fluorescence intensity throughout the 5 slices of each nucleus.  (????????????? ???
???????? ???? ?????????? ??????????? ???? ???????????? ?????????????????????????? ????
?????????????? 
 
// @File(label="Select the folder of images to process", 
style="directory") myFolder 
// @Integer(label="DAPI channel",value=2) chDAPI 
// @Integer(label="channel to measure",value=1) chMeasure 
 
??? ???????? ??????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
?????????
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????????? ??????????????
?
?????????????????????????????????????????????????????????
 
function isImage(filename){ 
extensions= newArray("lsm", "lei", "lif", "tif", "ics", "bmp", 
"png", "TIF", "tiff", "czi", "zvi", "nd2");  
for (i=0; i<extensions.length; i++) { // for each index of the 
array extensions  
if(endsWith(filename, "."+extensions[i])) {  
   return true;  
  }  
 }  
 return false;  
} 
 
???????????????????
?
??????????? ?????
?
???????????????????????????????????????????????????????
call("BIOP_LibInstaller.installLibrary", 
"BIOP"+File.separator+"BIOPLib.ijm"); 
run("Set Measurements...", "area mean standard min display 
redirect=None decimal=5"); 
???????????????????? ??????????????????????????????????? ??????
saveDir = myFolder + File.separator + "results" + File.separator ; 
File.makeDirectory(saveDir); 
run("Close All"); 
 
???????????????????? ?????????????
 
f = File.open("");  
print(f, "Image, ROI, Mean \n"); 
 
????????????????????????????????????????????????????????????
filesList = getFileList(myFolder); 
 
??????????????????????????????????????????????????
partLimit = "20-2000" 
 
setBatchMode(true);  
 
??????????????????????????????????????????
for (j = 0 ; j < lengthOf(filesList) ; j++) 
{ 
run("Close All"); 
run("Clear Results"); 
roiManager("Reset"); 
??????????????????????????
if ( isImage( filesList[j] ) ) {  
 open(myFolder+File.separator+filesList[j]);  
  
run("Set Measurements...", "area mean standard min display 
redirect=None decimal=5"); 
  
????????????????????????????? ?????? ????????????????????
 imageName = getTitle(); 
 getDimensions(width, height, channels, slices, frames); 
 getVoxelSize(widthPixel, heightPixel, depthPixel, unitPixel); 
 print(imageName); 
 slicesToAnalyze=slices-2; 
    118
  
??????????????????
 run("Split Channels"); 
????????? ????????????
 selectWindow("C"+chDAPI+"-"+imageName+"");  
??????????????????? ?????
 run("Stack to Images"); 
???????????????????? ???????
 selectWindow("C"+chMeasure+"-"+imageName+"");  
??????????????????? ?????
 run("Stack to Images"); 
 
??????? ?? ????? ??? ??? ???????? ???? ??????? ??? ????????? ?????? ??? ????????? ??? ???? ??????? ??? ????????
??????????
???? ????? ???????? ???? ?????????? ??? ?????? ????? ??? ???? ?????????????? ?????? ??? ???? ???????? ???
???????????
?
??????????????????
 for (i = 0 ; i < slicesToAnalyze ; i++ ) 
 { 
?????????? ??????????????????????????????????????????? ????????? ?????????????????????
  run("Set Measurements...", "area mean standard min 
display redirect=None decimal=5"); 
???????????? ???????
  roiManager("Reset"); 
???????????????????? ??????????
selectWindow("c:"+chDAPI+"/3 z:"+(i+1)+"/"+slices+" - 
sdcGFP/sdcDAPI/Brightfield"); 
  setAutoThreshold("Li dark"); 
  run("Convert to Mask"); 
  run("Median...", "radius=3"); 
???????????????????????????????????????????????? ???????
run("Analyze Particles...", "size="+partLimit+" 
show=[Count Masks] exclude add"); 
???????????????????????
  ROIcount=roiManager("Count"); 
? ? ???????????????????????????????????????????????????????
  intensity_roi = newArray(ROIcount); 
print(ROIcount+" ROIs have been counted in slice "+i+" in 
image "+imageName); 
???????????????? ??????? ???????????????????????
  if (ROIcount == 0) 
  { 
   waitForUser("No ROI detected"); 
  } 
??? ???????????????????????????????????????????????????
selectWindow("c:"+chMeasure+"/3 z:"+(i+1)+"/"+slices+" - 
sdcGFP/sdcDAPI/Brightfield"); 
  roiManager("Measure"); 
   
???????????????????????????????????????????????????????????? ????????????????????
        for (x=0; x< ROIcount; x++ )  
        { 
         intensity_roi[x]=getResult("Mean", x); 
         Array.print(intensity_roi); 
        } 
  IJ.renameResults("Results", "temp"); 
  writeResults("Final_Results", "Label", "next", 
imageName); 
        writeResults("Final_Results", "Slice", "current", 
"Slice_"+(i+1)); 
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???????????????????????????????????? 
        for (l=0; l< ROIcount; l++ )  
        { 
run("Set Measurements...", "area mean standard min 
display redirect=None decimal=5"); 
writeResults("Final_Results", "ROI_"+(l+1), "current", 
intensity_roi[l]); 
        } 
 
        selectWindow("temp");  
      run("Close"); 
 } 
  
???????????????????????????????????????????????????????????????????????? 
 selectWindow("Final_Results"); 
 waitForUser("check final results table"); 
 IJ.renameResults("Final_Results", "Results"); 
 
?????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????
 ROI = newArray(slicesToAnalyze); 
?????????????????????????????????? ????????????????????????????????? each ROI 
 Mean_ROI = newArray(ROIcount); 
 for(r=0; r<ROIcount; r++) 
 { 
  for (s=0; s<slicesToAnalyze; s++) 
  { 
   print("the intensity of ROI "+r+" in slice "+s+" is 
"    +getResult("ROI_"+(r+1), s)); 
   ROI[s]=getResult("ROI_"+(r+1), s); 
  } 
?????????? ????????????????????????????????????????????????
  Array.print(ROI); 
  Array.getStatistics(ROI,MIN,MAX,MEAN,STDDEV);  
print("the mean of ROI "+r+1+" in image "+imageName+" is 
"+MEAN);  
??????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????
  Mean_ROI[r]=MEAN; 
  Array.print(Mean_ROI); 
???????????? ???????????????????????????????????????????????????
  print(f, imageName +", "+r+1+", "+Mean_ROI[r]+"\n"); 
 } 
 run("Close All"); 
 run("Clear Results"); 
}else{ 
???????????????????????????????????????????
  print(filesList[j]+" is not an image");  
 } 
}         
????????? ?????
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